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Abstract 
Idiopathic intracranial hypertension (IIH) is a blinding condition amongst the young obese 
female population characterised by elevated intracranial pressure (ICP). The aetiology of 
IIH is not known and, as highlighted in the 2005 Cochrane review, an evidence base for 
treatment has not been established, although weight loss is frequently advocated. 
Obesity is associated with dysregulation of cortisol metabolism by 11β-hydroxysteroid 
dehydrogenase type 1 (11β-HSD1).  Additionally, 11β-HSD1 has a role in the regulation 
of intraocular pressure. This thesis hypothesised that 11β-HSD1 is involved in the 
aetiology of IIH and examined the roles of obesity, 11β-HSD1 and metabolic changes in 
the pathogenesis and treatment of IIH. 
We demonstrated that ICP regulating structures (choroid plexus and arachnoid granulation 
tissue), are potential glucocorticoid target tissues expressing 11β-HSD1. Metabolomic 
analysis identified a unique biofluid metabolite biomarker profile, with potential 
implications for IIH pathogenesis. We established the therapeutic efficacy of weight loss 
in IIH (improving headaches, papilloedema and ICP) and provided evidence that the 
beneficial effects may relate to alterations in the glucocorticoid profile driving 11β-HSD1 
and potentially, 5α reductase. These studies have started to address the important issues of 
causation and treatment in IIH and provide avenues for future research into this complex 
condition. 
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ELISA   enzyme linked immunosorbant assay 
EMA   epithelial membrane antigen 
ENaC   epithelial sodium channel 
EPiCM  epithelial cell media 
Et    etiocholanolone 
F    cortisol 
FAM    6-carboxyfluorescein  
FBS    foetal bovine serum 
FCS    foetal calf serum 
FV111   factor V111 related antigen 
GAG   glycosaminoglycans 
GC    glucocorticoids 
GC/MS  gas chromatography / mass spectrometry 
GE    glycyrrhetinic acid 
glog    generalised log 
GR    glucocorticoid receptor 
GRE    glucocorticoid response element 
GRα    glucocorticoid receptor alpha 
GRβ    glucocorticoid receptor beta 
H&E    haematoxylin and eosin 
H6PD   hexose- 6-phosphate dehydrogenase 
HCPEpi  human choroid plexus epithelial cell line  
HIT-6   headache impact test-6 
HOMA  Homeostasis Model Assessment 
HPA    hypothalamic pituitary adrenal 
HPLC   high performance liquid chromatography 
HRP    horseradish peroxidase 
HRT    Heidelberg Retina Tomography 
HSP    heat shock protein 
HVF    Humphrey visual field 
ICP    intracranial pressure 
Ig    immunoglobulin 
IHS    International Headache Society 
IIH     idiopathic intracranial hypertension 
IOP    intraocular pressure 
IR    insulin resistance 
JRES   J-resolved spectroscopy 
LC/MS  liquid chromatography / mass spectrometry 
LogMAR  logarithm of the minimum angle of resolution 
LP    lumbar puncture 
LPS    lumboperitoneal shunting 
LV    latent variable 
MD    mineralocorticoid receptor 
MRI    magnetic resonance imaging 
mRNA   messenger RNA 
MRV   magnetic resonance venography 
MS    multiple sclerosis 
MYOC  myocilin 
NAD+   nicotinamide adenine dinucleotide 
NADH   reduced nicotinamide adenine dinucleotide 
NADP+  nicotinamide adenine dinucleotide phosphate 
NADPH  reduced nicotinamide adenine dinucleotide phosphate 
NDS    normal donkey serum 
NMR   nuclear magnetic resonance 
NPE    non-pigmented epithelium 
NSD    nerve sheath diameter 
NTP    nucleotide triphosphates  
NZWAR  New Zealand White Albino rabbit 
OCT    optical coherence tomography 
ONSF   optic nerve sheath fenestration  
P/S    penicillin and streptomycin 
PBS    phosphate buffered saline 
PC    principal components  
PCOS   polycystic ovarian syndrome 
PCR    polymerase chain reaction 
PE    pigmented epithelium 
p-JRES  1D projections of 2D JRES spectra 
PLSDA  partial least squares discriminant analysis 
POAG   primary open angle glaucoma 
ppm    parts per million 
PSD    pattern standard deviation 
QC    quality control 
RIA    radioimmunoassay 
RNA    ribonucleic acid 
RNFL   retinal nerve fibre layer 
SEM    standard error of the mean  
sgk 1    serum and glucocorticoid regulated kinase 
SHBG   sex hormone binding globulin 
SUMO -1  small ubiquitin related modifier-1 
T2    transverse 
TG    triglycerides 
THE    tetrahydrocortisone 
THF    tetrahydrocortisol 
TIGR   trabecular meshwork inducible glucocorticoid response 
TLC    thin layer chromatography 
TM    trabecular meshwork 
TMSP    trimethylsilyl-2,2,3,3-tetradeuteropropionic acid  
TOVS   total obscuration of major vessel segments 
USG    ultrasonography 
VAS    visual analogue pain scale 
VLCD   very low calorie total meal replacement liquid diet 
VPS    ventriculoperitoneal shunt 
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1.1. Introduction to Idiopathic Intracranial Hypertension  
Idiopathic intracranial hypertension (IIH), formerly referred to as serous meningitis, 
pseudotumour cerebri or benign intracranial hypertension, is a condition of unknown 
aetiology characterised by elevated intracranial pressure (ICP) and papilloedema in the 
absence of intra-cerebral space occupation or venous sinus thrombosis (Friedman and 
Jacobson 2002). The previouse nomenclature of “benign” intracranial hypertensions was 
felt inappropriate in a condition where affected individuals suffer with significant 
morbidity from chronic headaches, together with progressive visual loss, which is severe 
and permanent in up to 25% of case (Corbett et al. 1982). Of particular interest is that IIH 
is almost exclusively diagnosed, greater than 93% of cases, amongst young obese female 
subjects (Giuseffi et al. 1991). The reasons for this association are unclear and will be 
discussed in more detail in section 1.5.  
The reported incidence of IIH is 0.9 to 2.2 per 100,000 in the general population (Durcan 
et al. 1988; Radhakrishnan et al. 1993), rising to above 19 per 100,000 in studies confined 
to young, overweight women. This background incidence is likely to increase further in 
developed countries with the epidemic of obesity.  
Despite the disability associated with IIH, the pathogenesis remains unidentified and an 
evidence base for treatment has not been established. This thesis, will explore the putative 
role of obesity, metabolic changes and glucocorticoid regulation, via 11β-hydroxysteroid 
dehydrogenase (11β-HSD), in ICP regulation and IIH.  The therapeutic role of weight loss 
in IIH will also be assessed and metabolic implications characterised. 
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1.2. Intracranial pressure homeostasis 
ICP homeostasis is dependent on cerebrospinal fluid (CSF) dynamics and cerebral blood 
circulating pressure.  ICP in turn influences the cerebral perfusion pressure (CPP) which 
controls cerebral blood flow (Miller et al. 1972), a vital determinant of viable brain tissue. 
CPP = mean arterial blood pressure – ICP 
As the fragile tissue of the brain is enclosed in a rigid cranium, relatively small changes in 
either CSF pressure or cerebral blood volume can significantly alter the ICP. In turn, 
fluctuations in ICP can have dramatic effects on cerebral blood volume through 
compression of the venous sinuses with consequential reduction in venous blood flow. 
Significantly impaired venous blood flow may contribute to venous infarction with 
resultant loss of brain function. Numerous pathological and physiological processes 
(space occupying lesion, obstructed CSF flow, jugular vein compression) can impair ICP 
homeostasis and result in either locally or globally impaired cerebral blood flow with 
potential implications for brain function. 
1.3. Cerebrospinal fluid dynamics 
CSF dynamics are dependent on the balance between CSF production and drainage. The 
brain is surrounded by approximately 150 ml of CSF (Praetorius 2007), this has two 
predominant functions. Firstly, to protect the brain from external mechanical trauma, and 
secondly, to provide a medium for the transfer of nutrients and waste products to and from 
the brain tissue. 80 % of the CSF is produced in the lateral, third and fourth ventricles by 
the choroid plexus (CP) (Welch 1963) with a smaller volume being produced by the 
ventricular ependyma, arachnoidal membrane and brain tissue itself (McComb 1983; 
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Adams and Graham 1988). CSF circulation is shown in Figure 1-1. CSF drains 
predominantly via the arachnoid granulation tissue (AGT) into the venous circulation. 
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ventricle
Interventricular foramen
Aqueduct of Sylvius
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Choroid plexus of 4th Ventricle
Arachnoid granulation
Venous flow
Dura matter
Subarachnoid space
Central canal of spinal cord
 
 
Figure 1-1 Sagittal section through the brain illustrating the circulation of 
cerebrospinal fluid. 
 CSF is secreted by the choroid plexus (1),  CSF then flows from the lateral 
and third ventricle through the aqueduct of Sylvius into the forth ventricle 
(2),CSF then passes into the cisterna magna via the bilateral foramen of 
Luschka and the midline foramen of Magendie (3). CSF in the cisterna 
magna is in continuity with the subarachnoid space and flows upwards 
over the cranium towards the arachnoid granulations (4), finally, CSF 
drains via the arachnoid granulations into the venous blood (5). The 
arrows indicate the direction of CSF flow. Reproduced and adapted with 
permission from McGraw-Hill Companies Inc, USA. 
 
There is evidence that CSF drainage can occur via sites other than the AGT. As long ago 
as 1869, it was suggested that CSF could drain via lymphatic channels (Schwalbe 1869) 
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and this has been demonstrated in a number of animal studies (McComb 1983). More 
recently, post-mortem subarachnoid injection of microfil has demonstrated the drainage of 
CSF via nasal lymphatics in large mammals, and also in one human (Johnston et al. 
2004). The precise pathway by which CSF enters the nasal lymphatics is unclear. In 
addition, the extent to which extra-arachnoid CSF drainage takes place needs to be 
established. 
1.3.1. Arachnoid granulation tissue 
AGT is continuous with the arachnoid membrane and projects into venous sinuses, 
predominantly at the superior sagittal sinus but also into veins associated with spinal 
nerve roots (Weller 1974) (Figure 1-2). 
Arachnoid granulation
Falx cerebri
Skin           
Periosteum
Bone of Skull
Periosteal layer and meningeal 
layer of dura matter             
Subdural space                         
Arachnoid       
Subarachnoid space
Pia matter
Cerebral cortex   
White matter
Superior sagittal sinus
 
Figure 1-2  Coronal section through the brain illustrating the location of arachnoid 
granulation tissue.  
 Reproduced and adapted from McGraw-Hill Companies Inc, USA (with 
permission). 
 
The number of arachnoid granulations (AG) varies with gender and ethnicity, being 
higher in men and in African Americans (Grzybowski et al. 2006a). By convention AGT 
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visible to the naked eye are known as AG’s (around 4 mm in diameter); arachnoid villi are 
smaller (Upton and Weller 1985). AGT increases in size with increasing age (Turner 
1961) and becomes more lobulated. Each AG is composed of four zones: an arachnoid 
cell layer, a cap cell cluster, a fibrous capsule and a central core (Kida et al. 1988) (Figure 
1-3). Arachnoid cells are mesothelial cells with both epithelial and fibroblastic 
characteristics.  Epithelial cells cover the AG and form a thickened layer at the apex of the 
granulation, the cap cell cluster. The cap cell cluster projects into the lumen of the venous 
sinus and is not covered by a fibrous, endothelial capsule (Kida et al. 1988).  
The central core of the AG is made up of arachnoid cells and connective tissue formed 
into multiple channels of variable diameter. The core contains no blood vessels or nervous 
tissue.   
It is thought that CSF travels through the honeycomb of channels to the venous sinus 
(Figure 1-4). In support of this, the channels  have been shown to contain red blood cells 
after subarachnoid haemorrhage (Upton and Weller 1985). Mechanisms which control 
CSF movement across the AG are not known. Vacuoles have been noted in the AG core 
from the basal to the apical region and it has been suggested that they may transfer fluid 
and proteins into the venous sinus (Tripathi and Tripathi 1974). 
Histological identification of AGT is facilitated by vimentin which stains both the cap cell 
cluster and the central core, while factor eight related-antigen (FVIII) localises 
exclusively to the AG endothelium, and epithelial membrane antigen to the cap cell 
cluster epithelium (Kida et al. 1988). 
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Figure 1-3 Schematic drawing of a human arachnoid granulation 
 CSF travels through the channels of the central core towards the apex of 
the arachnoid granulation and then into the venous sinus. The apex is 
composed of the cap cell cluster covered by a layer of epithelium, the 
arachnoid cell layer, which projects into the lumen of the venous sinus. A 
fibrous capsule encloses the granulation, except at the apex. Adapted and 
modified from Kida et al. J Neurosurgery 1988; 69:429-435. 
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Figure 1-4 Schematic diagram of a sagittal section through an arachnoid 
granulation 
 CSF flows through the connective tissue core to the epithelial cap cell 
cluster and then into the venous sinus. The mechanisms that control CSF 
flow across the connective tissue core and epithelial cap cell cluster are 
not known. 
 
1.3.2. Choroid plexus and cerebrospinal fluid secretion  
The dynamic circulation of CSF is driven by the secretion of CSF from the CP at the rate 
of 25 ml/h  (Wright 1978). The CP is one of the most efficient secretory tissues in the 
body (Speake et al. 2001). Macroscopically the CP is a branched structure of microvilli. 
Each villus is composed of a core of connective tissue and fenestrated capillaries 
surrounded by an epithelial monolayer (Figure 1-5).  The epithelial cells are joined by 
tight junctions at their apical surface; this arrangement forms the blood-CSF barrier. The 
epithelial cells of the CP are highly specialised in their orientation and structure. The 
apical surface is composed of a brush border facing into the ventricle, while the folded, 
basal surface, is orientated towards the capillary endothelium (Speake et al. 2001). 
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Figure 1-5 Haematoxylin and eosin stain of a choroid plexus villus 
The villus is composed of single layer of epithelial cells surrounding an 
abundant capillary net work and stromal cells. The villus projects into the 
cerebrospinal fluid filled ventricle. 
 
The initial step in CSF secretion is likely to be passive due to ultrafiltration of plasma 
from the leaky, fenestrated capillary network into the connective tissue stroma of the CP. 
Thereafter, CSF secretion is thought to be predominantly an active process. This is 
supported by the findings that 1) CSF is hypertonic compared to plasma (Table 1-1), 2) 
ion concentrations in the CSF remain stable despite wide fluctuations in plasma ion 
concentrations, 3) capillary pressure is insufficient to drive ultrafiltration and  4) there is 
an electrical potential difference of 5mV across the CP epithelium (Speake et al. 2001; 
Praetorius 2007). 
Chapter 1   
10 
 
 Plasma CSF 
Na+ (mM) 155 151 
K+ (mM) 4.6 3.0 
HCO3-(mM) 26.2 25.8 
Glucose 6.3 4.2 
Amino acids (mM) 2.3 0.8 
pH 7.4 7.4 
Osmolality (mosmol/Kg H2O) 300 305 
Protein (mg/100g) 6500 25 
Table 1-1 Comparison of CSF and plasma constituents in the dog. 
 Adapted from Davson et al. 1987. 
 
The process of CSF secretion from the CP epithelial cells is not fully characterised but is 
known to involve multiple ion channels on both the basal and apical surfaces of the CP 
epithelium.  Sodium ions are transported from the CP connective tissue across the CP 
epithelial cell and into the ventricular space containing CSF. This creates an osmotic 
gradient which pulls water into the ventricles. This process is analogous to fluid secretion 
in other epithelia e.g. saliva and sweat secretion (Speake et al. 2001), and was originally 
described in the shark rectal gland (Silva et al. 1977). Central to this process is the Na+K+ 
ATPase which is located exclusively on the apical surface of the CP epithelial cell (Ernst 
et al. 1986). This localisation is unusual, as in most other secretory epithelia, the Na+K+ 
ATPase is on the basal surface (Speake et al. 2001). The Na+K+ ATPase consists of 3 
subunits, which vary between tissues but in the CP consist of the α1, β1 and β2 subunits, 
in conjunction with a membrane spanning protein, phospholemman (Feschenko et al. 
2003). The importance of the Na+K+ ATPase is highlighted by the finding that ventricular 
application of ouabain, a Na+K+ ATPase inhibitor, completely abolishes Na+ influx and 
CSF secretion (Welch 1963; Davson and Segal 1970; Zeuthen and Wright 1978). 
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There is considerable interplay between numerous other ion transporters in the CP 
epithelial cells (Figure 1-6). The effects of these other ion transporters, on CSF secretion 
are illustrated by the ability of inhibitors to reduce CSF secretion. CSF secretion is 
impaired by bumetanide, via its actions on the Na+ K+  2Cl- co transporter (Wu et al. 
1998), frusemide, due to inhibition of the K+ Cl- co transporter (Zeuthen and Wright 
1981) and amiloride, due to inhibition of the basal Na+/H+ exchanger (Murphy and 
Johanson 1989), which is thought to control Na+ entry into the epithelial cell. In addition 
Cl- secretion is blocked by  4,4’-diisothiocyanatostilbene-2,2’-disulphonic acid   at the Cl-
/HCO3- transporter in the CP (Deng and Johanson 1989) 
Carbonic anhydrase, an enzyme which catalyses the reversible hydration of carbon 
dioxide (CO2 + H2O «to» H2CO3 «to» H+ + HCO3-) also has a role in CSF secretion. 
Twelve isoforms of carbonic anhydrase have been identified, which vary between tissues 
and species (Halmi et al. 2006). Carbonic anhydrase II has been localised to the 
cytoplasm of rat CP epithelial cells (Masuzawa and Sato 1983; Masuzawa et al. 1984) 
while carbonic anhydrase III has been identified in the lateral ventricle of  rat CP as well 
as in human CP epithelial cells (Nogradi et al. 1993). Acetazolamide, a carbonic 
anhydrase inhibitor, reduces CSF secretion in rats by 50% (Vogh et al. 1987), supporting 
the importance of this enzyme in CSF secretion. Acetazolamide does not inhibit carbonic 
anhydrase III, potentially explaining why it is only partially effective in inhibiting CSF 
secretion. The effects of acetazolamide on reducing CSF secretion and thus potentially 
ICP have lead to its widespread use in the treatment of patients with IIH. The use of 
acetazolamide in IIH has, however, been questioned, following the results of a 
randomised controlled study which failed to demonstrate clinical efficacy (Ball et al. 
2009a). 
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Aquaporins, small hydrophobic integral membrane proteins with the primary function of 
facilitating water transport, are also thought to have a role in CSF secretion (Speake et al. 
2001). 13 mammalian aquaporin channels have been identified and are expressed in both 
epithelium and endothelium involved in fluid transport, as well as in brain glia and 
adipocytes (Verkman 2009). There has been considerable recent interest in anti aquaporin 
4 antibodies due to their discovery in association with Devic’s disease, a multiple 
sclerosis (MS) variant (Lennon et al. 2004; Lennon et al. 2005). Within the CP, aquaporin 
1 and 4 have been identified in rat models (Nielsen et al. 1993; Venero et al. 1999) 
although the contribution of aquaporin channels to CSF production has not been studied.  
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Figure 1-6 Schematic representation of CSF secretion in the CP by ion transporters 
 ENaC indicates epithelial sodium channel, CA, carbonic anhydrase, AQP, 
aquaporin channel. 
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1.4. Pathogenesis of IIH  
1.4.1. What is known about the pathogenesis of IIH? 
Although the hallmark of IIH is raised ICP, the underlying aetiology of IIH is not known. 
Elevated ICP is likely to relate to abnormalities in the balance between production, by the 
CP, and drainage, primarily at the AGT, of CSF. Several possible mechanisms for the 
raised ICP have been postulated: increased CSF secretion, increased cerebral volume, 
increased CSF outflow resistance and increased cerebral venous pressure.  
1.4.2. CSF hypersecretion 
The first suggestion that CSF hypersecretion resulted in IIH was made over a century ago 
(Quincke et al. 1897) when alcohol, stress or changes in the weather were thought to lead 
to CSF hypersecretion and subsequent raised ICP. In 1979, ventricular infusion studies 
(which monitor CSF dilution and calculate the  rate of CSF production), demonstrated 
elevated CSF secretion in five patients with IIH (Donaldson 1979).  These findings were 
supported by velocity sensitive magnetic resonance imaging (MRI), a calculation of CSF 
flow, which also showed hypersecretion in IIH (Gideon et al. 1994). These studies, 
however, were confounded by small numbers and assumptions made in the mathematical 
modelling. Nevertheless the  observation that CSF protein levels are reduced in IIH 
supports the theory of CSF hypersecretion (Chandra et al. 1986), although low protein in 
IIH is not a universal finding (Johnston et al. 1991). In other conditions in which there is 
CSF hypersecretion, such as choroid plexus papilloma, hydrocephalus is a feature. The 
absence of hydrocephalus in IIH suggests that increased CSF secretion may not be a 
feature. Increased brain water content has been postulated as the cause of IIH but 
evidence, based on histology of brain biopsies and diffusion weighted MRI scanning, is 
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sparse (Gideon et al. 1995; Wall et al. 1995). In summary, the limited studies 
investigating CSF hypersecretion in IIH have been inconclusive but continues to be 
debated in the literature (Ball and Clarke 2006).  
1.4.3. Increased CSF outflow resistance 
Impaired CSF drainage is increasingly recognised as a probable cause of IIH. The 
majority of evidence to support this has come from CSF infusion studies which 
demonstrated reduced CSF drainage in IIH (Malm et al. 1992).  Studies scrutinising the 
transit time of a radio-labelled tracer injected into the CSF (cisternography) have 
demonstrated delayed uptake into the circulation in patients with IIH, implicating 
compromised CSF drainage (Orefice et al. 1992). These findings have not been 
universally replicated (Janny et al. 1981).  
The importance of CSF drainage in CSF dynamics is highlighted by observations of 
secondary intracranial hypertension in conditions such as Guillain Barré syndrome 
(Ropper and Marmarou 1984), spinal cord tumour (Feldmann et al. 1986), malignant / 
infective meningitis (Cremer et al. 1997) and subarachnoid haemorrhage (Kida et al., 
1988). These conditions are characterised by CSF hypercellularity or hyperproteinaemia 
which is believed to block the AGT, thereby restricting drainage and elevating CSF 
pressure. This has been shown histologically in cases of subarachnoid haemorrhage which 
demonstrate red blood cells obstructing the AGT core (Kida et al. 1988).  Elevated ICP is 
also noted in patients with AGT agenesis (Gilles and Davidson 1971; Gutierrez et al. 
1975). These observations emphasise the importance of AGT in CSF drainage and ICP 
homeostasis  
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1.4.4. Increased cerebral venous pressure 
There is considerable evidence from venography and manometry studies that venous sinus 
pressure is raised in IIH, particularly in the transverse and superior sagittal sinus 
(Karahalios et al., 1996) (King et al. 1995). In addition, focal cerebral venous stenoses 
have been reported in IIH patients (Higgins et al. 2004), and stenting the stenosed veins 
has been shown to improve symptoms in a few cases of IIH (Higgins et al. 2003; Rajpal et 
al. 2005). The underlying cause for the stenoses remains controversial and may represent 
either small venous sinus thromboses, congenital variations (Johnston et al. 2002), intra-
luminal septa (Subramaniam et al. 2004) or indentations from giant arachnoid 
granulations swollen by  raised ICP (Kollar et al. 2001). It is most likely, however, that 
the stenoses are a consequence of raised pressure, originating from brain parenchyma or 
the CSF compartment, on the venous system  (Farb et al. 2003).  This is substantiated in 
an elegant study by King et al in 2002 in which patients with IIH underwent cerebral 
venous manometry before and after a lumbar puncture (LP) (King et al. 2002). The 
pressure in the superior sagittal and transverse sinus, which was initially elevated, 
significantly reduced following LP, with subsequent reduction of CSF pressure and 
disappearance of the apparent venous stenoses. This study, and others, conclude that the 
cerebral venous stenoses and elevated venous pressure in IIH result from collapse of the 
venous sinus walls due to raised intracranial pressure, that is the stenoses occur as a 
secondary phenomenon and are not the primary cause of IIH (Goodwin 2003; McGonigal 
et al. 2004). It is also possible that the cerebral venous stenoses play an important role in 
aggravating IIH by further decreasing CSF drainage across the AGT and thus further 
increasing the CSF pressure (Pickard et al. 2008). 
 
Chapter 1   
16 
1.4.5. Other 
A number of other studies have highlighted possible aetiological factors in IIH. Elevated 
retinol has been identified in the CSF of patients with IIH (Warner et al. 2007). In 
addition, elevated ICP has been noted in individuals taking vitamin A containing drugs 
and following ingestion of vitamin A rich foods, such as polar bear liver (Rodahl and 
Moore 1943). Vitamin A has, therefore, been implicated in the pathogenesis of IIH, 
although the mechanism remains unclear.  Elevated plasma and CSF leptin levels have 
also been documented in patients with IIH (Lampl et al. 2002; Ball et al. 2009b). Leptin, 
an adipokine (cytokine predominantly secreted by adipose tissue), has a key role in 
appetite regulation (Klok et al. 2007) but its role in ICP regulation has not been studied. 
Microthrombi obstructing the AGT have been postulated as a cause of IIH with 
thrombophilic defects being reported in between 14 and 68% of patients with IIH 
(Sussman et al. 1997; Glueck et al. 2005), although a number of patients in these studies 
had underlying venous sinus thrombosis.  
In summary although raised ICP in IIH suggests disordered CSF dynamics, there is no 
consensus regarding the mechanism.  This thesis will, therefore, focus on the control of 
CSF dynamics via CSF secretion at the CP and drainage at the AGT.  
1.5. Obesity and IIH 
IIH is strikingly associated with obesity, 87.8 – 94% of patients with IIH being obese 
(Giuseffi et al. 1991; Wall and George 1991; Galvin and Van Stavern 2004). The 
incidence of IIH increases to between 19.3 and 21 per 100,000 in the obese population 
compared with 0.9 to 2.2 per 100,000 in the general population (Durcan et al. 1988; 
Ireland et al. 1990; Radhakrishnan et al. 1993).  
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The mechanism by which obesity causes IIH is debated. Obstructive sleep apnoea, a 
condition associated with obesity, leads to nocturnal hypercapnia, right heart failure and 
surges in intra-thoracic pressure which can elevate ICP particularly in the morning 
compared to the evening (Jennum and Borgesen 1989). It has also been suggested that 
pressure effects of centrally distributed adiposity elevate intra-abdominal pressure which 
subsequently elevates intra-thoracic pressure and cerebral venous pressure and finally ICP 
(Sugerman et al. 1995). This theory does not explain why despite ubiquitous elevation of 
intra-abdominal pressure in obese patients (Sugerman et al. 1997; Whiteley et al. 2006), 
only a small proportion of patients develop IIH. Furthermore, there is only a weak, non 
significant relationship between BMI and LP opening pressure (Whiteley et al. 2006). The 
current literature does not establish whether obesity in IIH represents cause or effect. In 
addition, these mechanisms do not explain the sexual dimorphism seen in IIH.  We 
therefore suggest that the relationship of IIH to obese patients strongly suggests that 
neuroendocrine dysfunction plays an important aetiological role in these patients. 
1.5.1. Obesity, glucocorticoids and 11β-HSD1  
The effects of glucocorticoids on body mass index (BMI) have long been recognised and 
are illustrated in Cushing’s syndrome; a condition characterised by central obesity and 
elevated plasma cortisol levels. Although patients with obesity are not characterised by 
elevated plasma cortisol (Fraser et al. 1999) there is growing evidence that dysfunctions 
of 11beta-hydroxysteroid dehydrogenase (11β-HSD1) may be pathological.  11β-HSD1, a 
cortisol activating enzyme which regulates intracellular cortisol availability, will be 
discussed in detail in section 1.8. 
Overexpression of  adipose 11β-HSD1 causes visceral obesity in mouse models 
(Masuzaki et al. 2001). In human idiopathic obesity, aberrant hepatic 11β-HSD1 activity 
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has been demonstrated using cortisol generation curves (administration of cortisone 
acetate following an overnight dexamethasone suppression test) (Stewart et al. 1999; Rask 
et al. 2001). Global 11β-HSD1 activity, determined from urinary tetrahydrocortisols 
(THF+5αTHF): tetrahydrocortisone (THE) ratios, are also disrupted in the obese, with 
reports of increased, unaffected and reduced activity (Marin et al. 1992; Andrew et al. 
1998; Rask et al. 2001; Reynolds et al. 2001). Microdialysis fluid from the subcutaneous 
tissue of obese patients shows enhanced 11β-HSD1 activity (Sandeep et al. 2005). 
Additionally, increased 11β-HSD1 mRNA expression has also been documented in 
subcutaneous (Paulmyer-Lacroix et al. 2002; Tomlinson et al. 2002; Goedecke et al. 
2006; Li et al. 2007; Michailidou et al. 2007; Paulsen et al. 2007) as well as visceral fat 
(Desbriere et al. 2006; Michailidou et al. 2007) from obese individuals. Increased 11β-
HSD1 activity in human subcutaneous adipose tissue, associated with altered lipid 
metabolism and insulin resistance (Veilleux et al. 2009),  have implicated 11β-HSD1 in 
the development the metabolic syndrome. Recombinant mice lacking 11β-HSD1 and 
therapeutic inhibition of the enzyme in man improves glucose tolerance and insulin 
resistance (Boyle and Kowalski 2009). 
These studies suggest that 11β-HSD1 is dysregulated in obesity and it is possible that 
dysregulation of 11β-HSD1 may contribute to IIH. Of note, weight loss has been shown 
to alter 11β-HSD1 activity and reduce glucocorticoid generation in human idiopathic 
obesity (Tomlinson et al. 2004b; Tomlinson et al. 2008) and, therefore, may represent a 
possible mechanism explaining the potential therapeutic effect of weight loss in IIH. 
1.5.2. Gender dimorphism in IIH and 11β-HSD1 
11β-HSD1 activity shows sexual dimorphism. Hepatic 11β-HSD1 activity was noted to be 
greater in male rats compared to female rats (Low et al. 1994). Studies of urinary 
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metabolites  in humans identified higher 11β-HSD1 activity in males compared to females 
after puberty (Low et al. 1994; Dimitriou et al. 2003). This gender discrepancy may be 
due to inhibitory affects of estradiol on 11β-HSD1. Estradiol has been shown to inhibit 
11β-HSD1 in rat liver, kidney and testis, although in other tissues such as the uterus and 
endometrium this is not the case (Arcuri et al. 1997; Ho et al. 1999; Nwe et al. 2000; 
Gomez-Sanchez et al. 2003). Testosterone can also inhibit 11β-HSD1 as described in the 
rat testis (Nwe et al. 2000). These studies indicate that sexual dimorphism in 11β-HSD1 is 
likely due to a more complex mechanism than simply inhibition by sex steroids, although 
they may well be an important factor.   
Aberrant sex hormone metabolism is suggested in IIH, as patients are almost universally 
female (female to male ratios ranging from 4:1 to 15:1) (Durcan et al. 1988; 
Radhakrishnan et al. 1993)  and of reproductive age (with the mean age of onset being 28 
– 35) (Galvin and Van Stavern 2004; Glueck et al. 2005). It is possible that the 
suppression of 11β-HSD1 activity normally seen in women may be lost in IIH as a result 
of abnormal sex hormone metabolism.  
1.6.   IIH and endocrinopathies 
Numerous case reports have linked IIH to endocrinopathies (Table 1-2) and 
glucocorticoid therapy (Table 1-3)(Kiehna et al. 2010). There is also a strong association 
with polycystic ovarian syndrome (PCOS), 39 – 57% of patients with IIH having PCOS 
(the background risk in the general population is 7-15% (Glueck et al. 2003; 
Tsilchorozidou et al. 2004; Glueck et al. 2005)). 27% of these patients have significant 
hyperandrogenism (Glueck et al. 2005) and it is possible, therefore, that 
hyperandrogenism may be pathological in IIH.  IIH is, however, typically a disease 
related to females and therefore an oestrogen and progesterone dominated hormone 
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profile may be more important. PCOS has also been linked to an increase in 11β-HSD1, 
demonstrated both in mRNA expression from adipose tissue (Svendsen et al. 2009) as 
well as from urinary metabolites (Vassiliadi et al. 2009). Additionally, some patients have 
been reported to have concomitant defects in both the 11β-HSD1 and H6PDH genes 
(Draper et al. 2003) although this has not been confirmed in more recent studies (Draper 
et al. 2006; Smit et al. 2007). The potential relationship between PCOS and IIH will be 
discussed further in section 5.4.3. 
 
Disorder Number 
of cases 
Reference 
Cushing's disease/ 
syndrome 
9 (Britton et al. 1980; Newman et al. 1980; Kiehna et al. 
2010) 
Adrenal hyperplasia 1 (De Campo et al. 1988) 
Primary aldosteronism  2 (Weber et al. 2002) 
Addison’s disease 1 (Condulis et al. 1997) 
Hypothyroidism 1 (Serratrice et al. 2002) 
Growth Hormone 6 (Crock et al. 1998; Clayton and Cowell 2000; Reeves and 
Doyle 2002) 
Hypoparathyroidism 1 (Madan Mohan et al. 1993) 
ACTH deficiency 1 (Aanderud and Jorde 1988) 
Oral contraception 2 (Janzik 1973; Ivancic and Pfadenhauer 2004) 
Pregnancy 2 (Elian et al. 1968; Gumma 2004) 
Table 1-2 Case reports of endocrinopathies associated with IIH 
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Treatment Number of 
cases  
Reference 
Corticosteroid therapy 1 (Valentine 1959) 
1 (Dees and Mc 1959) 
1 (Dees and Mc 1959) 
1 (Lorenzo and Avellanal 1961)  
4 (Walker and Adamkiewicz 1964) 
1 (Ivey and Denssesten 1969) 
1 (Jewell 1972)   
1 (Vyas et al. 1981) 
1 (Pampapathi and Kabuubi 1987)  
1 (Lucas et al. 1991)  
2 (Newton and Cooper 1994)  
1 (Lorrot et al. 1999)   
1 (Chebli et al. 2004)   
Chronic corticosteroid withdrawal 5  (Greer 1963)  
1 (Hosking and Elliston 1978) 
4  (Liu et al. 1994)  
1 (Saigusa et al. 2002) 
Table 1-3 Case reports of IIH attributed to corticosteroid therapy 
 
1.7. Summary 
IIH, a condition of raised ICP, results from disordered CSF dynamics but detailed 
understanding of the role of CSF secretion and drainage are still debated. Additionally, 
the association between obesity, female gender and CSF balance in IIH are not 
understood. Dysregulation of 11β-HSD1 has been established in idiopathic obesity and 
may also have a role in the pathogenesis of IIH and ICP regulation at the CP and AGT. 
1.8. Corticosteroids and 11B-HSD1  
1.8.1. Corticosteroids 
Corticosteroids, encompassing glucocorticoids and mineralocorticoids, are steroid 
hormones. Steroidogenesis occurs as a result of cholesterol being converted, initially, to 
pregnenolone by cytochrome p450 side chain cleavage enzyme (Farkash et al. 1986) 
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within the mitochondrion. Pregnenolone is then converted to progesterone and thereafter 
hydroxylated to either 11β-deoxycorticosterone, which is further metabolised to form 
aldosterone or 17α-hydroxyprogesterone, the latter being further converted to cortisol via 
21-hydroxlase and 11β-hydroxylase ( 
Figure 1-7). The synthesis of cortisol occurs within the middle layer of the adrenal cortex. 
 
Pregnenolone
Progesterone 17α-OH-Progesterone
3β-HSD2
Cholesterol
11-Deoxycortisol
Cortisol
CYP11B1
P450scc
CYP21A2CYP17A1
 
 
Figure 1-7  Summary of cortisol synthesis 
Cholesterol is converted to pregnenolone by P450 side chain complex 
(P450scc) in association with steroidogenic acute regulator protein. 3β-
hydroxysteroid dehydrogenase 2 (3β-HSD2) then converts pregnenolone to 
progesterone which is then metabolised to 17α-hydroxyprogensterone 
(17α-OH-Progesterone) by 17α-Hydroxylase (CYP17A1). Further 
hydroxylation at carbon 21 (by 21-hydoxylase (CYP21A2)) and carbon 11 
(by 11β-hydroxylase (CYP11B1)) produces cortisol.  
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The hypothalamic pituitary adrenal (HPA) axis regulates the secretion of cortisol from the 
adrenal cortex (Papadimitriou and Priftis 2009). Corticotrophin releasing hormone (CRH) 
is released from parvocellular neurons of the paraventricular nucleus of the hypothalamus, 
influenced by (1) negative feedback from systemic cortisol levels, (2) cytokine signals, (3) 
neural signalling, including emotional responses regulated by the limbic system and (4) 
circadian oscillations, regulated by the suprachiasmatic nucleus (Moore and Silver 1998). 
CRH stimulates the release of adrenocorticotrophic hormone (ACTH) from the anterior 
pituitary which in turn drives cortisol synthesis in the adrenal cortex. The action of CRH 
is potentiated by arginine vasopressin, also produced by the hypothalamus. Circulating 
cortisol exerts negative feedback on the release of CRH and ACTH. The circadian 
secretion of cortisol ensures peak levels following a period of sleep, in preparation for a 
metabolically active awake period (06:00 – 08:00 am in humans). Levels then reach a 
nadir when returning to sleep (24:00 in humans). 
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Figure 1-8  Hypothalamic pituitary adrenal regulation of cortisol homeostasis 
Corticotropin releasing hormone (CRH), potentiated by arginine 
vasopressin (AVP) drives the release of adrenocorticotrophic hormone 
(ACTH) from the anterior pituitary gland which stimulates the synthesis 
and secretion of cortisol from the adrenal cortex. Cortisol, in turn, exerts 
negative feedback on CRH and ACTH release. 
 
The majority of the secreted cortisol (90-95%) is transported in the blood bound to plasma 
protein, corticosteroid-binding globulin (CBG). Only 5-10% of cortisol remains unbound, 
“free”, and represents the biochemically active fraction (Hammond 1990; Breuner and 
Orchinik 2002). Approximately 1% of free cortisol is excreted by the kidneys. 
Glucocorticoids have widespread effects on every system of the body and multiple 
mechanisms of action including potent anti-inflammatory properties, driving hepatic 
gluconeogenesis and regulating adipocyte differentiation (Tomlinson et al. 2004b).  
Hypothalamus
paraventricular nucleus 
ACTH
CortisolAdrenal cortex 
negative 
feedback 
CRH
Anterior pituitary
AVP 
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1.8.2. Glucocorticoid signalling 
Unbound glucocorticoid exerts effects via either genomic or non-genomic pathways. 
Genomic signalling is thought to predominate over the rapid, seconds to minutes non-
genomic signalling although much controversy remain about the precise mechanisms and 
roles of non genomic signalling (Losel et al. 2003). 
Glucocorticoid genomic signalling occurs predominantly via the glucocorticoid receptor 
(GR), but also through the mineralocorticoid receptor (MR), both members of the nuclear 
receptor super-family. Activation typically occurs within  15–30 minutes of ligand 
binding, although continuous ligand exposure can activate the receptor for days (Datson et 
al. 2008). These receptors have differing ligand binding affinity (MR has a 10-fold higher 
affinity for corticosteroids than the GR (Reul and de Kloet 1985), tissue localisation and 
effects. The GR is almost ubiquitously expressed, whereas the MR is more selectively 
expressed, in both epithelial and non epithelial tissues. In epithelial tissues, aldosterone 
predominantly binds to the MR, however, in non epithelial tissues, glucocorticoids also 
bind to the MR (Odermatt and Atanasov 2009).  In these non epithelial tissues,  such as 
the brain, the MR binds low concentrations (basal levels) of glucocorticoid continuously 
whereas the GR binds glucocorticoid only at peak circulating levels (van Steensel et al. 
1996). The majority of glucocorticoid actions are, however, mediated via the lower 
affinity GR. 
 GR (nuclear receptor family 3, group C, class1) has two main isoforms resulting from 
alternate splicing of a single gene transcript (Hollenberg et al. 1985) although a number of 
other splice variant have also been described (Beck et al. 2009). Glucocorticoid receptor 
alpha (GRα) has  higher affinity for exogenous dexamethasone and endogenous cortisol 
than for mineralocorticoids and progesterone (Beato and Klug 2000). The sparsely 
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expressed glucocorticoid receptor beta (GRβ) does not bind hormones evaluated thus far 
(Oakley et al. 1996) but can bind to the nuclear glucocorticoid response element and act 
as a dominant negative inhibitor of GC function (Bamberger et al. 1995). This may be 
important in modulating tissue sensitivity to GC’s, potentially mediating GC resistance 
particularly in inflammatory diseases (van der Vaart and Schaaf 2009). In support of this 
elevated mRNA expression of GRβ has been demonstrated, in conjunction with relative 
glucocorticoid resistance, in patients with asthma (Goleva et al. 2006), ulcerative colitis 
(Honda et al. 2000), Crohn’s disease (Towers et al. 2005) and nasal polyposis (Hamilos et 
al. 2001). 
 The GR is composed of a central DNA binding region (C domain), which targets the 
receptor to the hormone response element, and a ligand binding region (E domain), which 
switches the receptor’s function (Beato 1989) (Figure 1-9).  
 
 
Figure 1-9 The domain structure of the human glucocorticoid (GR) and 
mineralocorticoid (MR) receptors and isoforms 
 The numbers refer to amino acid positions. Domain C is the DNA binding 
domain, domain E the ligand binding domain. The two isoforms of the GR 
are identical until amino acid 727 where after they differ with GRα being 
longer. 
 
The un-stimulated GR resides in the cytoplasm. The receptor is maintained in a functional 
but inactive state, by forming complexes with chaperones such as Heat Shock Protein 
A/B C D E FDomains
421 532 727
777 GRα
421 532 727
742 GRβ
603 738 965
984 MR
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(HSP)-90KD and  HSP-70 KD, as well as a multiprotein complex (p59 immunophilin, 
FKBP2 and p23) (Pratt and Toft 1997). Lipophilic steroid hormones pass through the 
plasma membrane by simple diffusion to bind the GR. A conformational change then 
occurs which decouples the chaperones and protein complex, exposing nuclear 
localisation signals which allow the GR to translocate to the nucleus.  The C domain of 
the nuclear GR binds, as a homodimer, to a section of DNA known as the glucocorticoid 
response element (GRE). This process is referred to as dimerisation as the GRE has a 
partially pallendomic nucleotide sequence to the GR C domain. Nuclear location is 
stabilised by Small Ubiquitin Related Modifier-1 (SUMO-1)(Tian et al. 2002). Gene 
transcriptional activation (transactivation) then typically occurs and can be further 
modified following interactions with histone-modifying enzymes and cofactors 
(coactivators and corepressors) (Newton and Holden 2007). In addition to homodimer 
ligand binding, glucocorticoids can also form heterodimers by binding to both the GR and 
MR in tissues where the receptors co-localise, for example the hippocampus. 
Heterodimerisation potentially fine tunes glucocorticoid regulation (Liu et al. 1995). 
The GR can also regulate gene transcription through binding as a monomer (Reichardt 
and Schutz 1998). Typically this leads to inhibition of gene transcription 
(transrepression). This is thought to be particularly important in driving the anti-
inflammatory effects of GC’s, where the effectiveness of GC’s relies on their ability to 
reduce gene expression (Newton and Holden 2007). In this situation transrepression of the 
anti-inflammatory transcription factors, nuclear factor ⱪB (NF-ⱪB) and activator protein 1 
(AP1) are thought to be important (De Bosscher et al. 2003) although the precise 
mechanism of gene repression is still debated (Glass and Ogawa 2006). 
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1.8.3. 11β-hydroxysteroid dehydrogenase 
In peripheral tissues, corticosteroid hormone availability is regulated at a pre-receptor 
level by 11β-hydroxysteroid dehydrogenase (11β-HSD), a bidirectional enzyme which 
resides in the endoplasmic reticulum. 11β-HSD, originally identified over 50 years ago 
(Amelung et al. 1953), has two isozymes: 11β-HSD1, which acts predominantly as an 
oxoreductase in vivo, activating cortisol from cortisone, and a dehydrogenase, 11β-HSD2, 
which inactivates cortisol to cortisone.  
1.8.3.1. 11β-HSD2 
 In tissues such as the kidney, salivary glands, colon and placenta, the high affinity 11β-
HSD2 isozyme is abundantly expressed (Shimojo et al. 1997). In the renal collecting 
ducts 11β-HSD2  expression protects the mineralocorticoid receptor (MR) from 
glucocorticoid excess, mediating sodium reabsorption from the urine (Stewart and 
Krozowski 1999) (Figure 1-10). Inherited deficiency in 11β-HSD2 causes hyper-
stimulation of the MR by cortisol with subsequent elevated sodium resorption and 
potassium excretion.  This results in the syndrome of apparent mineralocorticoid excess 
which is characterised by hypertension (Stewart et al. 1988). Inhibitors of 11β-HSD such 
as liquorice, carbenoxolone and glycyrrhetinic acid have similar hypertensive effects. 
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Figure 1-10 Schematic diagram illustrating corticosteroid regulation of sodium 
reabsorption in the human kidney 
 11β-HSD2 inactivates cortisol to cortisone allowing aldosterone (Aldo) to 
bind to the mineralocorticoid receptor (MR) and consequently sodium 
(Na+) reabsorption from the urine. (ENaC, epithelial sodium channel) 
 
1.8.3.2. 11β-HSD1 
The type 1 isoform is a distinct entity to 11β-HSD2, sharing only 14% sequence 
homology (Stewart and Krozowski 1999). The 11β-HSD1 gene localises to Chromosome 
1 (1q32.2) and is 30 Kb in size consisting of 6 exons and 5 introns (Tannin et al. 1991; 
Draper et al. 2002). 11β-HSD1 has a lower affinity for steroids than 11β-HSD2 and acts 
predominantly as an oxoreductase in vivo and in intact cells but can function as a 
dehydrogenase in cellular homogenates (Lakshmi and Monder 1988; Bujalska et al. 
1997).  
Recent work has highlighted the importance of hexose-6-phosphate dehydrogenase 
(H6PD) in influencing the directionality of 11β-HSD1. H6PD is an enzyme located in the 
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endoplasmic reticulum, which converts glucose-6-phosphate to 6-phospho-gluconolactone 
generating reduced nicotinamide adenine dinucleotide phosphate (NADPH) from NADP+.  
NADPH drives 11β-HSD1 oxoreductase activity (Bujalska et al. 2005). There are 
numerous other compounds which regulate 11β-HSD1 including glucocorticoids, sex 
hormones, vitamin D and cytokines. The effects of these regulators are not straight 
forward and like the function and expression of 11β-HSD1, varies between tissues and 
species (Tomlinson et al. 2004b; Chapman and Seckl 2008). For example, oestrogen 
reduces rodent 11β-HSD1 activity in the liver, testis and kidney (Low et al. 1993; Nwe et 
al. 2000; Gomez-Sanchez et al. 2003) but not in the hippocampus, uterus or endometrium 
(Arcuri et al. 1997; Ho et al. 1999; Chapman and Seckl 2008). 
Oxo-reductase
NADPH dependent
11β-HSD 1
Dehydrogenase
NAD dependent
11β-HSD 2
Cortisone 
Inactive
Cortisol
active
O
O
OH
CH3
CH 3
CH 2OH
C
O
O
CH 3
CH 3
CH 2OH
C
OHOH
O
 
Figure 1-11  11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) metabolism 
11β-HSD1 activates cortisone to cortisol while 11β-hydroxysteroid 
dehydrogenase type 2 (11β-HSD2) inactivates cortisol to cortisone.  11β-
HSD1 activity is driven by the co factor nicotinamide adenine dinucleotide 
phosphate (NADPH) provided by hexose-6-phosphate dehydrogenase. 
NAD indicates nicotinamide adenine dinucleotide. 
 
11β-HSD1 was originally characterised in the liver but is widely expressed in other 
glucocorticoid target tissues such as the adipose, lung, bone, muscle, heart, lymphoid 
tissues, and the central nervous system (Moisan et al. 1990; Whorwood et al. 1992; Cai et 
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al. 2001; Tomlinson et al. 2004b; Jang et al. 2009) as well as in immune cells (Thieringer 
et al. 2001; Zhang et al. 2005; Hardy et al. 2006).  
In humans, the principle roles of 11β-HSD1 are in mediating hepatic gluconeogenesis and 
in regulating adipocyte differentiation. In humans, a defect of 11β-HSD1, known as 
apparent cortisone reductase deficiency (ACRD), has been described in 11 patients. These 
cases present with hyperandrogenism in females and precocious puberty in males as well 
as obesity in some cases (Phillipov et al. 1996; Jamieson et al. 1999; Tomlinson et al. 
2004b). A recent series of four patients with ACRD were found to have inactivating 
mutations in H6PD, potentially preventing oxoreductase activity of 11β-HSD1 (Lavery et 
al. 2008). 11β-HSD1 knock-out mice reflect reduced glucocorticoid actions with 
enhanced insulin sensitivity, reduced hyperglycaemia and an improved lipid profile 
(Kotelevtsev et al. 1997; Morton et al. 2001). In contrast the mice over-expressing 11β-
HSD1 in adipose tissue, demonstrate features of the metabolic syndrome with 
hyperglycaemia, dyslipideamia, hypertension and visceral obesity (Masuzaki et al. 2001; 
Masuzaki et al. 2003). This metabolic phenotype is less apparent in mice with hepatic 
over-expression of 11β-HSD1 (Paterson et al. 2004). 
Within the CNS, research to date has focused on the importance of 11β-HSD1 in 
mediating mood and memory. An increase in cortisol exposure has been linked to 
cognitive decline and Alzheimer’s disease (Meaney et al. 1995). In mouse models, 
elevated cortisol levels increase the pathological hallmarks of Alzheimer’s disease 
(amyloid β-peptide and tau protein) (Green et al. 2006) and impair cognition (Issa et al. 
1990). Adrenalectomy reduces age related cognitive decline in rats (Landfield et al. 
1978). Glucocorticoid mediated effects on memory are thought to occur via the 
hippocampus, a site of high expression of 11β-HSD1, GR and MR (Moisan et al. 1990). 
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11β-HSD1 expression has also been demonstrated in the rodent hypothalamus, parietal 
cortex, anterior pituitary and cerebellum with lower levels in the brain stem, pre-optic 
nucleus and amygdale (Moisan et al. 1990; Lakshmi et al. 1991; Whorwood et al. 1995; 
Jellinck et al. 1999). In keeping with cortisol mediating memory loss through 
hippocampal damage, patients with Cushing’s syndrome demonstrate  memory deficits in 
the context of hippocampal shrinkage (Starkman et al. 1992) and primates exposed to 
chronic glucocorticoids develop hippocampal atrophy (Sapolsky et al. 1990). The role of 
11β-HSD1 in mediating memory loss and hippocampal atrophy is supported by data 
demonstrating that inhibition of 11β-HSD1 in cultured hippocampal cells reduced 
glucocorticoid induced neurotoxicity (Rajan et al. 1996) and additionally, improved 
cognition in humans (Sandeep et al. 2004).  
In line with its widespread distribution, 11β-HSD1 has multiple other physiological and 
pathological roles, discussion of which is beyond the limits of this thesis. This thesis will 
focus on the role of 11β-HSD1 in obesity and fluid dynamics. 
1.8.3.3. 11β-HSD inhibitors  
Most inhibitors of 11β-HSD are non specific and consequently inhibit both the type 1 and 
type 2 isoforms of 11β-HSD. Inhibitors include the naturally occurring bile acids 
(lithocholic acid and Chenodeoxycholic acid), liquorice, glycyrrhetinic acid (GE) and the 
anti-diabetic drug, arylsulfonamidothiazole (Tomlinson et al. 2004b). 11β-HSD1 
inhibition, coupled with the insulin sensitising properties of arylsulfonamidothiazole 
derivatives highlighted the potential for 11β-HSD1 inhibitors in diabetic therapy and has 
lead to the development of more selective 11β-HSD1 inhibitors (Boyle and Kowalski 
2009). To date, rodent studies have confirmed benefit of 11β-HSD1 inhibition in treating 
the metabolic syndrome (obesity, insulin resistance and hyperlipidaemia) (Lloyd et al. 
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2009) (Berthiaume et al. 2009) and potentially promoting weight loss (Berthiaume et al. 
2007). Additionally, 11β-HSD1 inhibition in a mouse model of atherosclerosis, reduced 
aortic plaque formation (Hermanowski-Vosatka et al. 2005). 
Study of the effect of 11β-HSD1 inhibitors in humans is currently underway (Webster et 
al. 2007; Bujalska et al. 2008), with a number of patents being issued in this area (Boyle 
and Kowalski 2009). Initial studies of the selective 11β-HSD1 inhibitor, INCB013739 
(Incyte Corporation, Wilmington, DE, USA), have shown the drug to be well tolerated 
and safe in patients with type 2 diabetes, whilst significantly improving insulin sensitivity 
and lipid profiles (Rosenstock et al. 2009). INCB013739 is currently being studied in 
phase 2 clinical trials in type 2 diabetes. Although much interest has focused on the anti-
metabolic and anti-obesity potential of 11β-HSD1 inhibition, there may be wider 
advantages in other glucocorticoid mediate conditions, including the treatment of 
osteoporosis, glaucoma, muscle atrophy as well as potentially enhancing wound healing 
and modifying the detrimental effects of elevated cortisol on cognition (Cooper et al. 
2002; Rauz et al. 2003a; Sandeep et al. 2004; Small et al. 2005).  
There are, however, a number of possible complications of 11β-HSD1 inhibition and 
consequent reduced cortisol generation (Cooper and Stewart 2009). Reduced tissue 
cortisol generation may induce stimulation of the HPA axis, which could in turn increase 
adrenal androgen secretion, potentially virilising women. Recent clinical data 
demonstrated that a 12 week course of the 11β-HSD1 inhibitor INCB013739, 
significantly elevated ACTH levels, in the context of normal salivary cortisol levels, while 
androgen levels only marginally increased (Rosenstock et al. 2009). There are also 
concerns regarding the potential pro-inflammatory actions of 11β-HSD1 inhibitors, 
particularly with chronic exposure (Chapman et al. 2009). Additionally, the clinical 
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impact of H6PD, a known modulator of 11β-HSD1 inhibitor efficacy, needs evaluating 
(Balazs et al. 2009). 
1.9. Corticosteroids and ocular fluid dynamics 
Aqueous humour (AH), a transparent fluid, circulates in the eye providing nutrition to 
avascular structures such as the cornea. AH is produced by the ciliary body and circulates 
from the posterior to the anterior segment of the eye after which it is drained via the irido-
corneal angle (see section 1.9.3). The circulation of AH is vital in maintaining intraocular 
pressure (IOP). The dynamic balance, formed by the production and drainage of AH, is 
comparable to the regulation of ICP via the secretion and resorption of CSF. The ocular 
ciliary body is composed of two opposing apical epithelia, the pigmented epithelium (PE) 
and the non-pigmented epithelia (NPE) which function as a syncytium.  Sodium ions are 
drawn across the epithelia from the PE to the NPE from where they are secreted by the 
Na+K+ATPase pump. The ion shift causes an osmotic gradient which drives water into the 
posterior segment of the eye creating AH. This sodium dependant mechanism of fluid 
secretion is akin to the mechanism of CSF secretion by the embryonic-related CP (see 
section 1.3.2).  
1.9.1. The role of corticosteroids in aqueous humour production 
In the ciliary epithelium, 11β-HSD1 has been demonstrated to have a role in the control of 
AH production (Rauz et al. 2001).  Cortisol generation within the ciliary body, with 
subsequent up-regulation of transcriptions factors such as serum and glucocorticoid 
regulated kinase (sgk-1) and stimulation of epithelial sodium transport, causes a net 
movement of Na+ ions into the posterior chamber of the eye and production of AH. 
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Inhibition of 11β-HSD1 at this site reduces intraocular pressure by 15-20% (Rauz et al. 
2003a) (Figure 1-12).  
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Figure 1-12 Schematic diagram illustrating corticosteroid regulation of sodium 
transport in the human ocular ciliary epithelium 
Cortisone is converted to active cortisol in the non-pigmented epithelium 
by 11β-HSD1. Subsequent activation of the mineralocorticoid receptor 
(MR)/ glucocorticoid receptor (GR) drives epithelial sodium channels 
(ENaC), via the serum and glucocorticoid regulated kinase 1 (sgk-1), and 
Na+/K+ATPase pumps. The osmotic gradient consequently created across 
the basolateral boarder of the non-pigmented epithelium promotes aqueous 
humour production. 
 
1.9.2. Potential role of corticosteroids in CSF production 
It is possible that in the CP epithelium an 11β-HSD1-dependent mechanism, akin to that 
occurring in the embryologically related ocular ciliary body, may regulate CSF production 
(Figure 1-13). 
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Figure 1-13 Proposed schemata for the corticosteroid regulation of CSF secretion in 
the human choroid plexus epithelium 
In an analogous mechanism to the ciliary epithelium above, cortisone is 
converted to active cortisol in the choroid plexus epithelium by 11β-HSD1. 
Subsequent activation of the mineralocorticoid receptor (MR)/ 
glucocorticoid receptor (GR) drives epithelial sodium channels (ENaC), 
via the serum and glucocorticoid regulated kinase 1 (sgk-1), and 
Na+/K+ATPase pumps. The osmotic gradient consequently created across 
the apical boarder of the choroid plexus epithelium promotes secretion of 
CSF. 
 
1.9.3. The role of corticosteroids in aqueous humour drainage 
In the eye, AH is drained via either the uveoscleral pathway or the trabecular meshwork 
(TM). The uveoscleral pathway involves fluid diffusing out of the anterior chamber of the 
eye between the fibres of the ciliary muscle. However, the majority of AH is thought to 
drain via the TM (Llobet et al. 2003), a reticular tissue composed of extracellular matrix.  
The AH then passes into Schlemm’s canal and thereafter in to the aqueous veins. The TM 
is composed of 3 layers of connective tissue which increase in density near the canal of 
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Schlemm. The AH traverses the inner endothelial wall of the TM into the canal of 
Schlemm via intercellular or intracellular routes (Llobet et al. 2003).  
Glaucoma, a condition attributed to elevated intra ocular pressure (IOP), is thought to 
result principally from a disruption to drainage of AH at the TM (Tan et al. 2006). This is 
likely to involve alteration of the TM extracellular matrix, increasing resistance to AH 
drainage. In support this , AH flow is impeded in cultured TM cells and tissue perfused 
with dexamethasone due to increased cross-linked actin networks in the TM (Clark et al. 
2005). This is particularly relevant when considering the mechanism of corticosteroid 
induced glaucoma.  
Myocilin (MYOC), also known as trabecular meshwork-induced glucocorticoid 
responsive protein (TIGR) is implicated in glaucoma. Mutations in the myocilin (MYOC) 
gene have been detected in 4% of adult onset primary open angle glaucoma (POAG) and 
in most cases of juvenile POAG (Wiggs et al. 1998).  The exact mechanism of MYOC 
induced glaucoma is poorly defined. Dexamethasone induces the MYOC gene (Ishibashi 
et al. 2002) and TM cells are known to secrete MYOC in response to glucocorticoid 
stimulation.  The mechanism by which MYOC obstructs ocular drainage at the TM is 
debated: Secreted MYOC may obstruct the TM (Polansky et al. 1997), the mutant MYOC 
may be toxic to TM cells (Zillig et al. 2005), myocilin may alter the function of TM cells 
(Jacobson et al. 2001), or alternatively MYOC could alters the structure of associated 
microfibrils in the extracellular matrix of the TM (Ueda et al. 2002). 
In this thesis we propose that a mechanism analogous to that observed in the TM may 
occur in the AGT, the site of CSF drainage. Here paracrine actions of glucocorticoids on 
the AGT may induce MYOC expression impeding CSF drainage (Figure 1-14). 
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Figure 1-14 Schematic diagram of an arachnoid granulation epithelial cell 
illustrating the proposed mechanism by which glucocorticoids could 
impede CSF drainage 
1) Secretion of soluble myocilin in the AG core could form a mechanical 
block. 2) Cross linking of fibres in the AG core could restrict CSF flow. 3) 
Toxic effects of myocilin on the AG may disrupt CSF flow. GAG’s indicates 
glycosaminoglycans, GR/MR, the glucocorticoid /mineralocorticoid 
receptor. 
 
1.10. Diagnosis of IIH 
IIH is diagnosed in the setting of elevated ICP with normal neurological imaging. The 
diagnostic criteria were initially suggested by Dandy (Dandy 1937), but these were later 
revised to the modified Dandy Criteria (Smith 1985) and then to the updated modified 
Dandy criteria (Friedman and Jacobson 2002) (Table 1-4). These diagnostic criteria are 
limited as they fail to highlight the importance of universally excluding venous sinus 
thrombosis, using MRV or CT venography. In addition the criteria fail to define a cut-off 
for elevated CSF opening pressure, an issue recently addressed by Whiteley (Whiteley et 
al. 2006). Throughout this thesis we have used the updated modified Dandy criteria 
(Friedman and Jacobson 2002) to diagnose IIH with the refinements that all patients had 
MRV, to exclude a venous sinus thrombosis, and additionally had ICP greater than 25 
cmH2O. 
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1. If symptoms present, they may only reflect those of generalized intracranial hypertension or 
papilloedema.  
2. If signs present, they may only reflect those of generalized intracranial hypertension or papilledema. 
3. Documented elevated intracranial pressure measured in the lateral decubitus position. 
4. Normal CSF composition. 
5. No evidence of hydrocephalus, mass, structural, or vascular lesion on MRI or contrast-enhanced CT 
for typical patients, and MRI and MR venography for all others. 
6. No other cause of intracranial hypertension identified. 
 
Table 1-4 Updated modified Dandy criteria for the diagnosis of IIH 
Reproduced from (Friedman and Jacobson 2002). Magnetic resonance 
imaging (MRI), computerised tomography (CT). 
 
A number of other conditions can mimic IIH. These secondary forms of IIH need to be 
distinguished from primary IIH as the underlying pathophysiology and treatments are 
very different (Table 1-5). This thesis will focus solely on the primary forms of IIH. 
 
Venous sinus thrombosis (Karahalios et al. 1996) 
Anaemia (Biousse et al. 2003) 
Obstructive sleep apnoea (Asensio Sanchez et al. 2004) 
Drug related (antibiotics, non–steroidal anti-inflammatory drugs, 
vitamin A, lithium, cimetidine) 
(Ball and Clarke 2006) 
Guillain Barré syndrome (Ropper and Marmarou 1984) 
CSF hyperprotinaemia or hypercullularity (spinal cord tumour, 
malignant meningitis) 
(Ridsdale and Moseley 1978; 
Feldmann et al. 1986; Cremer et al. 
1997) 
Table 1-5 Secondary causes of elevated intracranial pressure 
 
1.11. Treatment of IIH 
Effective treatment strategies in IIH have not been established and a recent Cochrane 
review concluded that there was insufficient evidence to determine which treatments were 
potentially beneficial and which were potentially harmful (Lueck and McIlwaine 2002; 
Lueck and McIlwaine 2005).  
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1.11.1. Medical therapies 
Drugs used to treat IIH aim to reduce CSF production. Carbonic anhydrase inhibitors 
(acetazolamide) are most commonly employed although a number of other diuretics 
(frusemide, amiloride) can also be utilised. The clinical benefits of medical therapies have 
not been fully evaluated. The most recent and largest randomised controlled study to 
assess treatment in IIH evaluated the efficacy of acetazolamide and failed to demonstrate 
a beneficial effect (Ball et al. 2009a). Although the study was under-powered (n=50) it 
highlighted that acetazolamide was extremely poorly tolerated, with 48% of subjects 
discontinuing acetazolamide (all at doses of less than 1500 mg per day) through choice or 
due to side effects, typically nausea and parasthesia (Ball et al. 2009a). The current 
extensive use of acetazolamide in IIH needs to be questioned in light of these results and 
further studies are awaited to clarify the situation. The Neuro-Ophthalmology Research 
Disease Investigator Consortium (NORDIC group) began enrolment to a multi-centre US 
trial in January 2010, aiming to recruit 154 patients in a randomised, placebo controlled 
trial of acetazolamide (www.ClinicalTrials.gov identifier: NCT01003639); hopefully this 
study will shed further light on the area. Topiramate, is emerging as an alternative to 
acetazolamide (Çelebisoy et al. 2007) owing to multiple mechanisms of action including 
carbonic anhydrase inhibition (Rosenfeld 1997), weight modifying effects (reduces 
weight in IIH by 9.75 Kg at 12 months (Çelebisoy et al. 2007)) and efficacy in treating 
migraine (a frequent co morbidity in IIH). 
Limited case reports have utilised therapeutic corticosteroids in IIH (Paterson et al. 1961; 
Liu et al. 1994; Soler et al. 1998) but this approach has not been substantiated (Johnston 
and Paterson 1974; Wall and George 1991). In fact, considerable evidence suggests a 
causative role for corticosteroids in the aetiology of IIH (see Table 1-3). This, coupled 
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with the additional problem of corticosteroid associated weight gain, has negated their use 
in IIH. 
1.11.2. Surgical therapies 
Surgical strategies are typically reserved for patients with declining visual function, 
despite medical therapy. Surgery may also be undertaken in cases where medical therapy 
is contraindicated (renal failure) or in those experiencing significant side effects from 
medical therapy. Occasionally, a surgical approach, typically CSF diversion, is carried out 
in patients with treatment refractive headaches. Surgical approaches include CSF 
diversion or decompressions of the optic nerve sheath with a fenestration procedure.  
1.11.2.1. CSF diversion 
Reducing ICP by surgical CSF diversion is performed most commonly by 
lumboperitoneal shunting (LPS) (87%) (Rosenberg et al. 1993), reflecting the less 
invasive nature of LPS insertion. Ventricular shunts such as ventriculoperitoneal shunts 
(VPS), ventriculoatrial shunts and ventriculojugular shunts are less frequently utilised 
(9%, 2% and 2% respectively) due to the potential difficulty of catheter placement in the 
small ventricles of IIH patients (Johnston et al. 1988; Rosenberg et al. 1993). 
Early reports hailed CSF shunting as the treatment of choice in IIH and claimed superior 
efficacy to medical treatment (Johnston et al. 1988).Certainly, symptomatic improvement 
in IIH is invariably documented in those with functioning shunts (Eggenberger et al. 
1996) and shunt insertion is associated with low initial morbidity (Eggenberger et al. 
1996).  There is, however, debate concerning the long term efficacy of CSF diversion in 
IIH due to shunt failure and the consequent need for revision. (Rosenberg et al. 1993; 
Burgett et al. 1997; Bynke et al. 2004).  Shunt failure occurs in up to 77% of patients 
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(Rosenberg et al. 1993) as a consequence of shunt obstruction (65% of revisions), 
overdrainage and ensuing low pressure headaches (15% of revisions), and less commonly, 
lumbar radiculopathy, shunt migration, disconnection and abdominal discomfort 
(Eggenberger et al. 1996).    
1.11.2.2. Optic nerve sheath fenestration 
Optic nerve sheath fenestration (ONSF), reputedly first conducted by the French 
ophthalmologist, Louis de Wecker (1832-1906), involves an incision in the retrobulbar 
optic nerve dural sheath, thereby creating a fistula allowing CSF to escape the confines of 
the optic nerve sheath (Keltner et al. 1977).  Decompression of the optic nerve sheath 
reduces ICP transmission to the optic nerve allowing papilloedema to remit and 
potentially reduces visual loss. The development of optic nerve sheath fibrosis following 
ONSF may also potentially reduce papilloedema by preventing the transmutation of CSF 
pressure to the optic nerve head (Davidson 1970). 
The efficacy of ONSF to reduce visual loss is documented (Corbett et al. 1988).  Delayed 
visual loss is, however, described up to 5 years post surgery in 10 – 32% of patients 
(Banta and Farris 2000).  Late visual deterioration post ONSF is usually attributed to 
closure of the dural fistulae, however, optic nerve compression, secondary to sheath 
fibrosis, may also be a contributory and irreversible factor. The variable visual outcome 
has resulted in ONSF being rarely performed in the United Kingdom. Additionally, 
surgical complications are common although usually transient (diplopia, orbital apex 
syndrome, corneal injury, anisocoria, and traumatic optic neuropathy) (Sergott et al. 1990; 
Banta and Farris 2000). The other significant disadvantage of ONSF, is that it typically 
does not improve the disabling chronic headaches experienced by IIH subjects. 
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1.11.3. Weight loss 
IIH has a striking association with obesity (greater than 93%) (Glueck et al. 2005)  and 
consequently weight loss is frequently suggested as a treatment strategy.  Nevertheless, 
there is only one prospective weight modifying  study in the published English literature, 
carried out over 35 years ago, which noted subjective improvement in the papilloedema in 
nine subjects with IIH on a low calorie rice diet (Newborg 1974). This data is supported 
by three further retrospective case note reviews (Johnson et al. 1998; Kupersmith et al. 
1998; Wong et al. 2007): The first described a correlation between change in weight and 
resolution of papilloedema in 15 subjects and found that subjects who lost 6.2% of body 
weight experienced the greatest improvement in papilloedema (Johnson et al. 1998). A 
second, larger study (58 subjects) described improvement in the papilloedema of 74% of 
subjects who lost weight (mean 13.3 kg) compared to 40% of subjects whose weight 
remained unchanged (Kupersmith et al. 1998). The third study, a retrospective case note 
evaluation, demonstrated that amongst 18 patients there was a significant difference in the 
BMI’s between those on treatment and those untreated (37.6 kg/m2 (95% confidence 
interval 30.6 kg/m2 to 44.7 kg/m2) and 30.2 kg/m2 (95% confidence interval 25.2 kg/m2 to 
35.2 kg/m2), respectively, p=0.05). There are also case reports describing improvement in 
papilloedema following weight loss achieved in the context of gastric reduction surgery 
(Noggle and Rodning 1986; Amaral et al. 1987; Sugerman et al. 1995; Sugerman et al. 
1997). These studies rely on subjective measures of papilloedema and included subjects 
with newly diagnosed IIH, many of whom are likely to improve irrespective of any 
treatment given. Furthermore, these studies did not monitor concomitant changes in ICP 
with either weight loss or resolution of papilloedema. There is, therefore, a pressing need 
for dedicated, prospective research to clarify the therapeutic effect of weight reduction on 
IIH; this will be explored in this thesis. 
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1.12. Clinical evaluation in IIH 
IIH is typically managed in neurology, neuro-ophthalmology, ophthalmology or less 
frequently in general medical clinics. In the absence of national guidelines monitoring 
practices vary widely. 
1.12.1. Visual assessment 
Visual loss in IIH can be insidious and silent (Rowe and Sarkies 1998), consequently, 
sensitive monitoring strategies are essential. The assessment of visual function in IIH 
focuses on evaluating both papilloedema severity and also the degree of visual loss.  
1.12.1.1. Papilloedema 
Papilloedema refers to swelling of the intra-ocular (pre-laminar) portion of the optic nerve 
head and in IIH occurs as a result of elevated ICP, transmitted via the CSF, in the confines 
of the retro-bulbar optic nerve sheath.  Increased optic nerve sheath CSF pressure impedes 
the vascular supply (branches of the posterior ciliary artery, circle of Zinn-Haller, pial 
network and recurrent choroidal network (Miller et al. 1999)) to the optic nerve head. 
Vascular compromise potentiates optic nerve ischemia and visual loss. 
Assessment of papilloedema is crucial in providing an indicator of disease activity and of 
potential visual loss. It should be noted, however, that some individuals with IIH do not 
develop papilloedema, despite significantly elevated ICP, likely as a result of anatomical 
variations in the optic nerve (Lipton and Michelson 1972; Marcelis and Silberstein 1991; 
Wang et al. 1998). The degree of papilloedema, viewed with either a direct 
ophthalmoscope (2-dimensional view) or via the more informative 3-dimensional views 
obtained from a slit lamp, is routinely recorded (Figure 1-15). Frisen grading, typically a 
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research tool, permits the classification of developing papilloedema but is limited by 
subjectivity and additionally lacks discrimination, particularly in resolving disc swelling 
(Frisen 1982) (Table 1-6). 
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 Signs 
Stage Nasal blur Temporal 
blur 
Peripheral 
TOVS* 
Central 
TOVS* or 
filled optic 
cup 
Smooth 
dome 
0 
- - - - - 
1 + - - - - 
2 + + - - - 
3 + + + - - 
4 + + + + - 
5 + + ± ± + 
Table 1-6 Frisen Grade  
The optic disc is grade according to appearance. *TOVS indicates total 
obscuration of major vessel segment(s) by swollen axons. + indicates 
present, - indicates absent.  Grading described by Frisen L.  JNNP 
1982;45:13-18. 
 
A B C
 
Figure 1-15 Fundus photographs  
(A) Papilloedema, Frisen Grade 2, (B) resolved papilloedema in the same 
patient and (C) optic disc pallor (optic atrophy) a sequelae of significantly 
elevated ICP and subsequent optic nerve head ischaemia.  
 
1.12.1.1.1 Objective assessment of papilloedema 
Although direct visualisation of the optic disc to assess papilloedema is typical in clinical 
practice, the subjective assessment lacks accuracy, reproducibility and sensitivity. New 
techniques are emerging in visual science, primarily designed to quantify optic atrophy in 
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condition such as glaucoma. These techniques may also have a role in quantifying 
papilloedema and their role is currently being evaluated in the literature. 
1.12.1.1.2 Optical Coherence Tomography  
Optical coherence tomography (OCT) is a relatively new technique, developed in 1990, 
with the first in vivo images published in 1993 (Fercher et al. 1993). The echo based 
imaging technique utilises a broad band-width light source to penetrate tissue; the 
majority of the light is scattered, but a proportion will be reflected off the structure of 
interest. The depth and intensity of the reflected (coherent) light is measured by an optical 
interferometer.  This enables real time, 3-dimensional imaged acquisition that has 
micrometer resolution (5–7 µm (Frohman et al. 2008)) which mirrors histological 
preparations (Rebolleda and Munoz-Negrete 2009).  The technique is non invasive, non 
damaging and unlike many other imaging techniques does not utilise ionizing radiation. 
The depth of penetration of the light source (2 mm), limits the application of OCT to deep 
structures. The optical translucency of the eye, however, makes this an ideal structure to 
image (retinal nerve fibre layer (RNFL) thickness, macula, fovea and optic nerve). 
RNFL analysis involves assessment of the peripapillary RNFL thickness using a 
circumferential scan of the intra-ocular optic nerve head (Figure 1-16A). The quantitative 
values obtained can be compared to normal population values, analysed according to disc 
sectors or used for monitoring progression over a time course of scans. OCT is 
predominantly used to accurately measure declining RNFL thickness in conditions such 
as glaucoma, Leber's hereditary optic neuropathy, traumatic optic neuropathy and more 
recently in multiple sclerosis associated optic neuritis (Medeiros et al. 2003; Medeiros et 
al. 2004; Barboni et al. 2005; Siger et al. 2008). Reports are however emerging, detailing 
the use of OCT to measure elevation (caused by axonal distension and oedema) of the 
Chapter 1   
48 
RNFL as seen in papilloedema (Savini et al. 2006).  RNFL OCT may have a role in 
monitoring IIH papilloedema, as demonstrated in a study of three children with IIH 
(Sanchez-Tocino et al. 2006), as well as in  an adult population (n=22) with mild 
papilloedema (Rebolleda and Munoz-Negrete 2009). In the latter study, RNFL was found 
to correlate with automated visual field perimetry. Caution however, should be employed 
when interpreting reductions in RNFL in IIH as this could represent either improving 
papilloedema or progression to optic atrophy. In these cases a discrepancy between RNFL 
and the automated perimetry should alert the physician to the possibility of developing 
optic atrophy. 
A B
C
 
Figure 1-16 Optical coherence tomography (OCT) imaging 
(A) OCT fundus image illustrating the circumferential marker for retinal 
nerve fiber layer (RNFL) measurement. (B) Schematic diagram illustrating 
light, reflected from the retina layers, which is then recorded by the optical 
interferometer (adapted from Frohman EM et al. Nature Clinical Practice 
Neurology 2008; 4: 664-675. (C) Cross sectional OCT image obtained, the 
arrow marks the diameter of the RNFL. 
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1.12.1.1.3 Ultrasonography  
Although the principles of USG were noted as far back as 1793 in Spallanzani’s study of 
bat echo-navigation, it was not until the 1960’s that the medical application was 
appreciated and images of the optic nerve obtained (Baum and Greenwood 1960). This 
echo technique utilised the reflection of sound waves to obtain 2-dimension, non-invasive, 
topographic images. Orbital USG has numerous application including evaluating ocular 
tumours, inflammation, vascular malformations, extra-ocular muscles, drusen and the 
optic nerve. Accurate optic nerve imaging has been developed (Beatty et al. 1998b; 
Beatty et al. 1998a) and studies are now emerging demonstrating the use of USG in IIH. 
USG can facilitate the differentiation of pseudo-papilloedema (e.g. drusen) from true 
papilloedema in IIH subjects (Khonsari et al. 2009). There are also reports of 
ultrasonographic evaluation of papilloedema in IIH measuring either intra-ocular optic 
disc height (Tamburrelli et al. 2000) or the retro-bulbar optic nerve sheath diameter 
(NSD) (Stone 2009).  Optic disc height is typically measured in both a horizontal and 
vertical plane using a high resolution real-time brightness scan (B-scan) at 10 - 20Hz 
pulse frequency (Tamburrelli et al. 2000) (Figure 1-17A). The optic nerve is imaged in 
cross-section in the retro-bulbar region, at the insertion into the optic globe. The maximal 
inter-pial diameter of the nerve sheath is measured with a 10Hz B-scan (Figure 1-17B). 
NSD is not a direct measure of papilloedema: The CSF filled subarachnoid space of the 
optic nerve sheath distends as a result of elevated ICP (Watanabe et al. 2008). 
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Figure 1-17 Ultrasonography of the optic nerve  
(A) Optic disc elevation, callipers measure from the maximal disc height to 
the lamina cribrosa, (B) cross section through the optic nerve (long arrow) 
with the callipers marking the maximal pial diameter, the short arrow 
marks the hypodense signal from the CSF. 
 
In this thesis we will use OCT and USG to quantify papilloedema in IIH. 
1.12.1.2. Assessment of visual loss 
There is considerable variability in the reported incidence of visual loss in IIH (Table 
1-7). Current figures on the incidence of blindness in IIH are expected following the 
monitoring program established by The British Ophthalmic Surveillance Unit in 
conjunction with the Royal College of Ophthalmologists (initiated October 2005).  
 
Number of 
patients in study 
Number with 
visual loss 
Study type Author 
24 1 (4%) Prospective (Sorensen et al. 1988) 
34 4 (8%) Retrospective (Boddie et al. 1974) 
50 5 (10%) Prospective (Wall and George 1991) 
35 6 (17%) Prospective (Rowe and Sarkies 1998) 
81 16 (20%) Prospective (Radhakrishnan et al. 1993) 
57 14 (25%) Retrospective (Corbett et al. 1982) 
68 21 (31%) Retrospective (Orcutt et al. 1984) 
Table 1-7 Reported visual loss in IIH. Adapted from (Ball and Clarke 2006) 
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Despite the uncertainty of the prevalence of blindness in IIH, this area of potential 
morbidity is the primary focus in IIH management. 
1.12.1.2.1 Visual acuity 
Visual acuity, defined as spatial resolving capacity, describes the minimum angle of detail 
which can be resolved (Westheimer 2001) and is the most frequently used test of visual 
function in research and clinical practice. Acuity testing not only guides refraction but is 
also performed to screen and monitor disease with consequent implications for an 
individual’s driving and occupational ability. Visual acuity testing is fundamental in 
monitoring IIH patients and guiding management decision.  
Visual acuity testing, originally described 140 years ago (Snellen 1862) utilises charts of 
optotypes (symbols) commonly letters (Figure 1-18A). Variations of the original Snellen 
chart are widely utilised but subject to criticisms, as too many variables affect the ability 
to discern the optotypes. On the  Snellen chart,  letter selection and style affects the ability 
to recognise an optotype (Woodruff 1947). The number of letters per row increases in 
successive rows of the chart. This increases the difficulty in reading the optotypes, rather 
than continuing with an equivalent task further down the chart (Flom et al. 1963). A 
further consequence of varying the number of letters per row, is that missing a letter at the 
bottom of the chart does not have the same significance as missing a letter near the top of 
the chart (Williams et al. 2008). Finally the decrease in letter size in successive rows is 
not proportional (the scale is irregular and arbitrary) and this limits subsequent statistical 
analysis, and risks over or underestimating visual acuity (McGraw et al. 1995).  
Alternatives to the Snellen chart have been developed to compensate for these limitations. 
The logarithm of the minimum angle of resolution (LogMAR) chart was designed to 
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ensure that the only factor which changed down the chart was the size of the letter, which 
progressed logarithmically (Figure 1-18B). The letter legibility, number of letters per row, 
distance between-letters and between rows was standardised (Bailey and Lovie 1976). 
Each letter on the LogMAR chart is, therefore, equally weighed and equivalent to 0.02. 
LogMAR charts are accurate and reliable both in clinical practice and in research (Elliott 
and Sheridan 1988; Sheedy 1993.). Standardisation of test conditions (distance and 
luminescence) is however, vital (Pandit 1994). The correction of the eye, whether 
unaided, best corrected (accurate refraction correction used), or habitual (under everyday 
conditions, with or without optical correction), must also be consistent. 
A B
 
Figure 1-18 Visual acuity measurement 
 Snellen chart (A), LogMAR chart (B). 
 
1.12.1.2.2 Colour vision 
Numerous methods exist to detect deficiencies in colour vision. The most frequently used 
in clinical practice are pseudoisochromatic plates. These plates consist of multiple 
coloured dots of varying sizes and brightness which, in the context of normal colour 
vision, display letters, numbers or shapes. Ishihara plates, which consist of either, 38, 24 
or 14 plates, are commonly used and provide a quick and reliable screening test of colour 
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vision abnormalities. There are, however, limitations to using pseudoisochromatic plates. 
Principally they lack sensitivity in detecting, classifying and quantifying acquired colour 
vision deficiencies, particularly in the yellow-blue range. 
The Farnsworth Munsell 100 Hue test permits the classification of colour deficiency and 
grades severity (Farnsworth 1957). The test consists of 85 different coloured caps, 
presented in four boxes, which the patient arranges in order of increasing hue between 
two reference caps. The pattern of errors varies depending on the type of colour vision 
defect. Standardised testing luminescence must be maintained throughout repeated 
assessments.  A total error score can be calculated as a measure of accuracy, with the 
greater the number of misjudgements equating to a higher score. As colour vision varies 
with age, being worst at extreme ages and peaking at 19 years, the total error score is 
interpreted with data from a normal age matched population (Kinnear and Sahraie 2002).  
Colour vision is affected in IIH (Nichols et al. 1997), and assessment, typically with 
Ishihara plates, is a standard component of visual assessment in IIH. The extent and 
characteristics of colour deficiency in IIH are not well described.  
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Figure 1-19 Farnsworth Munsell 100 Hue colour assessment 
 Subjects arrange randomly assorted colour discs by increasing Hue. 
 
1.12.1.2.3 Perimetry 
Focal perimetry is a mandatory component in the assessment of IIH serving to detect early 
abnormalities, reveal visual loss not apparent to the patient and to monitor progression 
and remission of visual field loss. The principle of perimetry, performed initially 150 
years ago, is to determine the detection sensitivity of a target, which can vary in size and 
brightness, in different locations of the visual field. The loss of detection of the target 
indicates dysfunction in the visual pathway. 
The visual field can be assessed using manual kinetic perimetry or automated perimetry. 
Manual perimetry (Goldman perimetry), relies on a perimetrist to move a target from an 
area of absent vision to a position that can be seen. This creates a map of the visual field 
and highlights areas that cannot be seen. The technique has the advantage of permitting a 
customised test, which can explore sectors of concern, whilst the technician can 
encourage the patient to optimise concentration. The technique is, however, time 
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consuming and dependant on the training of the perimetrist. Additionally, the resulting 
visual field map is not quantitative, merely descriptive. 
Automated perimetry, such as Humphrey visual field (HVF) analysis, utilises a computer 
program to create a standard test procedure with defined conditions (target size and 
luminescence). The repeated testing of set locations within the visual field permits the 
assessment of false positive (trigger-happy) and false negative (potentially inattentive 
patient) responses. HVF analysis is sensitive and specific, and also statistically 
quantifiable, and consequently the preferred method in a research setting. The test is, 
however, time consuming, fatiguing for patients and lacks flexibility to evaluate 
complicated patients.  
The HVF generates a numerical result which indicates the threshold of vision (the 
minimum intensity of light that can be detected) at each point in the visual field. This is 
displayed graphically (Figure 1-20A) as well as in grey scale, with black indicating that 
no stimulus was perceived (Figure 1-20B). The extent that the field deviates from an age 
matched control population is illustrated on the total deviation plot (Figure 1-20C). The 
mean deviation (MD), calculated from the total deviation, summarises the extent the field 
deviates from normal (Heijl et al. 1987). Negative values indicate an abnormal field.  The 
pattern deviation takes into account any global reduction in visual sensitivity (Figure 
1-20D) and, after comparison to an age matched population, the pattern standard deviation 
(PSD) is calculated. 
Visual field analysis if frequently abnormal in IIH patients; 88% have abnormal Goldman 
perimetry and 92% abnormal HVF analysis at presentation (Wall and George 1991). 
Characteristic visual field changes in IIH patients includes enlargement of the blind spot 
and peripheral field constriction, often with nasal loss or arcuate deficits (Rowe and 
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Sarkies 1998; Galvin and Van Stavern 2004). The severity of papilloedema, however, 
does not correlate with the visual field loss (Wall and George 1991). 
Outside normal limits
MD -9.29 p < 0.5%
PSD 8.01  p < 0.5%
(B) Greyscale diagram(A) Numerical result
(C) Total deviation (D) Pattern deviation
 
Figure 1-20 Humphrey visual field, Central 24-2 Threshold Test 
An abnormal test from the right eye of an IIH patient showing an enlarged 
blind spot with superior nasal visual field loss. The abbreviated analysis 
illustrates the (A) numerical results, (B) the greyscale diagram, (C) the 
total deviation, from which the mean deviation (MD) is calculated and (D) 
the pattern deviation, from which the pattern standard deviation (PSD) is 
calculated. 
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1.12.1.2.4 Contrast sensitivity 
The threshold to discern low contrast optotypes can be affected by disturbance in the 
visual system. Deficits in contrast sensitivity may highlight pathology in the visual system 
before abnormalities are demonstrated by alternative tests such as visual acuity testing.  
One method of assessing contrast sensitivity is the Pelli Robson chart. The chart displays 
rows of 6 letters with letter triplets having equivalent contrast. Contrast declines in 
successive rows (Figure 1-21). As this chart is in a similar format to a visual acuity chart 
it is simple for both patients and doctors to use and is also highly reproducible (Miller et 
al. 1999). 
 
Figure 1-21 The Pelli Robson contrast sensitivity chart. 
 
Contrast sensitivity has not been studied in detail in IIH although earlier studies have not 
found it to be as sensitive as HVF (Rowe and Sarkies 1998). Pelli Robson contrast 
sensitivity is, however, a sensitive method to identify visual dysfunction in other 
conditions characterised by optic nerve dysfunction such as multiple sclerosis (Balcer et 
al. 2003). 
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1.12.2. Headache assessment 
Headache is a significant cause of morbidity in IIH, affecting 68 – 97% of individuals, 
and frequently precipitates the initial referral to medical services (Durcan et al. 1988; 
Wall and George 1991; Radhakrishnan et al. 1993; Kesler and Gadoth 2001; Friedman 
and Rausch 2002).   
Headache in IIH has been classified by the International Headache Society (IHS) (Evers 
2004) (Table 1-8). The characteristics of IIH headaches are, however, more complex than 
this definition. Although often described as a constant headache, up to 52% of IIH 
headaches are episodic (Gonzalez-Hernandez et al. 2009).  Additionally, the headache 
frequently has characteristics attributed to other headache types; episodic tension type 
headache (37%), migraine (24 - 40%) and chronic tension type headache (12%). More 
than one headache type is also recognised to occur in IIH patients (23% of subjects) 
(Friedman and Rausch 2002). It is also apparent that headaches can continue in patients 
despite resolving papilloedema and normalisation of the  ICP (68% of subjects) (Friedman 
and Rausch 2002). Medication overuse may further confuse the headache phenotype.  
Headaches in IIH are, therefore, typically complicated and consequently challenging to 
monitor and treat. 
There are no guidelines on headache monitoring in IIH and this area is frequently 
neglected despite the pain predictably representing the primary concern for the patients. 
There are no biological markers for headache and consequently monitoring the clinical 
course relies on an accurate history.  Headache diaries and questionnaires, although not 
designed for IIH patients, are used to diagnose, quantify and characterise headaches and 
additionally minimise recall bias. Diary duration varies,  but typically records headache 
frequency, severity, duration and analgesics used (Nappi et al. 2006). Headache diaries 
Chapter 1   
59 
have also been used as outcome measures in migraine drug trials to monitor efficacy 
(Sandrini et al. 2002; Brandes et al. 2004).   
Numerous headache questionnaires have also been developed. The Headache Impact 
Test-6 (HIT-6) measures headache disability (Kosinski et al. 2003) and consists of 6 items 
which  explore social functioning, role functioning, vitality, cognitive functioning, and 
psychological distress (see appendix 7.2). The resultant score ranges from 36-78 
(interpretation in appendix, section 7.3). The questionnaire is self-administered, quick to 
perform (takes approximately 2 minutes to complete), validated, reliable and repeatable 
(Pryse-Phillips 2002; Bayliss et al. 2003).  We will be utilising headache diaries and HIT-
6 to monitor patients with IIH in this thesis. 
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Headache attributed to IIH 
IHS 7.1.1. 
A.  Progressive headache with at least one of the following characteristics and fulfilling criteria C 
and D: 
a) daily occurrence 
b) diffuse and/or constant (non-pulsating) pain 
c) aggravated by coughing or straining 
B. Intracranial hypertension fulfilling the following criteria: 
1. alert patient with neurological examination that either is normal or demonstrates 
any of the following abnormalities: 
  a)  papilloedema  
  b)  enlarged blind spot 
  c)  visual field defect (progressive if untreated) 
  d)  sixth nerve palsy 
2. increased CSF pressure (>200 mm H2O in the non-obese, >250 mm H2O in the 
obese) measured by lumbar puncture in the recumbent position or by epidural or 
intraventricular pressure monitoring 
3. normal CSF chemistry (low CSF protein is acceptable) and cellularity 
4.  intracranial diseases (including venous sinus thrombosis) ruled out by appropriate 
investigations 
5.  no metabolic, toxic or hormonal cause of intracranial hypertension 
C.  Headache develops in close temporal relation to increased intracranial pressure 
d) Headache improves after withdrawal of CSF to reduce pressure to 120-170 mm H2O and 
resolves within 72 hours of persistent normalisation of intracranial pressure 
Table 1-8 IIH headache classification from the International Headache Society 
 
1.13. Biomarkers in IIH 
The diagnosis of IIH is not always straightforward (see section 1.10) and the pathogenesis 
remains unknown (see section 1.4). Biomarkers have the potential to facilitate diagnosis, 
predict prognosis, monitor disease progression and impart information on disease 
causality. Accurate biomarkers would, therefore, have clear advantages in the 
management IIH. The National Institute of Health define a biomarker as “a characteristic 
that is objectively measured and evaluated as an indicator of normal biological processes, 
pathogenic processes, or pharmacological responses to a therapeutic intervention” (2001). 
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As a measure of disease process, biomarkers have roles in both patient care and in clinical 
trials. The latter are referred to as surrogate endpoints (Feigin 2004). The ideal biomarker 
should reflect pathogenesis and be validated in pathologically confirmed cases, as clinical 
diagnosis can be inaccurate in up to 15-20% of neurological patients (Stacy and Jankovic 
1992). Additionally, a clinically useful biomarker must be minimally invasive, cheap, 
sensitive, reproducible and rapid.   
The establishment of unique biomarkers for conditions affecting the brain and central 
nervous system have proven problematic. Traditionally, biomarkers have evolved from 
knowledge of the underlying disease aetiology.  The pathogenesis of many neurological 
conditions is not fully appreciated and biomarkers have therefore remained elusive. Even 
in conditions where knowledge of the underlying pathology is advancing, such as MS, 
there is a lack of reliable biomarkers. No biomarkers have currently been identified in IIH 
and this likely reflects the very limited understanding of the pathogenesis.  
1.13.1. Principles of metabolomics 
Metabolomics is a powerful technology which has the ability to determine metabolic 
variations and their response to disease processes. The technique involves the 
quantification of the metabolic complement in a biological sample (Griffin and Shockcor 
2004). As metabolites reflect both gene transcription and environmental factors, the 
generation of metabolite profiles are believed to have distinct advantages over genomics 
and proteomics in characterising biological systems (Griffin and Shockcor 2004).  
Metabolomics captures a snap-shot of metabolism and therefore provides information on 
current disease activity, rather than being informative of up-stream regulatory processes 
as in genomics.  
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Although in its infancy, metabolomics has already been demonstrated to have a number of 
clinical applications. Ex-vivo analysis of tumour biopsies can differentiate malignant 
tissue from normal tissue (Griffin and Kauppinen 2007; Yang et al. 2007). Metabolite 
profiles from the serum of patients with ischemic heart disease can distinguish varying 
degrees of coronary artery stenosis (Brindle et al. 2002). Urinary metabolite profiles are 
able to identify patients with renal cell carcinoma from healthy controls (Kind et al. 
2007), and partially separate MS patients from control subjects (sensitivity 65%) (t Hart et 
al. 2003).  
The feasibility of CSF metabolite analysis, using NMR spectroscopy, was initially 
demonstrated over 20 years ago (Shinar and Navon 1986) (Petroff et al. 1986) and 
recognition that CSF metabolites were related to clinical conditions (Bell et al. 1987) 
paved the way for further research in this area (Lutz et al. 1996; Lutz et al. 1998; Lutz et 
al. 2007).    Of particular relevance to the clinical application of CSF metabolomics was 
the identification of metabolites in MS, degenerative dementia, inflammatory spinal 
disease, vitamin B12 deficiency and in inborn errors of metabolism (Nicoli et al. 1996) 
(Koschorek et al. 1993) (Commodari et al. 1991) (Wevers et al. 1995).  More recently, 
studies of CSF metabolite profiles have demonstrated differentiation of schizophrenia 
from healthy controls (Holmes et al. 2006a) and separation of viral, tubercular and 
bacterial meningitis (Subramanian et al. 2005). Metabolite profiles have also 
discriminated sporadic Parkinson’s disease  from that associated with the familial LRRK2 
mutation (Johansen 2007), and Parkinson’s disease patients from normal ageing controls 
(Bogdanov et al. 2008).  
It is likely, therefore, that pathologically distinct diseases are characterised by unique 
metabolite profiles or fingerprints. In IIH, metabolite profiles may potentially be useful as 
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biomarkers and the interpretation of individual metabolite variance may also give clues to 
underlying pathology.   
1.13.2. Metabolomic techniques 
A number of techniques can be used to measure metabolites (Table 1-9), and these will be 
discussed in the following section. 
Technique Description Advantage Disadvantage 
Gas chromatography/ 
mass spectrometry 
(GC/MS) 
Uses gas 
chromatography to 
separate metabolites 
prior to mass 
spectrometry to 
identify metabolites. 
 
Inexpensive, 
reproducible and highly 
sensitive. 
Sample preparation time 
consuming; not all 
compounds suitable for 
GC/MS. 
Liquid 
chromatography/ 
mass spectrometry 
Similar to GC/MS 
except separation 
occurs during liquid 
chromatography. 
Sample preparation less 
time consuming than 
GC/MS. Similar 
sensitivity to GC/MS. 
 
More expensive than 
GC/MS and less 
reproducible. 
 
Metabolite array A 96-well plate is used 
with over 700 different 
assay mixtures, e.g.  
phenotyping 
Escherichia coli. 
 
Useful screening tool 
when manufactured for 
a particular situation. 
Number of metabolites 
measured is limited by 
space on the chip. Cannot 
screen for unknown 
metabolites. 
Nuclear Magnetic 
resonance (NMR) 
spectroscopy 
Used to screen 
biofluids and whole 
tissue in vivo or ex vivo 
Automated, rapid and 
reproducible. 
Metabolite 
quantification and 
identification possible.  
 
Lower sensitivity than 
mass spectrometry. Co-
resonant metabolites can 
be difficult to quantify. 
Fourier-transform 
infrared spectrometry 
Uses vibrational 
frequencies of 
metabolites to produce 
spectra. 
Cheap and can process 
a high throughput of 
samples. 
Very difficult to identify 
metabolites. Poor at 
distinguishing metabolites 
within a class of 
compounds. 
 
Raman spectroscopy Extension of FT-IR 
relying on light 
scattering following 
irradiation with a laser. 
Water only has a weak 
Raman spectra thus 
enabling observation of 
functional groups.  
Very difficult to identify 
metabolites. Poor at 
distinguishing metabolites 
within a class of 
compounds. 
Table 1-9 Methods used in metabolite analysis. 
Adapted from Griffin 2004 (Griffin and Shockcor 2004). 
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1.13.2.1. Proton nuclear magnetic resonance 
The Nobel Prize winning discovery of nuclear magnetic resonance (NMR) was made in 
1946 (Purcell 1946) and has since been developed into many scientific fields including 
biochemistry and medicine. NMR relies on the principle that nuclei or electrons have 
spin, i.e. behave like small bar magnets, and will align themselves when placed in a 
magnetic field. If pulsed with radiofrequency, the aligned particles will absorb energy and 
resonate. Particles resonate at different frequencies depending on their atomic mass and 
this can provide information on the structure of the molecule (Figure 1-22).  
 
Figure 1-22 Schematic diagram illustrating proton NMR Spectroscopy 
Proton atoms in metabolites have spin properties (1). The particles align in 
a strong magnetic field (2). Radiofrequency pulses excite the particles 
which then resonate (3). Energy emitted (4) from the resonating particles is 
recorded (5).  
 
One–dimensional (1D) Proton NMR spectroscopy is an ideal technique to assess 
metabolites in biofluids as it is automated and rapid: spectra are acquired in 10 minutes. 
After initial start up costs, samples are cheap to process, potentially enabling high 
throughput processing. The technique is reproducible (Lindon et al. 2003) and sensitive; a 
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cryoprobe enables the detection of metabolites in the nanogram range (Holmes et al. 
2006b). NMR is also non destructive, allowing samples to be reused and importantly, 
relies on only a small sample volume (300µl), to measure multiple metabolites. If used 
with a reference sample, the technique can also be quantitative.  
There are, however, a number of potential limitations associated with 1D 1H NMR as a 
result of spectral peak congestion, particularly in the lower region on the spectrum (0.7 – 
4.7 ppm) (Foxall et al. 1993). Spectral congestion, or chemical noise, occurs where 
multiple resonances overlap. Low concentration metabolites can potentially be obscured 
due to their overlap with other more prominent metabolites and thereby hinder metabolite 
identification.  With the use of higher strength magnets (500-600 MHz), and thus the 
resolution of increasing numbers of metabolites, this problem is enhanced. Signal 
assignment is also problematic when evaluating metabolites of similar resonances, as their 
resonances may superimpose. The resonance congestion in 1D spectrum, therefore, limits 
the accuracy of metabolite identification and impairs the pattern recognition multivariate 
analysis.  
Two-dimensional (2D) J-resolved spectroscopy (JRES) has developed to potentially 
ameliorate these issues.  2D JRES separates chemical shifts and the spin-spin coupling 
data on to different axis. The topographical “contour map” of 2D data is then projected in 
skyline, the appearances of which are much less congested than 1D spectrum. 2D spectral 
acquisition is, however, approximately three times as long as that needed for 1D 
spectroscopy. Additionally, interfering peaks composed of metabolites with coupled 
signals can be created which are problematic to interpret (Foxall et al. 1993). The analysis 
of proteinaceous biofluids can be difficult using 1D 1H NMR, as protein signals can 
dominate the spectra due to their short transverse (T2) relaxation time. 2D JRES attenuates 
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the protein resonances by editing the T2 relaxation during the JRES pulse sequences 
(Viant 2003). Eliminating the protein signal and thus simplifying the spectra, can facilitate 
metabolite differentiation and identification (Foxall et al. 1993), however, potentially 
valuable information from protein bound metabolite may be lost. 
1.13.2.2. Gas chromatography / mass spectrometry 
Gas chromatography / mass spectrometry (GC/MS) was originally used to identify 
metabolites in plant extracts,  but since 1966 has also been used to diagnose metabolic 
disorders such as inborn errors in metabolism (Tanaka et al. 1966). The analysis of urine 
samples enables identification of organic acids, amino acids and glucose derivatives. The 
technique uses gas chromatography to separate the metabolite components of a mixture. 
Subsequently, mass spectrometry ionises the metabolites which are then separated 
according to their mass to charge ratio and are thus identified. GC/MS is more sensitive 
than NMR and has the advantage of potentially using a very small volume of sample 
(100µl), however, as metabolites cannot be uniformly ionised, metabolite identification is 
restricted. Additionally, sample preparation and processing are time consuming, slowing 
sample throughput. 
Analysis of steroid pathways by urine GC/MS identifies and quantifies over 55 different 
metabolites or ratios of metabolites. The technique  can provide an index of cortisol 
secretion and global 11β-HSD activity (Shackleton et al. 2008), estimated from renal 
excretion of cortisol metabolites. Assessment of 11β-HSD1 activity is made via the ratio 
of cortisol to cortisone metabolites i.e. tetrahydrocortisol (THF) + 5αTHF: 
tetrahydrocortisone (THE) ratio, and 11β-HSD2 activity is estimated from measuring 
urinary free cortisol: urinary free cortisone ratio (Figure 1-23). Analysis of other steroid 
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metabolites enables identification of alternative aberrant steroid metabolic pathways and 
will be discussed in more detail in section 5.3.2.1. 
5a-dihydrocortisol 5ß-dihydrocortisol
5a-tetrahydrocortisol
(5a-THF)
5ß-tetrahydrocortisol
(THF)
dihydrocortisone
tetrahydrocortisone
(THE)
Cortisol Cortisone
11ß-HSD2
11ß-HSD1
5a-Reductase 5ß-Reductase 5ß-Reductase
3a-HSD 3a-HSD
Testosterone
5a-dihydro-testosterone
(DHT)
Androsterone
(An)
Etiocholanolone
(Et)
5a-Reductase
3a-HSD
 
Figure 1-23 Steroid metabolites and metabolic pathways analysed by urinary GC/MS  
 
1.13.2.3. Liquid chromatography mass spectrometry 
Liquid chromatography / mass spectrometry (LC/MS), like GC/MS can measure steroid 
metabolites and the intermediate products of hormone synthesis. Both techniques utilise 
similar techniques, however LC/MS separates samples using liquid chromatography.  
LC/MS offers several advantages over GC/MS. Unlike GC/MS, samples analysed by 
LC/MS can be non volatile and do not require extensive derivatisation. Consequently 
sample analysis time is reduced. The high specificity of LC/MS ensures consistent 
metabolite identification and quantification (Kushnir et al. 2009). Additionally, LC/MS is 
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more versatile than GC/MS allowing identification and simultaneous measurement of a 
greater spectrum of metabolites (Vogeser 2003). LC/MS is highly sensitive, potentially 
enabling smaller volumes of biofluids to be analysed (Kushnir et al. 2004) and 
additionally allowing the detection of low  concentration metabolites,  thereby enabling 
earlier diagnostic testing. The higher specificity does mean, however, that established 
reference levels for steroid metabolites are not transferable and need to be re-established 
in LC/MS. 
Numerous fluids are amenable to LC/MS analysis including serum, urine, microdialysis 
fluids, vitreous humour, auditory perilymph and CSF (Favretto et al. 2009; Guitton et al. 
2009; Jiang et al. 2009; Swan et al. 2009; Uutela et al. 2009). The technique is likely to 
be widely used in future diagnostic clinical chemistry. We aim to use LC/MS to analyse 
CSF glucocorticoid metabolites, an area not previously described. 
1.14. Hypothesis  
In summary there is no current consensus regarding the pathogenesis of IIH although 
disordered CSF dynamics either at the CP or AGT are likely to be key. IIH has clear 
endocrinological links, occurring almost exclusively (greater than 93%) in obese women. 
Additionally, numerous case reports document IIH in the context of corticosteroid therapy 
and endocrinopathies such as Cushing’s syndrome. The cortisol generating enzyme 11β-
HSD1 is implicated in obesity, a phenotypic characteristic of IIH and exhibits sexual 
dimorphism. 11β-HSD1 and glucocorticoids are also involved in IOP regulation via 
mechanisms which may be pertinent to CSF secretion and drainage at the CP and AGT 
respectively. These observations suggest that obesity and metabolic changes, particularly 
11β-HSD1 activity, may play an important aetiological role in CSF dynamics and IIH.  
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The 2005 Cochrane review highlighted that an evidence base for the treatment of IIH has 
not been established. Weight loss is a commonly advocated treatment as IIH patients are 
typically obese, however, there have been no previous prospective studies documenting 
the effect of weight loss on ICP in IIH.  Weight loss may potentially benefit patients with 
IIH due to manipulation of 11β-HSD1 activity. 
We hypothesis that 11β-HSD1 is important in the pathogenesis of IIH. Additionally, that 
11β-HSD1 and glucocorticoids influence ICP by driving CSF secretion at the CP and 
drainage at the AGT. Metabolic alterations may also provide clues to the pathogenesis of 
IIH. Finally, we suggest that weight loss will lower ICP in obese IIH patients, via 
manipulation of 11β-HSD1.  
This thesis aims to explore how obesity, 11β-HSD1 and metabolic changes may be 
involved in the pathogenesis and treatment of IIH. 
1.14.1. Objectives 
1. To characterise 11β-HSD1 in the CP of an animal model, the New Zealand White 
Albino Rabbit (NZWAR). 
2. To characterise 11β-HSD1 in human CP and AGT and additionally in an 
untransformed human choroid plexus epithelial cell line, thereby establishing an in 
vitro model to study the role of 11β-HSD1 in CSF secretion. 
3. To utilise NMR spectroscopy to identify key metabolites in the CSF and serum, 
specific to IIH subjects, which, in addition to facilitating diagnosis, may impart 
information about disease pathogenesis. 
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4. To define an evidence base for weight reduction in managing patients with IIH and if 
weight loss is beneficial in IIH to explore whether this effect occurs via modulation of 
11β-HSD1 and related metabolites. 
5. To characterise the obesity phenotype in IIH through examination of body 
composition and evaluation of the glucocorticoid, lipid and insulin profile. 
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Chapter 2.  Methods 
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This chapter describes the detailed methodology used in this thesis. Variations in these 
procedures and study designs are discussed in the appropriate chapter. 
2.1. In vitro techniques 
2.1.1. Haematoxylin and eosin stain  
All tissue samples were initially identified using haematoxylin and eosin stain (H&E) 
staining. Formalin fixed tissues were embedded in paraffin and cut into 5µm sections 
which were mounted on electrostatically charged slides (VWR, Lutterworth, UK) to aid 
tissue adhesion. Sections were initially dewaxed and rehydrated (emersion in xylene, 2 x 
5 minutes, and then in 100% ethanol, 2 x 5 minutes. Staining was then carried out using 
Meyer’s haematoxylin (Surgipath-Europe Ltd, Peterborough, UK) for approximately 30 
seconds. Excess haematoxylin was removed by washing in running tap water for 5 
minutes and then developed, through immersion in 1% acid alcohol for 30 seconds. 
Counter straining was carried out with 1% eosin (Surgipath-Europe Ltd, Peterborough, 
UK) and again irrigated for 5 minutes in tap water. Sections were dehydrated in 100% 
ethanol (2 x 5 minutes) and xylene (2 x 5 minutes) prior to mounting with dibutyl-
polystyrene-xylene (DPX) (BDH laboratory supplies, Poole, UK). 
2.1.2. Immunohistochemistry 
2.1.2.1. 11β-Hydroxysteroid dehydrogenase  
Tissue sections were initially dewaxed and rehydrated by processing in xylene (2 x 5 
minutes) and then in 100% ethanol (2 x 5 minutes). Antigen retrieval was achieved 
though immersion in citric acid buffer (pH 6) and boiling (microwaving for 2 minutes, 
allowing to cool for 2 minutes and then further microwaving for 2 minutes). Following 
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antigen retrieval, the sections were allowed to cool to room temperature and buffer 
removed through irrigation for 5 minutes in tap water. A 15 minute submersion in 
methanol hydrogenperoxide was carried out to reduce endogenous peroxidase activity.  
Sections were processed using a flat bed technique. Incubation with 10% normal donkey 
serum (NDS) in phosphate buffered saline (PBS) for 30 minutes was conducted to reduce 
non-specific binding. Sections were then incubated with primary antibody (Table 2-1). 
The  anti-human polyclonal 11β-HSD1 and anti-human polyclonal 11β-HSD 2  were 
generated in-house (Ricketts et al. 1998). After washing with PBS, the sections were 
incubated with the secondary antibody, donkey anti-sheep immunoglobulin (Ig) G 
horseradish peroxidase (HRP) conjugate (The Binding Site, Birmingham, UK). The 
reaction was visualised using, 3,3’-diaminobenzidine tetrahydrochloride (DAB) (Sigma-
Aldrich, Dorset, UK) for approximately 2 minutes. The chromagen reaction was stopped 
by irrigating in tap water for 5 minutes. Nuclear staining was achieved using Meyer’s 
haematoxylin (Surgipath-Europe Ltd, Peterborough, UK) for 30 seconds. Finally the 
sections were dehydrated by processing through 100% ethanol (2 x 5 minutes) and xylene 
(2 x 5 minutes) prior to mounting with dibutyl-polystyrene-xylene (DPX). Control 
sections included the use of antibody pre-treated with immunising peptide and omission 
of primary antibody. Liver and kidney sections were used as positive control tissues for 
11β-HSD1 and 2 respectively.  
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Antibody 
Primary Secondary 
Conditions 
 Concentration Duration 
(h) 
Concentration Duration 
(h) 
N
ZW
A
R
 
11β-HSD1 1:100 1.5 1:100 1 room temperature 
11β-HSD2 1:100 1 1:100 1 room temperature 
H
u
m
an
 
11β-HSD1 1:200 1.5 1:200 1 room temperature 
11β-HSD2 1:100 1 1:100 1 room temperature 
Table 2-1 Antibody conditions for 11β-HSD1 and 2   
 
2.1.2.2. Vimentin, Factor VIII related antigen and epithelial membrane antigen 
Human AGT was identified through staining with mouse monoclonal anti-human 
epithelial membrane antigen (EMA) IgG2a (Dako, Cambridgeshire, UK), 1:50 dilution, 
polyclonal rabbit anti-human Factor VIII related antigen (FVIII) (Dako, Cambridgeshire, 
UK), 1:1000 dilution, and mouse monoclonal anti-human vimentin IgG1, (Dako, 
Cambridgeshire, UK), 1:400 dilution, each incubated for 30 minutes. Positive control 
sections were the tonsil (EMA) and kidney (FVIII and vimentin).  Negative controls were 
incubated with no primary antibody. This work was carried out by Charlie Shaik, 
Academic Unit of Ophthalmology, Division of Immunity and Infection, University of 
Birmingham, Birmingham, United Kingdom. 
2.1.3. Cell culture 
2.1.3.1. Human choroid plexus epithelial cell line  
A commercial untransformed human choroid plexus epithelial (HCPEpi) cell line 
(ScienCell Research Laboratories, San Diego, USA) was utilised which had been 
previously characterised through staining with cytokeratin-18, -19 and vimentin. These 
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intermediate filament proteins, from the cytoplasmic cytoskeleton, are typical markers of 
CP epithelial cells (Sarnat 1998). Cells were cultured in epithelial cell medium (EpiCM),  
supplemented with 20% foetal bovine serum (FBS), 10% epithelial growth supplement 
and 10% penicillin and streptomycin (P/S), (all supplied by ScienCell Research 
Laboratories, San Diego, USA).  HCPEpi cells survive in culture for 15 population 
doublings. 
2.1.3.1.1 Cell recovery 
Vials of HCPEpi cells were removed from storage in liquid nitrogen and thawed at 37˚C 
in a water bath while being gently rotated. Vials were then transferred to a sterile field and 
sprayed with 70% ethanol. The contents of each vial were then re-suspended in 5 ml of 
culture media and transferred to T25 (surface area 25cm2) culture plate. 
2.1.3.1.2 Cell culture 
To aid tissue adhesion and growth, cells were grown in flasks pre-coated with poly-l-
lysine (ScienCell Research Laboratories, San Diego, USA). Poly-l-lysine, a positively 
charged synthetic amino-acid, altered the surface charge on the culture flask. Flasks were 
coated with poly-l-lysine (0.2 – 2 µg/cm2) for a minimum of 1 hour before being washed 
twice with sterile water and filled with cell media suspension. A seeding density of 750,00 
cells/cm2 was used. Cells were incubated at 37˚C in a humidified environment containing 
5% CO2 and 95% O2. Cell media was replaced on the day following passage and 
thereafter every 48 hours unless otherwise specified.  
2.1.3.1.3 Sub-culture 
Cells were sub-cultured when they were 80-90% confluent. Media was removed and the 
cells irrigated with PBS. Trypsin/ ethylenediaminetetraacetic acid (EDTA) solution was 
added (3 ml per T25 flask) and the cells incubated at 37˚C for 2 minutes. Flask agitation 
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aided cell detachment and when 80% of the cells were dislodged, the trypsin solution was 
neutralised with EpiCM supplemented with 20% FBS (3 ml per T25 flask). The cell 
suspension was then centrifuged at 1000 rpm and cells subsequently resuspended in fresh 
culture medium. Cells were passaged according to cell density and to accommodate future 
experiments. 
2.1.3.1.4 Cell storage 
Cells were collected with trypsin/EDTA as detailed above and resuspended in cell 
freezing media (ScienCell Research Laboratories, San Diego, USA), at a density of 
500,000 cells per ml. Cells were stored at -80˚C overnight and then transferred to liquid 
nitrogen for long term storage. 
2.1.3.2. Arachnoid granulation primary cell line 
The untransformed human arachnoid granulation primary epithelial cell line (AGEpi) was 
provided by collaborator Deborah Grzybowski, Ohio State University, Columbus, USA  
(Holman et al. 2005).  
2.1.4. Ribonucleic acid extraction 
2.1.4.1. Ribonucleic acid extraction from human choroid plexus epithelial cells  
The ribonucleic acid (RNA) yield, from HCPEpi cells, was found to be optimised by 
using a RNA extraction kit (Genelute mammalian total RNA extraction kit, Sigma-
Aldrich Company Ltd, Dorset, UK). Briefly, the cultured cell monolayer was covered in 
2-mercaptoethanol/lysis solution (10 µl:1 ml), agitated, and then transferred to a filtration 
column. The extraction process was then carried out according to the manufacturer’s 
protocol. The RNA pellet was resuspended in an appropriate volume of elution solution, 
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depending on the size of the pellet (typically 20 ul). All elements of RNA extraction were 
carried out on ice in a clean environment. RNA was stored at -80˚C. 
2.1.4.2. Ribonucleic acid extraction from tissue 
RNA was extracted from CP and AGT using the Genelute mammalian total RNA 
extraction kit (Sigma-Aldich Company Ltd, Dorset, UK) as described above. For all other 
tissues the RNA was extracted as follows: tissue was homogenised (approximately 
100 mg) in 500 µl of Tri-reagent (Sigma-Aldich Company Ltd, Dorset, UK). The tissue 
suspension was centrifuged for 5 minutes at 11269 g at 4˚C and the supernatant 
transferred to a separate eppendorf, the cell pellet was discarded. After standing for 5 
minutes the supernatant was mixed with 100 µl of chloroform. The sample was then 
incubated for 10 minutes at room temperature before being centrifuged for 30 minutes at 
12,000 rpm to separate the RNA into the aqueous layer. Isopropanol (250 µl) (Sigma-
Aldich, Dorset, UK) and glycol blue (1 µl) (Ambion, Cambridgeshire, UK) were then 
added to the aqueous layer prior to an overnight incubation at -20˚C. The following day, 
the sample was centrifuged at 11269 g for 30 minutes at 4˚C and the supernatant was then 
removed. The remaining RNA pellet was air dried for 5 minutes before being suspended 
in nuclease free water (approximately 20 µl, depending of the size of the pellet). RNA 
was stored at -80˚C.  
2.1.4.3. Ribonucleic acid confirmation 
RNA integrity was assessed (1 µl of RNA, 2µl of loading buffer and 9 µl of nuclease free 
water) by electrophoresis, using a 1% agarose gel and 1 µl/ml of ethidium bromide. Intact 
RNA, when visualised under UV light, exhibits 2 bands corresponding to the 28S and 18S 
ribosomal subunits. The RNA concentration was calculated after assessing the RNA 
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spectrophotometrically (OD260), 1 OD unit being equivalent to 40µg of RNA/µl. In the 
final year of study RNA concentration and quality were assessed using a Nanodrop 
spectrophotometer (Wilmington, DE, USA). 
2.1.4.4. Deoxyribonuclease treatment 
Deoxyribonuclease I (DNase I), amplification grade (Invitrogen, Paisley, UK), digests 
single and double-stranded DNA to oligodeoxyribonucleotides. Reaction components 
(Table 2-2) were mixed in a 1.5 ml eppendorf on ice and then incubated for 15 minutes at 
room temperature. The reaction was inactivated by the addition of 1 µl of EDTA (25 mM) 
and the sample heated on a hot block for 10 minutes at 65˚C. 
Reagent Volume (µl) 
RNA 
Reaction Buffer 
DNase I, Amp grade (1U/ul) 
Nuclease free water  
1.0 
1.0 
1.0 
variable 
Table 2-2 Deoxyribonuclease I reaction components 
The reaction volume was made up to a total volume of 10 µl with nuclease 
free water. 
 
The RNA was then recovered through the addition of 0.1 volume of 5M ammonium 
acetate and 1 µl of glycol blue (Ambion, Cambridgeshire, UK). RNA was precipitated 
though the addition of 1 volume of isopropyl alcohol. To maximise the RNA yield, the 
sample was incubated overnight at -20˚C. The following day, the supernatant was 
removed following centrifugation at 11269 g for 15 minutes at 4˚C. The remaining RNA 
pellet was washed with cold, 70% ethanol and centrifuged again under the same 
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conditions to remove further supernatant. The RNA pellet was then allowed to air dry 
before being resuspended in nuclease free water. 
2.1.5. Reverse-transcriptase polymerase chain reaction 
RNA was reverse transcribed to complementary DNA (cDNA) using a multiscribe reverse 
transcriptase kit according to the manufacturers protocol (Applied Biosystems, Cheshire, 
UK) (Table 2-3). Incubation times are listed in Table 2-4. 
Reagent Volume 
RNA 
10 x reaction buffer 
MgCl2 25mM 
Deoxy- nucleotide 
triphosphates (NTP’s) 
Random Hexamers 
RNase Inhibitor 
Multiscribe RT (500 µg/ml) 
1.0 µg 
5.0 µl 
11 µl 
10 µl 
2.5 µl 
1.0 µl 
3.2 µl 
Table 2-3 Reverse-transcriptase reaction components 
The reaction volume was made up to 50 µl using nuclease free water.  
 
 
 
Temperature (˚C) Time (minutes) 
25 
37 
48 
95 
4 
 
10 
60 
30 
5 
hold 
Table 2-4 Reverse transcriptase incubation 
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2.1.6. Conventional polymerase chain reaction  
The polymerase chain reaction (PCR) components (Promega, Southampton, UK) were 
mixed on ice, vortexed and placed in the PCR thermocycler (Table 2-5). The PCR cycle is 
detailed in Table 2-6. The PCR products were resolved on an agarose gel alongside a 
hyperladder (Bioline, London, UK) and viewed under UV light. Initially reverse 
transcription PCR was carried out on 18s to assess cDNA quality. Negative control 
reactions comprised of the above reaction mix with nuclease free water substituted for 
cDNA. In addition product from the reverse transcription reaction that had been carried 
out in the absence of multiscribe reverse transcriptase was also used as a control. 
 
Reagent Volume 
Nuclease free water   
PCR buffer with dye   
MgCl2 (25 mM)  
Deoxy-NTP’s (10 mM) 
Taq DNA polymerase (5 µg/µl) 
Primer Forward (10 µM)  
Primer Reverse (10 µM) 
cDNA  
variable 
4.0 µl  
1.6 µl (2 mM) 
0.5 µl (0.25 mM) 
0.1 µl (25ng/µl) 
1.0 µl (0.5 µM) 
1.0 µl (0.5 µM) 
2 .0µl 
Table 2-5 Polymerase chain reaction components 
The reaction is made up to a final volume of 20 µl with nuclease free 
water. 
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Temperature (˚C) Time (minutes) 
94 
94 
60 
72 
72 
4 
5 
0.5 
0.5 
0.5 
7 
hold 
Table 2-6 Polymerase chain reaction incubation cycle  
Details of modifications are documented in the respective sections. 
 
2.1.7. Real Time PCR 
Real-time PCR was performed using an ABI 7500 system (Perkin-Elmer, Biosystems, 
Warrington, UK) in 20 µl reactions on 96-well plates in reaction buffer containing 
TaqMan universal PCR master mix (Applied Biosystems, Warrington, UK), 3 mM Mg, 
2200 µM deoxy-nucleotide triphosphates (NTP’s), 1.25 U AmpliTaq Gold polymerase 
(PerkinElmer, Biosystems, Warrington, UK), 1.25 U AmpErase UNG (PerkinElmer, 
Biosystems, Warrington, UK), 900 nmol primers, 100–200 nmol TaqMan probe and 25–
50 ng cDNA. All reactions were singleplexed with primers specific for 18S RNA 
(provided as a pre-optimised mix; Perkin-Elmer, Beaconsfield, Bucks, UK) as an internal 
reference.  Measurements were carried out in triplicate for each sample.  All target gene 
probes were labelled with 6-carboxy-fluorescein FAM, and the housekeeping gene with 
VIC reported dye.  Reactions were as follows: 50°C for 2 minutes, 95°C for 10 minutes; 
then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute.  Data were expressed as 
cycle threshold (Ct) values (the cycle number at which logarithmic PCR plots cross a 
calculated threshold line) and used to determine ∆Ct values (∆Ct = Ct of the target gene 
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minus Ct of the housekeeping gene). All statistics were performed with ∆Ct values. 
Relative mRNA levels are expressed as fold changes (2-∆∆Ct). 
2.1.8. Primer design 
The primers for sgk-1 and MYOC were designed using the National Resource for 
Molecular Biology Information web site http://www.ncbi.nlm.nih.gov/. A search was 
carried out for the mRNA sequence of the gene of interest. The mRNA sequence was 
copied in FASTA (Pearson) format into an on-line primer design program (Primer3, 
provided by Whitehead Institute for Biomedical Research, USA), http://frodo.wi.mit.edu/. 
The guanine-cytosine % was limited to 40 – 60 %, and the primer annealing temperature 
was set at 60˚C. The primer sequences were then checked for hairpins, dimers, 
palindromes, repeats and runs using Net Primer (Premier Biosoft International, Canada) 
http://www.premierbiosoft.com/netprimer/. Primer sequences were generated by Alta 
Biosciences (University of Birmingham, UK). 
2.1.9. 11β-HSD enzyme assay 
2.1.9.1. Production of 3H-cortisone 
Tritiated cortisone (3H-E), was generated from tritiated cortisol (3H-F), using the 11β-
HSD2 enzyme activity inherent in human, term, placental tissue. In a glass tube, 20 µl of 
3H-F, 100.0 mCi/mM (Perkin Elmer, Boston, USA) was incubated with 1000 µg of 
homogenised placenta using 500 µM of NAD+ as a cofactor. The reaction mix was made 
up to 500 µl using 0.1 M phosphate buffer, pH 7.4. The reaction mix was incubated in a 
shaking water bath at 37˚C overnight. Steroid was then extracted and isolated as detailed 
below. 
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2.1.9.2. Steroid extraction and thin layer chromatography 
This technique was used both in the production of 3H-E and to extract steroid following 
enzyme activity assays. Steroids were extracted using 7 ml of dichloromethane and the 
reaction mixed agitated for 20 minutes. The sample was then centrifuged at 671 g for 15 
minutes to separate the aqueous and organic phases. The former was then aspirated and 
discarded. The organic phase was evaporated under air flow at 55˚C until dry, using a 
sample concentrator and Dry-Block (Techne, Staffordshire, UK). Dry steroid was then 
resuspended in 80 µl of dichloromethane and 1µl of solution pipette onto individual spots 
of a silica plate (Fluca, Sigma-Aldrich, UK). Unlabelled cortisol and cortisone standards 
(1mg/ml) were also “spotted” onto each sample to measure the solvent front. Steroids 
were separated using thin layer chromatography (TLC) in a tank containing a mobile 
phase of 200 ml chloroform: ethanol (92: 8 v:v) equilibrated for 1 hour before use.  The 
solvent front was run to within 1 cm of the end of the silica plate (approximately 90 
minutes). The silica plates were dried and scanned using a Bioscan 2000 radioimaging 
detector (LabLogic, Sheffield, UK) to localise tritiated steroids. The position and activity 
of 3H-E and 3H-F were then established. 
2.1.9.3. Steroid isolation 
To harvest 3H-E, the appropriate area of the silica plate was scraped into a glass tube, 
eluted in 1 ml of 100% ethanol and left overnight at 4˚C. Samples were then centrifuged 
at 700 g for 15 minutes to remove the silica. Supernatant, containing 3H-E, was then 
evaporated under air-flow at 55˚C. The 3H-E was re-suspended in 500 µl of 100% 
ethanol, and 5 µl was then spotted onto a silica plate before again separating by TLC. 
Activity and purity was then assessed using the Bioscan 2000 Radioimaging detector. 3H-
E was diluted in ethanol and stored in glass tubes at -20oC. 
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2.1.9.4. 11β-HSD enzyme assay protocol 
11β-HSD enzyme activity was assessed in both dissected whole tissue and in cultured 
cells. Both oxoreductase (cortisone to cortisol) and dehydrogenase activity (cortisol to 
cortisone) were assessed by incubating with unlabelled cortisone (100 nM) (Sigma-
Aldrich Company Ltd, Dorset, UK) and tracer amounts of 3H-E (50,000 c.p.m.) 
(synthesised in-house section 2.1.9.1) or unlabelled cortisol (100 nM) (Sigma-Aldrich 
Company Ltd, Dorset, UK) and tracer amounts (1·5 nM) of 3H-F (specific activity 100.0 
mCi/mmol, (Perkin Elmer, Boston, USA) respectively. Reactions were diluted in serum-
free medium and incubated at 37oC for 24 hours (unless stated otherwise). Assays were 
also incubated in the presence and absence of a 100-fold excess of glycyrrhetinic acid 
(GE) (5µM), a non-specific 11ß-HSD inhibitor. This concentration of GE has been 
previously shown to significantly reduce 11ß-HSD activity (Bujalska et al. 1997). After 
incubation, steroids were extracted and separated by TLC (detailed in section 2.1.9.2).  
The conversion of substrate to product was calculated after scanning analysis, using a 
Bioscan 2000 radioimaging detector (LabLogic, Sheffield, UK).  Enzyme activity was 
expressed as pmol mg-1 h-1 protein (see protein assay 2.1.10) or pmol g-1 h-1 wet weight 
for whole tissue explants. 
2.1.10. Protein assay 
Cells were washed in PBS and immersed in a minimal volume of distilled water and 
dislodged with a cell scraper. The cell suspension was then transferred to a 1.5 ml 
eppendorf and processed through 3 freeze-thaw cycles using liquid nitrogen and a 37˚C 
water bath.  The sample was then centrifuged for 1 minutes at 11269 g after which 5 µl of 
supernatant was transferred to a 96 well plate, in triplicate. Bovine serum albumin (BSA) 
5mg/ml was diluted in distilled water to establish a dilution series (0 mg/ml, 0.125 mg/ml 
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0.25 mg/ml, 0.5 mg/ml, 0.75 mg/ml, 1.0 mg/ml, 1.5 mg/ml and 2.0 mg/ml). 5 µl of each 
protein standard was transferred, in triplicate, to the 96 well plates. Standard protein assay 
reagents (Bio-Rad, Hemel Hempstead, UK), were added to each well using an automated 
pipette. The samples were incubated at room temperature for 10 minutes to allow a 
chromagen reaction. The absorbance of each well was then read for 0.1 seconds at 680 nm 
using the Victor3 1420 multilabel counter (Perkin Elmer, Wellesley, USA). A standard 
curve was plotted from the known protein concentrations and used to calculate unknown 
protein concentrations.  
2.2. Metabolite measurements  
2.2.1. Nuclear magnetic resonance spectroscopy 
Thawed samples (300µl), were centrifuged at 1000 rpm for 2 minutes prior to dilution 1:1 
with deuterium oxide containing NaCl (150mM), trimethylsilyl-2,2,3,3-
tetradeuteropropionic acid (TMSP) (2.5mM) and sodium phosphate (20mM) pH 7.4. 1H 
NMR spectra were obtained using a DRX 500MHz spectrometer (Bruker BioSpin, 
Rheinstetten, Germany) with a cryoprobe. 1D spectra were acquired using a standard 
spin-echo pulse sequence (8 µs (60˚) pulse with 3 s relaxation delay, 5.3 kHz spectral 
width) with 128 transients collected into 16,000 data points. Excitation sculpting was used 
to suppress residual water. Samples were analysed at 20˚C in 4.97 mm optical density 
NMR tubes (Norell INC, Landisville, USA).  2D JRES NMR spectra were obtained as 
previously described (Viant 2003). Briefly, the same conditions as that described for 1D 
spectra were employed, however, a 90˚ flip angles was applied and 16 transient per 
increment for 16 increments were collected into 16,000 data points. A spectral width of 50 
Hz in F1, the spin-spin coupling axis, and 5.3 Hz in F2, the chemical shift axis, were used. 
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The operator was masked to the clinical diagnosis, and samples were processed randomly. 
Spectra were phased manually, baseline corrected and referenced to the TMSP resonance 
(0.0 ppm). To facilitate analysis, each spectrum between 0.2 and 9.0 ppm was reduced in 
complexity, by segmenting into 0.005 ppm bins (2.5Hz) using ProMetab (version 2) 
(Viant 2003) within MATLAB (version 7.0, Matworks, Cambridge, UK). Bins between 
4.5 and 5.0 ppm containing residual water were removed, and the remaining bins were 
integrated. Each binned spectrum was normalised to a total spectral area of unity, 
transformed using a generalised log (glog) to increase the weighting of smaller peaks, and 
the peaks were aligned (Lee 2004). A data matrix was compiled with individual samples 
represented on rows, and chemical shifts delineated in columns. 
2.2.1.1. Data processing and analysis 
Data from the 2D JRES spectra were exported as 1D skyline projections, termed p-JRES. 
1D and p-JRES data were analysed using an unsupervised model principal components 
analysis (PCA) using PLS_Toolbox (version 3.5, Eigenvector Research, Washington, 
USA) within MATLAB. This technique reduces the dimensionality of the binned spectra 
(Ramadan et al. 2006). This is achieved by transforming the binned spectra into new 
variables, termed principal components (PC), which are weighted, linear combinations of 
the original spectral bins (presented as weighting plots). In effect, PCA identifies the most 
highly variable metabolites in the NMR spectra. 
Partial least squares discriminant analysis (PLS-DA) was then employed using 
PLS_Toolbox (version 3.5, Eigenvector Research, Washington, USA within MATLAB).  
This supervised analysis technique (Bijlsma et al. 2006; Ramadan et al. 2006) was used to 
build a model to evaluate separation between groups based on known clinical diagnosis. 
The PLS-DA model was cross-validated using Venetian blinds (Martens and Naes 1989; 
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Chauchard et al. 2004). This method re-assigns randomly selected blocks of data to the 
PLS-DA model to determine the accuracy of the model in correctly assigning class 
membership 
Identification of the discriminating peaks in the spectra was carried out using Chenomx 
NMR Suite (version 4.0, Chenomx, Alberta, Canada), an NMR analysis program, in 
conjunction with the human metabolite database (Wishart et al. 2007) and published 
literature (Brindle et al. 2002; Subramanian et al. 2005). 
Metabolomic processing and analysis was conducted with advice from Steven. P. Young, 
Rheumatology, School of Immunology, Infection and Inflammation, and Mark Viant 
School of Biosciences, University of Birmingham. 
2.2.2. Gas chromatography/ mass spectrometry 
GC/MS assays were carried out by Beverley Hughes at the Institute for Biomedical 
Research, University of Birmingham. The GC/MS assay performed was based on the 
method described by Palermo (Palermo et al. 1996).  Samples of urine (1 ml of a 24 hour 
urine collection) and serum (1 ml) were processed. 
The following isotope-labelled internal standards were used; (9,11,12,12-2H4) cortisol and 
(9,12,12-2H3) cortisone. The standards were calibrated by high-performance liquid 
chromatography (HPLC) analysis of solubilised, non-labelled standard of known weight. 
Free steroid was extracted using Sep-pak C18 cartridges (Shackleton and Whitney 1980). 
Labelled steroid, d4-cortisol (0.18 µg), and d3-cortisone (0.12 µg), as well as internal 
standards (stigmasterol and cholesteryl butyrate), 200 µg, were then added. The samples 
were then derivatised using 100 µl of 2% methoxyamine hydrochloride in pyridine and 50 
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µl of trimethylsilylimidazole. Lipidex chromatography was then used to purify the steroid 
derivative.  
GC/MS was carried out using a Hewlett Packard 5970 mass spectrometer and 15 m fused-
silica capillary column, 0.25 mm ID, 0.25µm film thickness (J&B Scientific, Folsom CA, 
and USA) using 2 µl of sample. Steroids were quantified by comparing individual peak 
area to the peak area of their internal standards, for cortisol fragment 605 m/z compared to 
609 m/z and for cortisone fragment 531 m/z compared to 534 m/z. The relative peak area 
was calculated and metabolite concentration expressed as µg/24h. A quality control (QC) 
was analysed with each batch. The intra and inter-assay coefficient of variance was <10%. 
2.2.3. Liquid chromatography / mass spectrometry  
Liquid chromatography / mass spectrometry (LC/MS) was carried out on our behalf by Dr 
Andre van Beek and Ido Kema, (Department of Endocrinology and Department of 
Laboratory Medicine, University Medical Centre Groningen, University of Groningen, the 
Netherlands). Extraction and quantification of CSF cortisol and cortisone was performed 
by on- line solid phase extraction coupled with liquid chromatography and tandem mass 
spectrometry 
100 µl of CSF was mixed directly in an autosampler vial with 20 µl internal standard 
solution (Cortisol-d4 , cortisone-d7 Cambridge Isotope Laboratories (Andover, MA, 
USA); and diluted with water to reach a final volume of 200 ul. 50 µl of the sample was 
injected into the XLC-MS/MS system. Sample clean-up took place by on-line SPE, using 
a Spark Holland Symbiosis® system (Spark Holland, Emmen, the Netherlands) as 
described previously (de Jong et al. 2007). HySphere® C18 HD 10 by 2 mm SPE 
cartridges (Spark Holland, Emmen, Netherlands) were used for sample extraction. 
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Chromatographic separation was achieved by using an Xbridge C8 (particle size 3.5 µm, 
2.1 mm internal diameter by 100 mm; Waters, Milford, MA).  
Detection was performed with a Quattro Premier® tandem mass spectrometer equipped 
with a Z Spray® ion source operated in positive electrospray ionization mode (Waters, 
Milford, MA). Cortisol, cortisone and their deuterated internal standards were protonated 
to produce ions at the form [M+H]+, with m/z 363 and m/z 367, and m/z 361 and m/z 368 
respectively. Upon collision-induced dissociation with argon gas, these precursor ions 
produced characteristic product ions of m/z 121 for both cortisol, and its deuterated 
internal standard. For cortisone and its internal standard, product ions were: m/z 163 and 
167. The A multiple reaction monitoring mode was developed for the specific m/z 
transitions 363→121 and 367→121 (cortisol and internal standard cortisol) and 361→163 
and 368→167 (cortisone and internal standard cortisone). 
2.2.4. Commonly used buffers and reagents 
Agarose gel 1% 
 Agarose  TBE      1% (w/v) 
 Ethidium Bromide     1.0 µg/100ml 
Tris/Borate/EDTA (TBE) [10x] 
 Tris       89 mM 
 Boric acid      89 mM 
 EDTA       2 mM  
Citric Acid buffer 0.01M (Ph 6) 
 Citric acid       0.1 M 
 Sodium citrate      0.1 M 
 Make to required volume with H20. Adjust to Ph 6 with hydrochloric acid 
Chapter 2   
90 
Methanol Hydrogen peroxide 30% 
 Methanol        
 H202      62.5:1 (v/v) 
PBS 
 NaCl      120 mM 
 KCl      2.7 mM  
 Phosphate salt     10 mM 
Trypsin 
 PBS 
 EDTA      0.5 M pH 8.0 
 Trypsin     0.25% 
 Make up with [1x] PBS and [1x] EDTA 
 
2.3. Clinical studies 
The clinical investigations carried out in this thesis were performed at the Birmingham 
and Midland Eye Centre, Sandwell and West Birmingham Hospitals NHS Trust or at the 
Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Trust.  
The majority of techniques employed to assess visual function are routinely utilised and 
validated (LogMAR visual acuity, Humphrey 24-2 central threshold automated perimetry, 
Pelli Robson contrast sensitivity and Farnsworth Munsell 100 Hue colour test). The novel 
techniques used to quantify papilloedema are detailed below. 
2.3.1. Ultrasonography 
Images were captured and measured by Dr Peter Good, visual function department, 
Birmingham and Midland Eye Centre. All images were obtained following application of 
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methylcellulose coupling gel to the closed eyelids. A high resolution scanner (Quantel 
Medical, Clermont–Ferrand, France) with a focal length of 25 mm and resolution of 
0.01mm was used. 
2.3.1.1. Optic disc elevation 
B-scan images of the optic disc were obtained at 20 MHz emission frequency. The 
imaging plane displaying the maximal disc height was frozen (oblique sections, which 
falsely represent the disc height, were not used). Measuring callipers were placed between 
the point of maximal optic nerve elevation and the highly reflective lamina cribrosa. 
Horizontal and vertical measurements were taken, and the mean established. 
2.3.1.2. Nerve sheath diameter 
The optic nerve sheath was imaged using a 10 MHz B scan. A still image of the 
retrobulbar optic nerve was obtained and the maximal inner pial diameter measured with 
callipers. 
2.3.2. Optical coherence tomography 
Images were obtained by members of the Visual Function Department, Birmingham and 
Midland Eye Centre. The Stratus OCTTM V4.0.1 (Carl Zeiss, Meditec, Welwyn Garden 
City, UK) was used to measure distension of the peripapillary RNFL. Circumferential 
measurements of the optic disc were made using Fast RNFL Thickness (3.4) acquisition 
protocol.  Pupils were under normal physiological conditions. Images were re-acquired if 
image quality was hampered by blinking or inadequate focus (signal strength greater than 
six was required). The same operator collected two optimised images of each eye 10 
minutes apart. The average RNFL thickness values were calculated using the “Average 
analysis” protocol.  
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2.3.3. Dual energy x-ray absorptiometry  
Dual energy x-ray absorptiometry (DEXA) (QDR 4500; Hologic, Bedford, MA) 
measured total body composition. Fat distribution and mass was calculated using 
standardised software (Stewart et al. 1999). The fat mass coefficient of variance was less 
than 3%.  Imaging was performed by Nicola Crabtree, Department of Nuclear Medicine, 
University Hospital Birmingham NHS Trust. 
2.3.4. Serum measurements 
Measures of total cholesterol, triglycerides and glucose were performed by the 
Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation 
Trust Selly Oak Hospital, Birmingham, using spectrophotometric assays (Roche 
Diagnostics, Burgess Hill, UK). Cholesterol inter-assay coefficient of variance was 0.8% 
at 5.98 mmol/l (minimum sensitivity 0.08 mmol/l). Triglycerides inter-assay coefficient of 
variance was 1.5% at 2.28 mmol/l (minimum sensitivity 0.05 mmol/l). Glucose inter-
assay coefficient of variance was 1.0% at 7.05 mmol/l (minimum sensitivity 0.11 mmol/l). 
2.3.4.1. Insulin enzyme linked immunosorbant assay 
Insulin was measured by enzyme linked immunosorbant assay (ELISA) (Mercodia AB, 
Uppsala, Sweden) in serum (25 µl). The inter-assay and intra-assay coefficient of variance 
was < 4% and <3.6% respectively, with a sensitivity range of 3 – 200 mU/l. The assay 
showed no cross reactivity with proinsulins or c-peptide. The assay was performed by 
Susan Hughes, Centre for Endocrinology, Diabetes and Metabolism, School of Clinical 
and Experimental Medicine, University of Birmingham. 
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2.3.4.2. The Homeostasis Model Assessment (HOMA)  
The Homeostasis Model Assessment (HOMA) is based on the concept that fasting insulin 
levels are inversely related to insulin sensitivity. Under conditions of insulin resistance, 
elevated fasting glucose levels maintain the drive to the pancreatic islet B cells to secrete 
insulin (Turner et al. 1979). The HOMA score was calculated from the fasting glucose 
(mmol/l) and the fasting insulin (pmol/l) using software downloaded from the University 
of Oxford Diabetics Trials Unit (http://www.dtu.ox.ac.uk/index.php?maindoc=/homa/). 
The HOMA %B estimates steady state beta cell function, HOMA %S insulin sensitivity 
and HOMA IR (insulin resistance) as a percentage of a normal reference population, 
including young adults (Levy et al. 1998).  
HOMA %B= 20 × fasting insulin (µU/ml) / fasting glucose (mmol/ml) − 3.5 
HOMA %S = 1 / ((fasting insulin (µU/ml) × fasting glucose (mmol/ml)) / 22.5) 
HOMA IR = fasting glucose (mmol/l) × fasting insulin (µU/ml) / 22.5 
 
2.3.4.3. Biochemical hyperandrogenism screening 
The assays were performed by Dr Penny Clarke, Regional Endocrine Laboratory, 
Department of Clinical Biochemistry, University Hospitals Birmingham NHS Foundation 
Trust Selly Oak Hospital, Raddlebarn Road, Selly Oak, Birmingham, B29 6JD. 
Androstenedione was assessed by competitive radioimmunoassay using I,125-labelled D4 
androstenedione (Coat-a-Count kit TKAN2, Siemens Healthcare Diagnostics, Deerfield, 
USA). The inter assay coefficient of variance at 7.5nmol/l was 5.2% and 6.9 % at 16.7 
nmol/l, assay minimum sensitivity was 0.5 nmol/l. Dehydroepiandrosterone sulphate 
(DHAS) was measured by, Chemiluminescent immunometric assay (Immulite 2500, 
Siemens Healthcare Diagnostics, Deerfield, USA). The inter-assay coefficient of variance 
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at 1.79 µmol/l was 6.2% and at 13.3 µmol/L was 3.8%. Assay minimum sensitivity was 
0.8 µmol/l. Sex hormone binding globulin (SHBG), was also measured by, 
Chemiluminescent immunometric assay (Immulite 2500, Siemens Healthcare 
Diagnostics, Deerfield, USA). The inter assay coefficient of variance at 19.3 nmol/l was 
2.5% and at 71.0 nmol/L was 3.1%. Assay minimum sensitivity was 0.2 nmol/l. 
Testosterone was evaluated by liquid chromatography / tandem mass spectrometry, with 
testosterone-d5 used as an internal standard (Waters 2795 Quattro Premier XE system, 
Milford, MA). The inter-assay coefficient of variance at 1.0 nmol/l was 1.9% and at 10.0 
nmol/L was 1.9%, assay minimum sensitivity was 0.03 nmol/l. 
2.4. Statistical Analysis 
Statistical analysis was performed using SPSS versions 14 and 15 (SPSS Inc., Chicago, 
USA) and Prism for Windows Version 5.0 (GraphPad Software Inc, San Diego, CA, 
USA) software packages. Continuous data were summarised using means and standard 
deviations (or medians and ranges for non-normally distributed data).  Parametric data 
were compared using a paired t-test (Mann-Whitney for non-parametric data). Multiple 
comparisons were assessed using one way analysis-of-variance (ANOVA), with Kruskal-
Wallis for non-parametric data. Associations between variables were analysed using 
Pearson correlation for parametric data and Spearman rank correlation for non-parametric 
data. The level at which the results were judged significant was p <0.05. 
Throughout the thesis statistical advice was received from Dr Peter Nightingale, 
Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital, University 
Hospitals Birmingham NHS Foundation Trust, Birmingham, B15 2TT. 
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Chapter 3. Characterisation of 11β HSD in Choroid plexus and 
Arachnoid Granulation tissue 
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3.1. Introduction 
IIH is a condition of unknown aetiology characterised by elevated ICP. Improved 
understanding of the mechanisms which regulate ICP are consequently a vital component 
to enhancing our knowledge of IIH. We have discussed the potential role of 11β-HSD in 
modulating CSF dynamics (sections 1.9.2. and 1.9.3). To this end we characterise 11β-
HSD in CP and AGT. Experiments were initially carried out in an animal model (the New 
Zealand White Albino Rabbit (NZWAR)) and subsequently in human tissues. 
3.1.1. Animal studies 
CSF secretion by the CP epithelium occurs via a similar mechanism to that which controls 
AH secretion in the embryologically related, ocular ciliary body. The role of 11β-HSD1 in 
the pre receptor regulation of AH secretion has been established (Rauz et al. 2001; Rauz 
et al. 2003a; Rauz et al. 2003b; Rauz et al. 2003c). We suggest, that akin to the regulation 
of AH, 11β-HSD1 may also have a role in modulating CSF production. We have 
therefore, conducted a detailed analysis of 11β-HSD isozyme expression in the NZWAR 
CP and compared expression of key elements of the glucocorticoid signalling pathway, to 
the NZWAR ciliary body. The NZWAR was chosen, as the corticosteroid profile 
resembles that of humans. Additionally this model has been used for a variety of in vivo 
(Onyimba et al. 2006), CSF and intracranial pressure studies (Senay and Tolbert 1984; 
Greene et al. 1985; Uhl et al. 1999; Artru and Momota 2000; Taplu et al. 2003; 
Kostopoulos et al. 2006). The rodent was deemed to be a less suitable model as the steroid 
profile differs in man and rabbits (corticosterone and 11-dehydrocorticosterone in the rat) 
and additionally the small size impedes accurate dissection of brain structures.  
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3.1.2. Human Studies 
11β-HSD demonstrates considerable interspecies variability (Tomlinson et al. 2004b) and 
hence we sought to characterise 11β-HSD and the glucocorticoid signalling pathway in 
human CP as well as in AGT.   
3.2. Methods 
3.2.1. Animal studies 
3.2.1.1. Animal tissues 
Adult (2.5 – 3.0 kg), female, New Zealand White Albino Rabbits (NZWAR) were used in 
this study (Charles River, Margate, UK), (n=13). The rabbits were group-housed in open 
floor pens, (maximum of six rabbits per pen) illuminated from 07.00 to 17.00 (10:14 hour 
day-night cycle). Rabbits were maintained on a standard pelleted diet (SDS-FD1, Lillico, 
Surrey, UK) with water ad libitum. The rabbits were acclimatised for a period of 
approximately one week before lethal injection with pentobarbital sodium 60mg/ml (J.M. 
Loverage p.l.c., Southampton, UK) at a dose of 1ml/kg. All animals were studied in a 
manner consistent with FRAME Guidelines and according to the UK Home Office 
Guidelines for the care and use of laboratory animals. 
CSF was collected via puncture of the cisterna magna. CP and ciliary body were 
surgically dissected and stored in either  sterile eppendorfs containing Hams F12 
Dulbecco’s Modified Eagle’s Medium (DMEM – Invitrogen, Paisley, UK) for enzyme 
assay, or in RNA Later (Sigma-Aldrich, Dorset, UK) for RNA extraction. In four rabbits, 
the brain was dissected from the skull en bloc, following perfusion fixation with 50ml of 
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10% formalin. The whole brains were then immersed in 10% formalin for a further three 
days, prior to paraffin embedding and sectioning. 
3.2.1.2. Immunohistochemistry 
Histological conformation was carried out using H&E staining (section 2.1.1). 
Immunohistochemical analyses were performed on 5 µm thick coronal sections of 
NZWAR whole brain (four) mounted on coated slides (VWR, Lutterworth, UK). 11β-
HSD immunolocalisation was carried out as described (section 2.1.2.1), using primary 
antibody concentrations of 1:100 for both 11β-HSD1 and 11β-HSD2. 
3.2.1.3. 11β-HSD activity assay 
The rabbit CP was divided into five, of which four pieces were placed whole into 
individual wells of a 24-well plate. The fifth piece of tissue was fixed in formalin and 
embedded in paraffin for confirmatory histology with H&E staining. Tissue was 
incubated with 100 nM cortisol and 100 nM cortisone (Sigma-Aldrich Company Ltd, 
Dorset, UK)  with tracer amounts (1·5 nM) of tritiated steroids at 37˚C for 24 hours, as 
previously described (2.1.9.4 and 2.1.9.2). 100-fold excess of GE (5µM) was used as a 
non-specific 11ß-HSD inhibitor.  
3.2.1.4. Real Time polymerase chain reaction 
RNA was extracted and reverse transcribed from CP and ciliary body explants from three 
rabbits as described (section 2.1.4.2 and 2.1.5). As the intron exon boundaries were not 
defined for our genes of interest, total RNA was DNase I treated to remove any genomic 
DNA contamination (Deoxyribonuclease I, Invitrogen, Paisley, UK) (section 2.1.4.4).  
Quantity and quality of mRNA was assessed (section 2.1.4.3) prior to real time PCR 
(methodology detailed in section 2.1.5).   
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Primers and probes used for defining 11β-HSD1, GRα and sgk-1 mRNA levels were 
designed using Primer Express software (Applied Biosystems, Warrington, UK) (Table 
3-1). cDNA (50 ng) was used for real-time PCR, to define expression of the three genes of 
interest (section 2.1.7). All statistics were performed with ∆Ct and relative mRNA levels 
expressed as fold changes (2-∆∆Ct).  
Target Gene Primer Sequence 
GRα Forward 5'-AGAAAGCATCGCGAGCCTC  
Reverse 5'-AGCAGGCGCTGTGCTCC 
Probe - TCGGCTAGTGGTGCAGACAACCCC  
11β-HSD1   Forward 5'-CCCACTGCCTGAAGCTGG  
Reverse 5'-GCAAAGGTCATGTCCTCCATG 
Probe - CCTCCGCACACTACATTGCTGGCA  
sgk-1   Forward 5'-AGAAAGCATCGCGAGCCTC 
Reverse 5'-AGCAGGCGCTGTGCTCC 
Probe - TCGGCTAGTGGTGCAGACAACCCC  
 
 
Table 3-1 Real time PCR primer sequences 
Primers and probes used in real time PCR. GRα indicates the 
glucocorticoid receptor α; 11β-HSD1, 11β-hydroxysteroid dehydrogenase 
type 1; sgk-1, serum and glucocorticoid-regulated kinase1 
 
3.2.1.5. Cerebrospinal fluid cortisol measurements 
The CSF from nine female rabbits was centrifuged at 176g for 2 minutes to remove any 
contaminating cells, and the CSF supernatant was stored at -80˚C until analysis. The CSF 
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cortisol was analysed using an ELISA technique according to manufacturer’s protocol 
(Assay Design’s Incorporated, Michigan).  
3.2.2. Human studies 
3.2.2.1. Human tissues and cells 
Human tissue and cells were obtained from four sources: (1) Surgically acquired tissue 
specimens of CP and AGT  obtained from the neurosurgical department (University 
Hospital Birmingham NHS Foundation Trust, UK) from patients undergoing tumour 
excision; (2) Formalin fixed, snap frozen, and fresh tissue specimens of CP and AGT 
from the Parkinson’s Disease Society Tissue Bank at Imperial College, London, UK 
(funded by the Parkinson’s Disease Society of the United Kingdom, registered charity 
948776); (3) A commercial untransformed primary HCPEpi cell line; and (4) An 
untransformed primary AGEpi cell line established by collaborator Deborah Grzybowski 
(Grzybowski et al. 2006b). Ethical approval was in place for all aspects of the study 
(Dudley Local Research Ethics Committee (LREC) 06/Q2702/19). Tissue specimens were 
transported in three different ways; 1) fixed in 10% formalin, 2) fresh frozen, after snap 
freezing in liquid nitrogen and 3) in sterile pots containing DMEM (Invitrogen, Paisley, 
UK) supplemented with 1% penicillin and streptomycin (P/S).  
3.2.2.2. Immunohistochemistry 
Formalin fixed human CP and AGT (n=6) were embedded in paraffin and 5µm sections 
mounted on electrostatically charged slides (VWR, Lutterworth, UK). Tissue 
identification was facilitated using H&E staining. AGT was further characterised through 
staining with vimentin, FVIII and EMA (section 2.1.2.2). Immunolocalisation for 11β-
HSD1 and 2 was then conducted as described (sections 2.1.2.1) on CP and AGT.  Primary 
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and secondary antibody dilutions were 1:200 for 11β-HSD1, and 1:100 for 11β-HSD2. 
Human liver and kidney was utilised as positive control tissues for 11β-HSD1 and 2 
respectively, and antibody pre-treated with immunising peptide as a negative control. 
3.2.2.3. Reverse transcriptase polymerase chain reaction 
RNA was extracted from fresh frozen CP and AGT as well as from HCPEpi and AGEpi 
cells using the Genelute mammalian total RNA extraction kit (Sigma-Aldich Company 
Ltd, Dorset, UK), and reverse-transcribed using Multiscribe reverse transcriptase 
according to the manufacturer’s protocol (Applied Biosystems, Warrington, UK) (section 
2.1.4). RNA concentration and quality were confirmed, and standardised mRNA 
expression was monitored through comparison to housekeeping gene 18s. PCR was 
carried out using GoTaq DNA polymerase (section 2.1.6).  Primer sequence (Alta 
Biosciences, Birmingham, UK) and cycle details are listed in Table 3-2. 
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Gene Primer cDNA, 
bp 
Annealing 
temp 
PCR 
cycles 
Accession 
number 
11β-HSD1 5’ACCAGAGATGCTCCAAGGAA 3’ 
5’ATGCTTCCATTGCTCTGCTT 3’ 
411 60 30 NM 
005525 
11β-HSD2 5’TGGAGGTGAATTTCTTTGGC 3’ 
5’GGATTCTTTAGGCCAGGGTC 3’ 
774 60 30 U27318 
 
GRα 5’TCGACCAGTGTTCCAGAGAAC 3’ 
5’TTTCGGAACCAACGGGAATTG 3’ 
693 60 30 NM 
001024094 
MR 5’AACTTGCCTCTTGAGGACCAA 3’ 
5’AGAATTCCAGCAGGTCGCTC 3’ 
450 60 30 NM 
000901 
H6PD 5’AGAAGCGAGACAGCTTCCAC 3’ 
5’GCTGCTGGGAAAAGAACAAC 3’ 
603 60 30 NM 
004285 
sgk-1 5’AGGGCAGTTTTGGAAAGGTT 3’ 
5’GCTTTGTCCTGTCCTTCTGC 3’ 
699 60 34 NM 
005627 
Myocilin 5’ CTGCCTACAGCAACCTCCTC 3’ 
5’CTCGCATCCACACACCATAC 3’ 
399 60 34  NM 
000261 
 
5α 
Reductase 1  
 
5’CAGATCCCCGTTTTCTAATAGG 3’ 
5’AAACGTGAAGAAAGCAAAAGC 3’ 
239 60 30 NM 
001047.2 
5α 
Reductase 2 
 
5’ CTGGAGAAATCAGCTACAGG 3’ 
5’ GCTTTCCGAGATTTGGGGTA 3’ 
226 60 30 NM 
000348.3 
AR 5’CGGAAGCTGAAGAAACTTGG 3’ 
5’ATTTTTCAAGCCCATCCACTG 3’ 
584 60 34 NM 
000044.2 
ERα 5’AGACATGAGAGCTGCCAACC 3’ 
5’GCCAGGCCATTCTAGAAGG 3’ 
299 55 34 NM 
000125.3 
ERβ 5’TCACATCTGTATGCGGAACC 3’ 
5’CGTAACACTTCCGAAGTCGG 3’ 
346 55 34 NM 
001437.2 
Table 3-2 Primer sequences used for PCR 
temp indicates temperature. 
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3.2.2.4. 11β-HSD assay 
Human CP (n = 5) and AGT (n = 2), within  30 hours of post-mortem, were washed in 
PBS, surgically dissected from surrounding tissue and divided into equal sized pieces 
(approximately 100 mg). Activity assays were conducted in an identical manner to that 
described in rabbit tissues (section 3.2.1.3). Enzyme activities were expressed as pmol h-1 
g-1 wet weight. 
11β-HSD activity assays were also conducted on HCPEpi and AGEpi cell cultured to 
90% confluence in 12 well plates. Cells were washed twice with sterile PBS prior to 24 
hour enzyme assay, which was carried out using serum free media. 24 hour incubation 
was chosen as 11β-HSD oxoreductase reaction kinetics were assessed over a time course 
(4, 6, 8, 10, 12, 16, 24 h, n = 3) with a linear reaction phase demonstrated between 10 and 
24 hours (data not shown). Additionally, enzyme assays carried out on HCPEpi cells of 
varying passage (range 3-8, n = 6) demonstrated non significant variation with cell 
passage. However, the HCPEpi cells, at passages greater than 8, altered in morphology 
and were therefore no longer deemed to be truly representative of epithelial cells and so 
not utilised.  
3.3. Results 
3.3.1. Animal studies 
3.3.1.1. Immunohistochemistry 
Cross-species reactivity of the 11β-HSD1 anti-human antibody was confirmed using 
sections of rabbit liver as previously described (Onyimba et al. 2006). The rabbit liver 
probed with the 11β-HSD1 antibody, revealed intracellular staining surrounding the 
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central vein (Figure 3-1A), a pattern typical of human liver (Ricketts et al. 1998). A pre-
adsorbed antibody specifically removed the staining (Figure 3-1B). Sections of whole 
NZWAR brain demonstrated immunoreactivity confined to the epithelial layer of the CP 
(Figure 3-1C) that was reduced after prior treatment of the antibody with immunising 
peptide (Figure 3-1D). Kidney cortical collecting ducts, an area of high 11β-HSD2 
expression in the human, stained intensely for 11β-HSD2 in the rabbit (Figure 3-1E), 
compared to a section incubated with no primary antibody (Figure 3-1F). CP tissue 
probed with 11β-HSD2 antibody revealed no staining (Figure 3-1G and H). 
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Figure 3-1 Immunohistochemistry using anti- human 11β-HSD1 antibody  
Characteristic distribution of 11β-HSD1 staining in the rabbit liver 
surrounding the central vein (CV) (A). No staining was detected using the 
pre-adsorbed antibody (B). 11β-HSD1 staining was seen in the choroid 
plexus epithelial cells (CPE), (C) and was specifically removed with pre-
adsorbed immunising peptide (D). Immunohistochemistry using anti- 
human 11β-HSD2 antibody demonstrated intense staining of the rabbit 
kidney collecting ducts (CD) confirming cross-species reactivity (E), which 
was absent when the section was incubated with no primary antibody (F). 
There was no expression of 11β-HSD2 in the CPE (G), when compared to 
a section incubated with no primary antibody (H). 
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3.3.1.2. 11β-HSD activity assays 
11β-HSD activity assays confirmed predominant oxoreductase activity in dissected CP 
(Figure 3-2), and indicated a significantly higher substrate conversion of cortisone to 
cortisol versus cortisol to cortisone (median conversion 5.0 (range 4.1- 5.6) pmol h-1mg-1 
versus 1.1 (range 0.7 -1.6) pmol h-1mg-1 respectively; p<0.001)). Co-incubation with GE 
reduced both oxoreductase activity and dehydrogenase activity (median conversion 0.2 
pmol h-1mg-1; p<0.001) versus 0.3 pmol h-1mg-1; p<0.05 respectively).  
Ox
o-
re
du
cta
se
Ox
o-
re
du
cta
se
 
+ 
GE
De
hy
dro
ge
na
se
De
hy
dro
ge
na
se
 
+ 
GE
0
2
4
6
***
***
*
pm
o
l h
-
1 m
g-
1
 
Figure 3-2 11β-HSD activity in rabbit choroid plexus 
Range plots (median, full range; n=6) show oxoreductase activity was 
significantly higher than dehydrogenase activity (*** p<0.001). Oxo-
reductase and dehydrogenase activities were significantly inhibited when 
co-incubated with 100-fold excess of glycyrrhetinic acid (GE) 
(oxoreductase *** p<0.001; dehydrogenase * p<0.05). 
 
3.3.1.3. Real time polymerase chain reaction 
Real time PCR analyses of CP and ciliary body whole tissue revealed comparable 
expression of 11β-HSD1, GRα and sgk-1 genes in both tissues (Figure 3-3); n=3, ciliary 
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body:CP ratios: 11β-HSD1, 1:0.9; GRα, 1:0.8; sgk-1, 1:1.2.  sgk-1 is  a glucocorticoid 
regulated transcription factor which drives epithelial sodium transport. 
 
Figure 3-3 Real time (Taq Man) PCR in rabbit choroid plexus and ciliary body 
Expression of 11β-HSD1, GRα and sgk-1 in choroid plexus compared to 
levels in the ocular ciliary body,(n=3). Relative mRNA expression is 
documented as fold change, (2-∆∆Ct), with ∆Ct’s and standard error of the 
mean (SEM). 
 
3.3.1.4. CSF cortisol enzyme linked immunosorbant assay 
Cortisol was detected in rabbit CSF in 6 out of the 9 rabbits, median 1.7 (range 1.4 – 4.3) 
nmol/l. CSF and cortisol levels were undetectable in 3 rabbits due to the haemolysed 
nature of the samples.  
3.3.2. Human studies 
3.3.2.1. Immunohistochemistry 
H&E staining provided confirmatory histology of human CP and AGT (Figure 3-4).  
Immunohistochemistry in the AGT, confirmed characteristic staining for vimentin in the 
AG core and cap cell cluster (Kida et al. 1988), compared to a section incubated with no 
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primary antibody. FVIII specifically stained the AG endothelium but did not stain the cap 
cell cluster when compared to a section incubated with no primary antibody (Kida et al. 
1988). The epithelial cells of the arachnoid cap stained positively for EMA, while the 
section incubated with no primary antibody did not (Figure 3-5). 
11β-HSD 1 antibody showed a characteristic distribution of staining around the liver 
central vein, which was specifically removed when incubated with a pre-adsorbed 
antibody (Figure 3-6A and B). The CP epithelium stained positively for 11β-HSD1, this 
was specifically removed with a pre-absorbed antibody (Figure 3-6C, D, E and F). In the 
AGT, 11β-HSD1 stained the arachnoid cap cell cluster, compared to sections incubated 
with a pre-absorbed antibody (Figure 3-4G, H, I and J). No staining was seen when 
sections of CP or AGT were incubated with anti-human 11β-HSD2 antibody, although 
kidney collecting ducts stained in a characteristic distribution (data not shown). 
3.3.2.2. Reverse transcriptase polymerase chain reaction 
Reverse transcriptase PCR of HCPEpi cells, AGEpi cells, human CP tissue and human 
AGT tissue identified mRNA expression for key elements of the glucocorticoid pathway 
and sex hormone receptors. 11β-HSD2 was not expressed in tissues or cell lines (Figure 
3-7). The HCPEpi cells differed from the human CP tissue in that it did not express 
oestrogen receptor α or MYOC. 5α Reductase 1 expression was noted in both the HCPEpi 
and AGEpi cell lines but expression was very weak in the AGT and not seen in the CP 
tissue. 5α Reductase 2 was not expressed in either tissues or cell lines. 
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Figure 3-4 Haematoxylin and eosin staining 
Confirmatory histology of (A) arachnoid granulation tissue, (B) arachnoid 
granulation tissue core, (C) choroid plexus and (D) single choroid plexus 
villus.  
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Figure 3-5 Immunohistochemistry in human arachnoid granulation (AG) tissue 
Anti human vimentin shows characteristic staining in the AG cap cell 
cluster (A) and core (C) compared to sections incubated with no primary 
antibody (B) and (D). Anti-human FVIII stained the AG endothelium 
(arrow, E) compared to a control section with no primary antibody (F). 
Anti-human EMA stained the arachnoid cells in the AG cap cell cluster 
(arrow, G) compared to a control incubated with no primary antibody (H). 
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Figure 3-6 11β-HSD immunohistochemistry in human choroid plexus and 
arachnoid granulation tissue 
Characteristic distribution of 11β-HSD1 staining in the human liver 
surrounding the central vein (CV) (A). Minimal staining when the primary 
antibody was pre-absorbed with immunising peptide (B). 11β-HSD1 
staining in the choroid plexus epithelial cells (CPE) (C, D), specifically 
removed with pre-adsorbed immunising peptide (E, F). 11β-HSD1 staining 
in the arachnoid granulation cap cell cluster (AGC) (G, H,) which was 
specifically removed with pre-adsorbed immunising peptide (I, J).  
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Figure 3-7 Polymerase chain reaction mRNA expression in human choroid plexus 
and arachnoid granulation primary cells and tissue 
Expression of 11β-HSD1,  glucocorticoid receptor alpha (GRα), 
mineralocorticoid receptor (MR), hexose-6-phosphate dehydrogenase 
(H6PD), serum and glucocorticoid-regulated kinase isoform 1 
(sgk),myocilin (myo), 5α reductase 1 and 2, androgen receptor (AR), 
oestrogen receptor alpha  & beta (ERα & β) in a human choroid plexus 
epithelial cell line (HCPEpi),  human arachnoid granulation epithelial cell 
line (AGEpi), human choroid plexus (CP) and human arachnoid 
granulation tissue (AGT). Positive controls (+ve) were liver (11β-HSD1, 
GR, H6PD, sgk-1, 5α reductase 1 and 2); kidney (MR); differentiated 
adipocyte cell line (11β-HSD2); heart (myocilin); testis (AR) and placenta 
(ER α & β). Negative control (-ve) no cDNA template. 
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3.3.2.3. 11β-HSD assay 
3.3.2.3.1 Tissue 
11β-HSD assays were performed on CP tissue explants (n=4), all donors were male 
patients with Parkinson’s disease, none of which had used glucocorticoid therapy, with a 
mean age 75 ± 7.4 years. Activity assays were initiated at 23 ± 6 hours (range 16 – 29 
hours) post mortem. 11β-HSD activity decreased dramatically after 30 hours post mortem 
(data not shown). Activity assays demonstrated predominant oxoreductase (cortisone to 
cortisol; 19.0 (range 9.6-29.3) pmol h-1g-1 (wet weight)) versus dehydrogenase activity 
(cortisone to cortisol; 2.0 (range 0.7-3.1) pmol h-1g-1; p<0.001). Oxoreductase activity was 
significantly inhibited (0.5 (range 0.0 – 1.0) pmol h-1g-1) when co-incubated with 100-fold 
excess of GE (p<0.001) (Figure 3-8). No 11β-HSD activity was detected in the AGT.  
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Figure 3-8 11β-HSD activity enzyme assays conducted on whole choroid plexus 
tissue 
Explants (n=4) demonstrated predominant oxoreductase versus 
dehydrogenase activity (*** p<0.001). Oxoreductase activity was 
significantly inhibited when co-incubated with 100-fold excess of 
glycyrrhetinic acid (GE) a non-specific inhibitor of the 11β-HSDs (*** 
p<0.001).  
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3.3.2.3.2 Cell lines 
Activity studies in HCPEpi cells demonstrated significantly higher oxoreductase activity 
(8.7, range 3.5 – 16.2 pmol h-1mg-1, n=6) compared to dehydrogenase activity (0.0, range 
0.0 – 0.5 pmol h-1mg-1, p=0.01, n=4) that was reduced in the presence of GE (Figure 
3-9A).  
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Figure 3-9 11β-HSD activity enzyme assays conducted on a primary choroid plexus 
cell line 
HCPEpi cells incubated with 100nM of cortisol or cortisone in the 
presence and absence of an 11β-HSD inhibitor (glycyrrhetinic acid) 
demonstrated predominant oxoreductase activity compared to 
dehydrogenase (8.7 pmol h-1mg-1, n=6 and 0.0 pmol h-1mg-1, n=4 
respectively, **p= 0.01).  
 
3.4. Discussion 
3.4.1. Animal studies 
Previously, work within the group has shown expression of 11β-HSD1 and epithelial 
sodium channels within the ciliary body epithelium, and corticosteroid regulation of sgk-1 
via the GR and MR. These data indicate that 11β-HSD1 may be a feature of sodium 
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transport in the human ocular ciliary epithelium, capable of manipulating IOP (Rauz et al. 
2001; Rauz et al. 2003a; Rauz et al. 2003b; Rauz et al. 2003c).   In our current study, 
immunohistochemistry localised 11β-HSD1 to the NZWAR CP epithelial cells. This 
mirrors the localisation of 11β-HSD1 in the NZWAR NPE, the secretary epithelia of the 
ciliary body (Onyimba et al. 2006).The localisation of 11β-HSD1 to the CP secretary cells 
is unusual as, with the exception of the ocular ciliary body epithelial cells, most other 
secretory epithelia express 11β-HSD2 (Burton and Anderson 1983; Rusvai and Naray-
Fejes-Toth 1993). We have also shown that the rabbit CP and ciliary body epithelium 
express similar levels of 11β-HSD1, GRα and sgk-1 mRNA.  
The 11β-HSD activity assays demonstrate predominant oxoreductase activity, compared 
to dehydrogenase activity in the CP tissue, (median conversion 5.0 (range 4.1- 5.6) pmol 
h-1 mg-1 versus 1.1 (range 0.7 -1.6) pmol h-1 mg-1 respectively; p<0.001)) indicating 11β-
HSD1 activity. As this is a bi-directional enzyme, it is also likely to have resulted in the 
minimal dehydrogenase activity demonstrated. 11β-HSD1 mediated dehydrogenase 
activity possibly reflects cell disruption following dissection of the CP tissue, as has been 
noted in other systems (Lakshmi and Monder 1988). Since 11β-HSD2 was not localised 
to the CP by immunohistochemistry, the dehydrogenase activity is unlikely to reflect 
activity of this isozyme. The level of 11β-HSD activity in the NZWAR CP was 
comparable to that of the NZWAR ciliary body (oxoreductase median conversion 2.1 
(range 1.3- 2.8) pmol h-1mg-1 versus dehydrogenase 0.9 (range 0.5-2.0) pmol h-1mg-1) 
(Onyimba et al. 2006).   
These data highlight the potential for the NZWAR CP to act as a glucocorticoid target 
tissue capable of regulating local cortisol availability through 11β-HSD1. 11β-HSD1 may 
therefore, be involved in regulating sodium transport in the CP, as well as in the ciliary 
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body, with the potential to influence CSF production and consequently ICP. AGT, 
through restriction of CSF drainage, is also vital in ICP balance. Unfortunately, it was not 
possible to study the AGT in the NZWAR as, despite considerable preliminary work 
dissecting rabbit meninges, AGT could not be reliably identified. 
Classically, 11β-HSD1 is not associated with sodium transport. This bidirectional 
isozyme functions in vivo as an oxoreductase, facilitating glucocorticoid mediated 
responses in key peripheral tissues including liver, adipose and bone (Tomlinson et al. 
2004b). Hence, within the CNS, it is exciting to speculate that in addition to mediating 
CSF production, 11β-HSD1 may have a role in regulating CSF cortisol bioavailability. It 
would be interesting to assess the activity of CP 11β-HSD1 in  a variety of neuro-
physiological processes associated with elevated CSF cortisol, for example memory loss 
(Lupien et al. 1999; Wolf 2003), CNS ageing (Guazzo et al. 1996; Arroyo et al. 2005), 
immune-modulation (Elenkov 2004), and pathological processes such as Alzheimer’s 
disease (Hoogendijk et al. 2005).  
Traditionally, the origins of CSF cortisol have been attributed to the activation of the HPA 
axis and diffusion from systemically circulating cortisol across the blood-brain-barrier 
(BBB) into the CSF (Marynick et al. 1976; Marynick et al. 1977; Poisson et al. 1984). 
Within the CNS, cortisol binds to the GR, expressed in the hippocampus, amygdala, pre-
frontal cortex and hypothalamus (Holmes and Seckl 2006; Nishi and Kawata 2006). 
These sites also express 11β-HSD1, which may serve to augment intracranial cortisol 
(Harris et al. 2001). CSF cortisol has a degree of self regulation via negative feedback on 
the HPA axis (Harris et al. 2001; Holmes and Seckl 2006) and according to our data, the 
CP could act as an alternative local source of cortisol. As many of the other glucocorticoid 
responsive tissues in the brain (Harris et al. 2001) modulate their own local cortisol 
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generation via 11β-HSD1, it is likely that the CP cortisol produced, acts in an autocrine 
fashion. In addition, the identification of key elements of the glucocorticoid response 
cascade (GR and sgk-1) in the CP, suggest a local mechanism of action for cortisol within 
the CP.  
We measured total CSF cortisol in the rabbit to be 1.7 (range 1.4 - 4.3) nmol/l whilst that 
in human CSF is reported to range from 4.0 – 8.8 nmol/l (Baker et al. 2005). No studies 
have accurately demonstrated the percentage of CSF cortisol originating from the 
circulation versus the percent synthesised from within the CNS. In primates and in 
humans, at low serum cortisol concentrations, the level of CSF cortisol mirrors unbound 
serum cortisol. This suggests diffusion of unbound serum cortisol across the blood brain 
barrier (BBB) into the CSF whereas other sources have alluded to a blood-brain cortisol-
barrier, possibly mediated by P-glycoprotein, preventing cortisol equilibrating between 
the serum and CSF (Ueda et al. 1992; Karssen et al. 2001). This is highlighted by the 
finding that increased plasma cortisol levels (greater than 300-400 nmol/l) in human 
adults, are not mirrored by a corresponding rise in CSF cortisol (Guazzo et al. 1996). In 
addition, CSF cortisol levels vary due to a number of factors such as (i) diurnal variation - 
this is opposite to that of serum (Kling et al. 1994) (ii) stage of the menstrual cycle (Parry 
et al. 2000), (iii) gender - serum cortisol is 19% higher in females (Laughlin and Barrett-
Connor 2000) and  (iv) age -  CSF cortisol levels increase with age (Guazzo et al. 1996; 
Van Cauter et al. 1996; Arroyo et al. 2005). Isolated measures of CSF cortisol are 
therefore prone to inaccuracy. Future studies quantifying CSF cortisone, or radiolabelling 
free circulating cortisol will help define the source of the cortisol within the cerebral 
ventricles. It is, however, clear that intracranial cortisol levels are not merely a function of 
systemic cortisol generation by the adrenal glands. Thus, this novel mechanism of cortisol 
generation by the CP may prove important in CNS neuroendocrine function. 
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In summary, this is the first description of a cortisol generating system in the CP epithelial 
cells mediated by 11β-HSD1. Here 11β-HSD1 oxoreductase activity potentiates levels of 
the biologically active corticosteroid, cortisol. This isozyme is likely to be integral to CP 
physiology and may be involved in regulating CSF production as well as possibly 
influencing CSF cortisol levels. Modulation of CSF secretion by CP 11β-HSD1 may have 
pathogenic implication in IIH. These findings provide a rationale for further 
characterisation of 11β-HSD and glucocorticoids in human tissue and CSF. 
3.4.2. Human studies 
3.4.2.1. Expression of 11β-HSD in human choroid plexus compared to rabbit CP  
Immunohistochemistry revealed an identical pattern of expression of 11β-HSD isozymes 
in human tissue sections compared to sections from the NZWAR. 11β-HSD1 localised to 
the CP epithelial cells in both species. There was no evidence of 11β-HSD2 expression in 
rabbit or human CP. Previous studies have shown that 11β-HSD2 expression in the brain 
rapidly declines after birth (Holmes et al. 2006c), remaining only in proliferating tissue 
such as the cerebellar external granular layer and thalamus (Roland et al. 1995; Robson et 
al. 1998). In these tissues, 11β-HSD2 inactivation of cortisol is thought to protect the 
proliferating tissue from cortisol stimulated neuronal damage (Diaz et al. 1998; Holmes et 
al. 2006c). MR’s in the adult brain are generally not protected by 11β-HSD2, and due to 
their high affinity for glucocorticoids (ten times that of the glucocorticoid receptor), bind 
cortisol at basal concentrations potentially mimicking GR action (Funder et al. 1988; 
Funder 1996). 
Activity assays in human CP tissue demonstrated predominant 11β-HSD1 activity in 
keeping with activity in the NZWAR CP. 11β-HSD1 is a bi-directional enzyme and could 
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therefore have been responsible for the low levels of dehydrogenase activity observed. 
11β-HSD1 mediated dehydrogenase activity likely reflects cell disruption following 
dissection of the CP tissue, as has been noted in other systems (Lakshmi and Monder 
1988). Since 11β-HSD2 was not expressed in the CP by immunohistochemistry, the 
dehydrogenase activity is unlikely to reflect activity of this isozyme. 
3.4.2.2. Characterisation of 11β-HSD in a human choroid plexus epithelial cell line 
HCPEpi cells demonstrated a comparable pattern of 11β-HSD activity to human tissue 
with predominant oxoreductase activity (8.7 (range 3.5-16.2) pmol h-1mg-1) compared to 
dehydrogenase activity (0.0 (range 0.0-0.5) pmol h-1mg-1, p=0.01) although the level of 
activity was lower than that established in CP tissue. These differences might be 
explained by the differences in cell types contained within the CP tissue (epithelial cell as 
well as CP stroma and capillaries) compared to the HCPEpi cells (exclusively epithelial 
cells). However, immunohistochemical characterisation did not demonstrate 11β-HSD1 in 
the CP stroma or capillary network suggesting these components of the CP tissue are 
unlikely to have significantly contributed to oxoreductase activity.  The HCPEpi cells, 
expressed 11β-HSD1, H6PD, GR, MR and sgk-1 mRNA.  
The results from the HCPEpi cells are in keeping with the data from the human CP tissue 
and further endorse the potential role of glucocorticoids and 11β-HSD1 in the human CP. 
Additionally, the similarities between HCPEpi cells and CP tissue suggests that the 
HCPEpi cells may provide a useful model for future in vitro work to clarifying the 
functional role of 11β-HSD1 in the secretion of CSF. 
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3.4.2.3. Characterisation of 11β-HSD in human arachnoid granulation tissue 
We were able to successfully identify human AGT using H&E staining in addition to 
immunolocalisation with vimentin, FVIII and EMA. The AGT did not demonstrate 
oxoreductase or dehydrogenase activity. This was surprising as immunohistochemistry 
localised 11β-HSD1 to the epithelial arachnoid cap cells. It is possible that 11β-HSD 
activity in the AGT declined rapidly after postmortem. Alternatively the enzyme may be 
expressed but not active or expressed at very low levels.  The AGT did, however, express 
key elements of the glucocorticoid pathway (GR, MR and MYOC). These results 
highlight the potential for the AGT to function as a glucocorticoid target tissue. In the 
ocular environment MYOC induction by glucocorticoids restricts the drainage of AH and 
elevates IOP (Rozsa et al. 2006).  It is possible that an analogous mechanism may occur 
in the AGT, influencing drainage of CSF. 
3.4.3. Conclusion 
The precise role of CP 11β-HSD1 has yet to be determined. As initially hypothesised, it 
may have a role in regulating CSF secretion, however, the ramifications of CSF cortisol 
generation are potentially diverse.  CNS glucocorticoids have detrimental effects on the 
developing foetal cerebellum (Holmes, 2006) as well as anti-inflammatory and immune 
regulatory properties with the potential to modulate diseases such as Multiple Sclerosis,  
Behçet’s Disease and CNS vasculitis (Sellebjerg et al. 2000; Siva et al. 2004; Younger 
2004). There are also a variety of neuro-physiological processes associated with elevated 
CSF cortisol, such as memory loss (Lupien et al. 1999; Wolf 2003; Miller and 
O'Callaghan 2005; Chapman and Seckl 2008), CNS ageing (Guazzo et al. 1996; Arroyo et 
al. 2005), immune-modulation (Elenkov 2004), and other pathological processes such as 
Alzheimer’s disease (Hoogendijk et al. 2005; Green et al. 2006).  Hence, within the CNS, 
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one could speculate, that in addition to mediating CSF production, CP 11β-HSD1 may 
have a role in regulating CSF cortisol bioavailability, and thus influence a diverse range 
of physiological and pathological processes.  
In summary, 11β-HSD1 activity is likely to be integral to CP physiology, potentiating 
levels of biologically active cortisol within the choroid plexus itself and secretion of 
cortisol into the CSF. 11β-HSD1 driven cortisol generation in the CP may represent an 
underlying mechanism mediating CSF secretion and ICP dynamics. Inhibition of 11β-
HSD1 may, consequently, represent a therapeutic strategy to modulate CSF secretion and 
ICP. 
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Chapter 4. NMR-Based Metabolomic Analysis of Cerebrospinal 
Fluid and Serum in Idiopathic Intracranial Hypertension 
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4.1. Introduction 
One approach to improving our understanding of disease aetiology, is through defining 
disease specific, metabolite biomarkers. The study of metabolites (metabolomics) reflects 
both genetic and environmental factors and consequently has the potential to accurately 
delineate a disease process. Metabolite biomarkers have the additional advantage of 
potentially facilitating disease diagnosis and monitoring. The knowledge of disease 
specific metabolites is particularity important in conditions such as IIH, where disruption 
of normal metabolic processes, manifesting as obesity and elevated ICP, are key factors in 
the disease process. Identification of IIH specific metabolites may enhance our 
understanding of the pertinent, metabolic processes in this condition. 
In this study, we aimed to establish a profile of disease specific metabolites in IIH. We 
also aimed to define metabolite profiles in two control conditions: MS and 
cerebrovascular disease (CVD). These control conditions were chosen as they represented 
distinct patho-physiological processes commonly admitted to the neurology unit for 
diagnostic evaluation. We evaluated whether the metabolite profiles of these conditions, 
IIH, MS and CVD, could be distinguished from a heterogeneous group of patients who 
attended for investigation of neurological diseases, using CSF and serum metabolic 
profiling. In addition, we aimed to validate the metabolite biomarker profiles, by 
demonstrating that the profiles identified, could be used to predict diagnosis in a second 
cohort of patients (prospectively collected in succession) whose diagnosis were masked. 
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4.2. Method 
4.2.1. Patients 
Patients were recruited from University Hospital Birmingham NHS Foundation Trust and 
Sandwell & West Birmingham Hospitals NHS Trust, UK. Cohort 1 study subjects 
consisted of a heterogeneous group of patients under investigation for neurological 
symptoms. All patients underwent lumbar puncture (LP) as part of their routine 
investigations. Subjects were excluded if aged less than 16 years or if unable to give 
written, informed consent. Patients with IIH were recruited at the time of initial 
presentation or following a clinical deterioration. They were diagnosed according to the 
updated modified Dandy Criteria (Friedman and Jacobson 2002). Subjects with MS were 
recruited during remission following a presenting, clinically isolated syndrome. Only 
those who went on to fulfil the McDonald criteria (McDonald et al. 2001), were included 
in the MS cohort. To avoid confounding effects of acute illness, patients with CVD were 
recruited during convalescence, after imaging confirmation of a cerebrovascular accident. 
All patient notes were reviewed at one year to confirm diagnosis. Those subjects having 
no neurological diagnosis and normal neurological investigations one year after 
recruitment were classified as “no diagnosis identified”. Clinical details including medical 
history, investigations, current medication and time of last meal were noted for each 
subject.  Anthropological measures were recorded; BMI was calculated as weight in kg/ 
height in m2. Permission for the study was obtained from the local research ethics 
committee (Solihull LREC 04/Q2706/65 approved 15/01/2005), all participants gave 
written informed consent. 
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4.2.2. Samples 
All LPs were carried out with the patient in the left lateral position, whilst breathing 
regularly (Neville and Egan 2005) and CSF opening pressure was measured by direct 
manometry. CSF and blood samples were collected at the time of LP and transported on 
ice, before being promptly centrifuged at 176 g for 10 minutes and aliquoted. All samples 
were stored at -80˚C and analysed after a maximum of one freeze-thaw cycle.  Thawed 
samples (300µl) were centrifuged at 1000 rpm for 2 minutes, prior to dilution 1:1 with 
deuterium oxide containing NaCl (150mM), TMSP (2.5mM) and sodium phosphate 
(20mM) pH 7.4. 
4.2.3. Experimental outline 
CSF and serum samples were processed and analysed separately. 1D and 2D JRES spectra 
were acquired from patients with IIH, MS, CVD as well as from those subjects under 
investigation for other neurological diseases (see section 2.2.1). Multivariate pattern 
recognition analysis was used to evaluate the NMR spectra and determine disease specific 
metabolite biomarkers (cohort 1). A second cohort of CSF and serum samples with 
unknown diagnosis were then prospectively collected (cohort 2) from consecutive 
patients, using the same technique and inclusion and exclusion criteria as for cohort 1. 
The ability of metabolite biomarker profiles, defined in cohort 1, to identify undiagnosed 
patients in cohort 2, were then assessed (Figure 4-1). 
4.2.4. Evaluation of disease specific metabolite profiles in matched cohorts 
Phenotypic features are known to influence metabolite profiles (Holmes et al. 2008). To 
reduce the effects of phenotype (gender, age, BMI) influencing the metabolite profile, the 
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disease groups were also compared to control subjects, matched for gender, age (± 5 yr) 
and BMI (± 2 kgm-2). 
4.2.5. Evaluation of experimental technical variance 
Five patients evaluated in cohort 1 were re-analysed at the start of cohort 2 processing, to 
evaluate technical variance between cohort 1 and 2. These five patients were further 
analysed at the end of cohort 2 to evaluate technical variance within cohort 2.  
 
Cohort 1 Cohort 2
Subjects
• Idiopathic intracranial hypertension
•Multiple sclerosis
•Cerebrovascular disease
•Other neurological diseases
Spectra
1D
2D JRES
Analysis
1. Evaluate diagnostic ability of metabolite 
biomarkers
2. Identify disease unique metabolites
Analysis
1. Evaluate technical variance between cohorts 1 
and 2
2. Evaluate technical variance within cohorts 2
3. Evaluate ability of biomarkers from cohorts 1 to 
diagnose samples from cohorts 2
Spectra
1D
Subjects
•Masked prospective collection
•Replicates of Cohort 1 (n=5)
CSF Serum
 
Figure 4-1 NMR metabolomics experimental design 
4.2.6. Statistical analysis 
Data were analysed using cluster modelling techniques, PCA and PLS-DA using 
PLS_Toolbox (version 3.5, Eigenvector Research, Washington, USA) within MATLAB 
(see section 2.2.1.1). The PLS-DA model was cross-validated using Venetian blinds. 
Disease specific metabolite profiles were identified in IIH, MA and CVD for cohort 1 
from the PLS-DA model. The cohort 1 metabolite profiles were then used to predict the 
diagnosis of patients from cohort 2.Results are expressed as sensitivity (the proportion of 
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positive (diseased) subjects who test positive with the biomarker profile) and specificity 
(the proportion of negative (control) subjects who test negative with the biomarker 
profile) (Loong 2003). Positive and negative predictive values are not quoted, as they are 
dependent on the underlying prevalence of disease in a population. Thus they would not 
be appropriate in our study, as the disease cohorts are not representative of population 
prevalence. We quote the positive likelihood ratios (the increased probability of disease if 
the test is positive) and negative likelihood ratios (the decreased probability of disease if 
the test is negative). Continuous data were summarised using means and standard 
deviations, or medians and ranges for non-normally distributed data.  
4.3. Results 
4.3.1. Patient characteristics 
CSF (n = 87) and matching serum (n = 72) samples were collected from the study 
population (cohort 1). The number of serum samples processed was less than that of CSF 
due to sample loss. Patient characteristics for cohort 1 are shown in Table 4-1. The 
diagnoses of the patients in the “other diseases” group are given in Table 4-2, which 
included 11 patients with no neurological diagnosis. The IIH patients were significantly 
younger (p < 0.001), had higher BMIs (p = 0.02) and higher LP opening pressures (p < 
0.001) than subjects in the other groups. There were no consistent medication trends in the 
diagnostic groups (in the IIH cohort only one patient was taking acetazolamide). 
The prospective patient cohort (cohort 2), comprised CSF and serum samples from twenty 
five consecutively collected patients whose diagnoses were masked. Following NMR 
spectral acquisition and processing, patient diagnosis was established from medical 
records. Eight patients were diagnosed with IIH (Friedman and Jacobson 2002) and three 
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with MS (McDonald et al. 2001), while there were no patients with CVD in this cohort. 
The remaining subjects, comprised a group with mixed neurological diseases (Table 4-2). 
The patient characteristics of cohort 2 are shown in (Table 4-3). The IIH patients had 
higher BMIs (p< 0.001) and opening pressures (p< 0.001) than patients in other diagnostic 
groups. 
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Characteristic 
 IIH  MS  CVD  Other  
Number 
 
CSF 
Serum 
25 
17 
12 
11 
9 
9 
41 
35 
Age a 
 
CSF 
Serum 
29.3 ± 7.5*** 
28.2 ± 7.7*** 
38.0 ± 10.4 
37.6 ± 10.8 
58.9 ± 7.6 
58.1 ± 7.5 
48.9 ± 13.3 
50.1 ± 13.8 
Female (%) 
 
CSF 
Serum 
100** 
100* 
75.0 
81.8 
50.0 
44.4 
66.7 
65.7 
BMI a (kgm-2) 
 
CSF 
Serum 
34.8 ± 5.4** 
34.9 ± 6.1** 
27.2 ± 5.9 
27.3 ± 6.2 
26.7 ± 5.2 
26.7 ± 5.2 
29.1 ± 8.1 
28.9 ± 8.0 
Opening pressure a 
(cm CSF) 
CSF 
Serum 
35.9 ± 6.2*** 
35.8 ± 7.3*** 
17.1 ± 3.5 
17.1 ± 3.8 
18.3 ± 4.6 
17.3 ± 5.3 
19.3 ± 8.5 
19.6 ± 9.2 
CSF Glucose a 
 
CSF 
Serum 
3.6 ± 1.0 
3.7 ± 1.2 
3.3 ± 0.4 
3.3 ± 0.4 
3.7 ± 0.8 
3.7 ± 0.8 
3.5 ± 0.6 
3.6 ± 0.7 
CSF Protein a 
 
CSF 
Serum 
0.3 ± 0.1 
0.3 ± 0.1 
0.4 ± 0.2 
0.4 ± 0.1 
0.4 ± 0.1 
0.5 ± 0.4 
0.6 ± 0.8 
0.6 ± 0.9 
Table 4-1 Subject characteristics for cohort 1 
a Mean ± standard deviation.  Characteristics of each diagnostic group 
are compared to all other groups including the “other” controls. The IIH 
group was significantly younger, more obese and had a higher opening 
pressure than all other groups including “other” controls. *** p < 0.001, 
** p <0.01, * p < 0.05. IIH = idiopathic intracranial hypertension, MS = 
multiple sclerosis and CVD = cerebrovascular disease. 
Chapter 4   
130 
 
Clinical diagnosis Number of cases 
 Cohort 1  Cohort 2  
No diagnosis identified 11  
Headache or migraine 6# # 4 
Motor neurone disease 2 1 
Peripheral neuropathy 2 2 
Dementia/Alzheimer’s disease 1# 1 
Aseptic meningitis 1  
Cervical myelopathy 1  
Cerebral vasculitis 2 1 
Secondary intracranial hypertension 1  
CNS tumour 1# 2 
Mixed connective tissue disease 1  
Subarachnoid haemorrhage 1#  
Spastic paraparesis 1  
Uveitis 1  
Unexplained optic neuropathy 1  
CNS Inflammation 1  
Parkinson’s Disease 1  
Spinal cord infarct 1  
other 5# 4 
Total 41 14 
Table 4-2 Clinical diagnoses in patients comprising the “Other diseases” group 
 
#
 indicates that a single serum sample was lost and subsequently not 
processed, # # refers to two lost samples. 
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Characteristic IIH  MS  Other  
Number 8 3 14 
Age a 32.0 ± 8.1 50.7 ± 19.1 47.4 ± 16.9 
Female (%) 87.5 100 64.3 
BMI a (kgm-2) 38.2 ± 6.7*** 21.0 ± 2.3 26.1 ± 4.8 
Opening pressure a (cm CSF) 34.1 ± 6.2*** 13.0 ± 1.0 16.6 ± 3.7 
CSF Glucose a 3.6 ± 0.7 3.3 ± 0.4 3.5 ± 0.8 
CSF Protein a 0.3 ± 0.1 0.5 ± 0.2 0.7 ± 0.5 
Table 4-3 Subject characteristics cohort 2 
a Mean ± standard deviation. Characteristics of each diagnostic group are 
compared to all other groups including the “other” controls. The IIH 
group was significantly more obese and had a higher opening pressure 
than MS patients and “other” controls. *** p < 0.001. IIH indicates 
idiopathic intracranial hypertension and MS indicates multiple sclerosis. 
 
4.3.2. Cohort 1 CSF metabolomics 
NMR spectra were excluded from further analysis if they displayed poor data quality, 
such as distorted baselines or unusually broad peak widths or had T2 Hotellings and Q 
residuals outside a 95 % confidence interval. Those with outlying metabolite profiles due 
to disease diversity were maintained in the analysis. 
4.3.2.1. Cohort 1, 1D CSF spectra- whole cohort analysis 
Eighty-seven CSF spectra were acquired. A glog 1x10-6 was applied to transform the 
spectra. Eleven samples were excluded from further analysis due to technically abnormal 
spectra (Figure 4-2A, B). The PCA scores plots illustrate partial clustering of data, 
particularly in the IIH and MS cohorts (Figure 4-2C). Data were then used to build a PLS-
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DA model to distinguish those spectra based on prior knowledge of the diagnostic groups 
(Figure 4-2D). 
 
Figure 4-2 Cohort 1, 1D CSF spectra whole cohort analysis 
Raw CSF spectra (A) and glog transformed, normalised, binned NMR 
spectra (B). Outlying spectra are shown in pink and have been excluded 
from further analysis. The PCA scores plot show the CSF spectra acquired 
(C) This unsupervised analysis illustrates partial clustering of spectra for 
the diagnostic groups. PLS-DA scores plot show CSF spectra acquired 
(D).  
 
Following cross-validation with Venetian blinds, the sensitivity and specificity of the 
PLS-DA model for predicting diagnosis of each diagnostic group was; 71% and 70% 
respectively for IIH, 83% and 53% respectively for MS, and 57% and 67% respectively 
for CVS (Figure 4-3A,B and C). 
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Figure 4-3 Cohort 1, 1D CSF spectra whole cohort prediction plots  
 The PLS-DA model identifies subjects with (A) IIH (sensitivity 71% and 
specificity 70%) using a prior cut-off of 0.32 for class membership. (B) 
Subjects with multiple sclerosis (MS) were identified (sensitivity 83% and a 
specificity 53%) using a prior cut-off of 0.19 for class membership. (C) 
Subjects with cerebrovascular disease were identified (sensitivity 57% and 
specificity 67%) using a prior cut-off of 0.11 for class membership. 
 
4.3.2.2. Cohort 1, 1D CSF spectra- matched analysis 
Diagnostic groups (IIH, MS and CVD) were further compared to a matched cohort with 
mixed neurological diseases, to eliminate bias in the regression model due to phenotype. 
PCA illustrated clustering of IIH patients (n=10) and matched controls (n=10) which was 
enhanced in the PLS-DA model (Figure 4-4A, B and C). Cross validation of the PLS-DA 
model confirmed a sensitivity of 80% and a specificity of 80%, using a cut-off of 0.41 for 
class membership. Patients with MS (n=10) were compared to matched controls (n=10) 
(Figure 4-4D, E and F). Clear discrimination was seen between classes using PLS-DA 
modelling, sensitivity 80% and specificity 80%, using a cut-off of 0.50 for class 
membership. Patients with CVD (n=7) were not as clearly separated from matched 
controls (n=7) (Figure 4-4G, H and I), sensitivity 57% and specificity 71% (cut-off for 
class membership of 0.50). 
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Figure 4-4 Cohort 1, 1D CSF spectra matched analysis 
IIH compared to a matched control group, PCA (A), PLS-DA (B) and 
prediction plot (80% sensitivity and 80% specificity) (C). MS compared to 
a matched control group, PCA (D), PLS-DA (E) and prediction plot (80% 
sensitivity and 80% specificity) (F). CVD compared to a matched control 
population, PCA (G), PLS-DA (H) and prediction plot (57% sensitivity and 
71% specificity) (I). 
 
4.3.2.3. Cohort 1, 2D CSF spectra- whole cohort analysis  
Eighty-seven 2D CSF spectra were acquired; a glog 1x10-5 was applied to transform the 
spectra. Nine samples were excluded from further analysis due to technically abnormal 
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spectra (Figure 4-5A, B). The PCA scores plot showed limited clustering of data (Figure 
4-5C) but separation was improved in the PLS-DA model (Figure 4-5D).  
 
Figure 4-5 Cohort 1, 2D CSF spectra whole cohort analysis  
 Raw CSF spectra (A) and glog transformed normalised binned NMR 
spectra (B). Outlying spectra, shown in pink, have been excluded from 
further analysis. PCA scores plot showing the CSF spectra acquired (C) 
This unsupervised analysis illustrates limited clustering of spectra for the 
diagnostic groups. PLS-DA scores plot showing CSF spectra acquired (D).  
 
Following cross-validation with Venetian blinds, the sensitivity and specificity of the 
PLS-DA model for predicting diagnosis of each diagnostic group was 64% and 75% 
respectively for IIH, 67% and 44% respectively for MS, and 0% and 66% respectively for 
CVD. 
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Figure 4-6 Cohort 1, 2D CSF spectra whole cohort prediction plots 
 The PLS-DA model identifies subjects with (A) IIH (sensitivity 64% and 
specificity 75%) using a prior cut-off of 0.33 for class membership. (B) 
Subjects with multiple sclerosis (MS) were identified (sensitivity of 67% 
and a specificity of 44%) using a prior cut-off of 0.16 for class 
membership. (C) Subjects with cerebrovascular disease were identified 
(sensitivity 0% and specificity 66%) using a prior cut-off of 0.13 for class 
membership. 
 
4.3.2.4.  Cohort 1, 2D CSF spectra- matched analysis 
The 2D spectra of the diagnostic groups were compared to a matched (age, gender and 
BMI) control cohort with mixed neurological diseases. PCA and PLS-DA models were 
used to distinguish the IIH patients from matched controls (n=10) (Figure 4-7A, B). The 
PLS-DA model was found to have a sensitivity of 60% and a specificity of 80%, using a 
cut-off of 0.48 for class membership (Figure 4-7C). The PCA and PLD-DA model of the 
MS cohort was separated from the matched control population (n=10) with a sensitivity of 
50% and a specificity of 80%, 0.59 was the cut-off for class membership (Figure 4-7D, E 
and F). The model was not accurate in distinguishing patients with CVD from matched 
controls (n=8) (sensitivity 88% and specificity 13%), prior cut-off of 0.62 for class 
membership (Figure 4-7G, H and I). 
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Figure 4-7 Cohort 1, 2D CSF spectra matched analysis 
IIH compared to a matched control group, PCA (A), PLS-DA (B) and 
prediction plot (60% sensitivity and 80% specificity) (C). MS compared to 
a matched control group, PCA (D), PLS-DA (E) and prediction plot (50% 
sensitivity and 80% specificity) (F). CVD compared to a matched control 
population, PCA (G), PLS-DA (H) and prediction plot (88% sensitivity and 
13% specificity) (I). 
 
4.3.3. Cohort 1 serum metabolomics 
4.3.3.1. Cohort 1, 1D serum spectra- whole cohort analysis 
Analysis of the serum spectra (n= 72), identified two technically anomalous spectra which 
were excluded. A glog 1x10-6 was used to transform the spectra (Figure 4-8A, B). PCA of 
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the serum spectra revealed limited clustering for each diagnostic group (Figure 4-8C). 
PLS-DA revealed modest data clustering (Figure 4-8D), but this was not as prominent as 
that observed for the 1D CSF spectra.   
 
Figure 4-8 Cohort 1, 1D serum spectra whole cohort analysis 
Raw CSF spectra (A) and glog transformed, normalised, binned NMR 
spectra (B). Outlying spectra are shown in pink and have been excluded 
from further analysis. Serum PCA scores plot (C) and PLS-DA scores plot 
(D). 
 
Using Venetian blinds to cross-validate the PLS-DA model, the sensitivity and specificity 
in predicting the diagnosis of each group were 50% and 83% respectively for IIH, 27% 
and 70% respectively for MS, and 27% and 69% respectively for CVD (Figure 4-9A,B 
and C). 
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Figure 4-9 Cohort 1, 1D serum spectra- whole cohort prediction plots 
 The PLS-DA model identified subjects with (A) IIH (sensitivity 50% and 
specificity 83%) using a prior cut-off of 0.42 for class membership. (B) 
Subjects with multiple sclerosis (MS) were identified (sensitivity of 27% 
and a specificity of 70%) using a prior cut-off of 0.38 for class 
membership. (C) Subjects with cerebrovascular disease (CVD) were 
identified (sensitivity 27% and specificity 69%) using a prior cut-off of 0.33 
for class membership. 
 
4.3.3.2. Cohort 1, 1D serum spectra- matched analysis 
The diagnostic groups were compared to a matched (age, gender and BMI) control cohort 
with mixed neurological diseases.  Discrimination of the IIH cohort (n=10) from matched 
controls (n=10) was not as pronounced as that observed with 1D CSF spectra. The PLS-
DA model was able to identify patients with IIH (sensitivity 70% and specificity 78%, 
using a cut-off of 0.39 for class membership) (Figure 4-10A, B and C). The MS cohort 
(n=10) was not clearly distinguished from a matched cohort with PCA or PLS-DA 
modelling, with validation of the PLS-DA model  exhibiting a sensitivity of 70% but a 
specificity of 20% (cut-off for class membership of 0.19) (Figure 4-10D,E and F). Of 
note, however, patients with CVD were clearly distinguished from matched controls (n=7) 
using PCA and PLS-DA models. The PLS-DA model revealed a sensitivity of 75% and a 
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specificity of 75% when cross validated and using a cut-off of 0.50 for class membership 
(Figure 4-10G,H and I). 
 
Figure 4-10 Cohort 1, 1D serum spectra matched analysis 
IIH compared to a matched control group, PCA (A), PLS-DA (B) and 
prediction plot (70% sensitivity and 78% specificity) (C). MS compared to 
a matched control group, PCA (D), PLS-DA (E) and prediction plot (70% 
sensitivity and 20% specificity) (F). CVD compared to a matched control 
population, PCA (G), PLS-DA (H) and prediction plot (75% sensitivity and 
75% specificity) (I). 
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4.3.3.3. Cohort 1, 2D serum spectra- whole cohort analysis 
Analysis of the serum spectra (n= 72) identified eight technically anomalous spectra 
which were excluded, glog 1x10-5 was used to transform the spectra (Figure 4-11A, B). 
The PCA and PLS-DA model for the 2D serum spectra was less discriminating than that 
observed for 1D serum spectra (Figure 4-11C, D).  
 
Figure 4-11 Cohort 1, 2D serum spectra whole cohort analysis 
Raw CSF spectra (A) and glog transformed normalised binned NMR 
spectra (B). Outlying spectra are shown in pink and have been excluded 
from further analysis. Serum PCA scores plots (C) and PLS-DA scores 
plots (D). 
 
The lack of clustering on the PCA and PLS-DA scores plots are reflected in the limited 
accuracy of the model to identify diagnostic groups following cross validation. In the IIH 
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patients, the sensitivity was 20% and specificity 80%, whereas the MS patients were 
identified with a sensitivity of only 18% and specificity of 72%. For the CVD patients, the 
sensitivity of the model was 14% and specificity 90% (Figure 4-12). 
 
Figure 4-12  Cohort 1, 2D serum spectra- whole cohort prediction plots 
 The PLS-DA model identified subjects with (A) IIH (sensitivity 20% and 
specificity 80%) using a prior cut-off of 0.48 for class membership. (B) 
Subjects with multiple sclerosis (MS) were identified (sensitivity of 18% 
and a specificity of 72%) using a prior cut-off of 0.49 for class 
membership. (C) Subjects with cerebrovascular disease (CVD) were 
identified (sensitivity 14% and specificity 90%) using a prior cut-off of 0.42 
for class membership. 
 
4.3.3.4. Cohort 1, 2D serum spectra- matched analysis 
The diagnostic groups were compared to a matched (age, gender and BMI) control cohort, 
with mixed neurological diseases. The IIH cohort was discriminated from matched 
controls (n=10) with similar accuracy to that observed with 2D CSF spectra, with 
clustering of diagnostic groups was observed in the PCA and PLS-DA model. Cross 
validation of this model was 60% sensitive and 80% specific, with a cut-off of 0.48 for 
class membership (Figure 4-13A, B and C). Modelling MS patients against matched 
controls (n=10) revealed very poor discrimination compared to both CSF and 1D serum 
spectra (sensitivity 50% and specificity 10%, with a cut-off of  0.21 for class membership) 
(Figure 4-13D,E and F). The CVD cohort (n=8) was discriminated more accurately than 
Chapter 4   
143 
that observed in the CSF models, with clustering of patients particularly identified in the 
PLS-DA model. The validated PLS-DA model was 63% sensitive and 75% specific 
(using a cut-off of 0.42 for class membership) (Figure 4-13G, H and I). 
 
Figure 4-13 Cohort 1, 2D serum spectra matched analysis 
IIH compared to a matched control group, PCA (A), PLS-DA (60% 
sensitivity and 80% specificity) (B) and prediction plot (C). MS compared 
to a matched control group, PCA (D), PLS-DA (E) and prediction plot 
(50% sensitivity and 10% specificity) (F). CVD compared to a matched 
control population, PCA (G), PLS-DA (H) and prediction plot (63% 
sensitivity and 75% specificity) (I). 
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4.3.4. Cohort 1 modelling summary 
The metabolite profiles were more accurate when derived from the 1D, rather than from 
the 2D spectra. Although phenotype is known to influence metabolite profiles (Holmes et 
al. 2008), we only found evidence of a weak (yet significant), correlation between the 
PC2 scores of the CSF dataset with age (r = 0.24, p = 0.025) and the PC1 scores of the 
serum dataset with BMI (r = -0.24, p = 0.04). It is likely, therefore, that in our cohorts, the 
relationship between age, BMI and principal components is more complex than a linear 
relationship. The matched analysis, did however, greatly enhance the accuracy of the 
metabolite biomarker profiles. No significant correlation was found between the principal 
component scores for the CSF and serum metabolite profiles. Amongst the IIH patient, 
the 1D matched metabolite profiles were sensitive and specific, in both CSF (80% and 
80% respectively) and serum (70% and 78%). Spectral data are summarised in Table 4-4. 
MS metabolites were more accurately identified from 1D, matched CSF profiles (80% 
sensitivity and specificity). CVD metabolite profiles were most accurate when derived 
from the 1D serum matched analysis (75% sensitivity and specificity). 
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Cohort 1  1D CSF spectra 
 % IIH MS CVD 
Whole cohort  Sensitivity 71 83 57 
Specificity 70 53 67 
 PLR:NLR 2.4:0.4 1.8:0.3 1.7:0.6 
Matched cohort Sensitivity 80 80 57 
Specificity 80 80 71 
 PLR:NLR 4.0:0.3 4.0:0.3 2.0:0.6 
Cohort 1  1D serum spectra 
 % IIH MS CVD 
Whole cohort  Sensitivity 50 27 27 
Specificity 83 70 69 
 PLR:NLR 3.0:0.6 0.9:1.0 0.9:1.1 
Matched cohort Sensitivity 70 70 75 
Specificity 78 20 75 
 PLR:NLR 3.2:0.4 0.9:1.5 3.0:0.3 
Cohort 1  2D CSF spectra 
 % IIH MS CVD 
Whole cohort  Sensitivity 64 67 0 
Specificity 75 44 66 
 PLR:NLR 2.6:0.5 1.2:0.8 0.0:1.5 
Matched cohort Sensitivity 60 50 88 
Specificity 80 80 13 
 PLR:NLR 3.0:0.5 2.5:0.6 1.0:0.9 
Cohort 1  2D serum spectra 
 % IIH MS CVD 
Whole cohort  Sensitivity 20 18 14 
Specificity 80 72 90 
 PLR:NLR 1.0:1.0 0.6:1.1 1.4:1.0 
Matched cohort Sensitivity 60 50 63 
Specificity 80 10 75 
 PLR:NLR 3.0:0.5 0.56:5.0 2.5:0.5 
 
Table 4-4 Summary of cohort 1 1D & 2D NMR multivariate modelling. 
Idiopathic intracranial hypertension (IIH), multiple sclerosis (MS), 
cerebrovascular disease (CVD), cerebrospinal fluid (CSF), positive 
likelihood ratio (PLR), negative likelihood ratio (NLR).  
 
4.3.5. Cohort 2 
The technically abnormal spectra from cohort 2 (CSF, n=2 and serum, n =0) were 
excluded from the analysis. The patient characteristics of cohort 2 subjects were not a 
direct match to those of patients analysed in cohort 1. This necessitated the use of the less 
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diagnostically accurate, whole cohort (i.e., unmatched), disease specific metabolite 
biomarker profiles, to predict the diagnoses of patients in cohort 2.  
The CSF IIH metabolite profile was used to build both PCA and PLS-DA scores plots 
which illustrated clustering of IIH patients from cohort 1 and 2 (Figure 4-14A,B). The 
cohort 1 (whole cohort, unmatched) PLS-DA prediction model for IIH (Figure 4-14C) 
was then applied to the cohort 2 data (Figure 4-14D). The CSF IIH metabolite profile 
from cohort 1 was able to predict the diagnosis of IIH in cohort 2 patients (sensitivity 63% 
and specificity 75%). This was similar to the accuracy observed in the cohort 1 (whole 
cohort, unmatched) IIH CSF profile (71% sensitivity and 70% specificity).   The accuracy 
of the unmatched serum IIH PLS-DA metabolite profile from cohort 1, although not 
useful diagnostically (sensitivity 50% and specificity 83%), was replicated when applied 
to the cohort 2 patients (sensitivity 50% and specificity 83%). 
The CSF metabolite profiles for MS subjects generated from cohort 1 and 2 data were 
analysed by PCA (Figure 4-15A) and PLS-DA (Figure 4-15B). The PLS-DA prediction 
model from cohort 1 (Figure 4-15C) was used to identify patients with MS in cohort 2 
(sensitivity 67% and specificity 75%) (Figure 4-15D).The sensitivity and specificity of the 
original cohort 1 MS biomarker profile was 83% and 53% respectively. The MS serum 
metabolite profile generated by the PLS-DA of cohort 1 predicted the diagnosis of MS in 
cohort 2 subjects, with a sensitivity of 67% and a specificity of 73%.  
There were no patients with CVD in cohort 2. Table 4-5 summarises the sensitivity and 
specificity of the PLS-DA, whole cohort (unmatched), metabolite biofluid profiles from 
cohort 1, in predicting the diagnosis of IIH and MS in cohort 2. No significant difference 
was identified between the diagnostic accuracy of the metabolite profiles when applied to 
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cohort 1 or 2 (IIH CSF profile p=0.673, IIH serum profile p=1.0, MS CSF profile p=0.078 
and MS serum profile p=0.054).  
Cohort 2 1D CSF spectra  
 
% IIH MS CVD 
Whole cohort  Sensitivity 63 67 - 
Specificity 75 75 - 
 PLR:NLR 2.5:0.5 2.7:0.4  
Cohort 2 1D serum spectra 
 % IIH MS CVD 
Whole cohort  Sensitivity 50 67 - 
Specificity 83 73 - 
 PLR:NLR 3.0:0.6 2.5:0.5  
Table 4-5 Summary of accuracy of cohort 2 1D unmatched metabolite profiles in 
predicting diagnosis of cohort 2 patients. 
Idiopathic intracranial hypertension (IIH), multiple sclerosis (MS), 
cerebrovascular disease (CVD), cerebrospinal fluid (CSF), positive 
likelihood ratio (PLR), negative likelihood ratio (NLR).  
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Figure 4-14  The cerebrospinal fluid PLS-DA models constructed with cohort 1 data 
were used to predict those patients with IIH in cohort 2 
(A) PCA, (B) PLS-DA, (C) prediction plot from cohort 1 and (D) prediction 
plot applied to cohort 2 (sensitivity 63% and specificity 75%).  The 
principal component (PC) and latent variable (LV) represent variance in 
the spectra, with contribution to the variance shown in brackets. Cohort 
membership threshold is indicated by the red dotted lines on the prediction 
plots. 
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Figure 4-15 The cerebrospinal fluid PLS-DA models constructed with cohort 1 data 
were used to predict those patients with MS in cohort 2 
 (A) PCA, (B) PLS-DA, (C) prediction plot from cohort 1 and (D) 
prediction plot applied to cohort 2 (sensitivity 67% and specificity 75%). 
The principal component (PC) and latent variable (LV) represent variance 
in the spectra, with contribution to the variance shown in brackets. Cohort 
membership threshold is indicated by the red dotted lines on the prediction 
plots. 
 
4.3.6. Technical variance 
The technical variance between the whole of cohort 1 and 2 are illustrated (Figure 4-16 
A&B). The variance was due to inconsistent resolution of ethanol (a contaminant) and 
urea. These areas were therefore excluded from analysis of cohort 2 (ethanol, 3.635 – 
3.695 and 1.13 – 1.35 ppm and urea, 5.5 – 6.0 ppm). The five CSF samples from cohort 1 
which were also analysed as part of cohort 2 showed a positive shift in PC1. Of the five 
serum replicates, one was technically anomalous and excluded, the remaining four 
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showed a negative shift in PC2 between cohorts 1 and 2. These PCA shifts were similarly 
explained by differing resolution of ethanol and urea. The CSF and serum samples run at 
the start and end of cohort 2 showed very similar principle components and thus there was 
little technical variance between the start and end of cohort 2 processing (Figure 4-16 
C&D). 
CSF Serum
A B
DC
 
Figure 4-16 Technical variance of cohorts 1 and 2 
The 1D normalised, glog transformed, binned spectra are shown for 
cohorts 1 and 2 (blue and green respectively) with anomalous spectra 
illustrated in pink (A) CSF and (B) serum. PCA plots are shown for five 
identical samples run in cohort 1, at the start of cohort 2 (Cohort 2a) and 
end of cohort 2 (Cohort 2b), (C) CSF and (D) serum.  
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4.3.7. Metabolite identification 
Identification of the primary spectral peaks involved in diagnostic discrimination was 
approached using weightings plots from the PLS-DA models. Metabolites were identified 
from the most diagnostically predictive biofluid. IIH and MS metabolites were therefore 
identified in the CSF while the CVD metabolites were identified in the serum (Figure 
4-17). Individual metabolites identified from the matched disease metabolite profiles were 
similar to those identified from the whole cohort (unmatched) profiles (data not shown).  
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 IIH MS CVD 
R
ed
u
ce
d 
1) Urea (5.83)  1) Oxaloacetate (3.70)  1) Glycine (3.52)  
2) Creatinine (3.05)  2) Citrate (2.55 & 2.69)  2) Betaine (3.23)  
3) Citrate (5.55 & 2.69)  3) Alanine (1.48)  3) Methylmalonate (1.27)  
4) 3-hydroxyisovalarate (2.38)  4) 3-hydroxybutyrate (1.20)  4) Butyrate (0.89)  
El
ev
a
te
d 
5) Lactate (4.13 & 1.33)  5) 2-aminobutyrate (3.72)  5) Oxaloacetate (3.73)  
6) Oxaloacetate (3.71)  6) 1,3-dimethylurate (3.36)  6) Glucose (3.91 & 3.24)  
7) Glucose (3.24)  7) Glutamate (2.07 & 2.45)  7) 1,3-dimethylurate (3.36)  
8) Acetate (1.93)  8) Acetate (1.93)  8) Lactate (4.13 & 1.33)  
9) 3-hydroxybutyrate (1.20)    
Figure 4-17 Metabolite identification from weightings plots 
Plots illustrate the key peaks contributing to the differentiation between 
diagnostic groups identified in the cohort 1 PLS-DA models. (A) Principal 
IIH metabolites are characterized by low CSF LV1 scores, (B) Principal 
MS metabolites are characterized by low CSF LV2 scores, (C) Principal 
CVD metabolites are characterized by low serum LV1 scores. NMR 
chemical shifts (ppm), which describe the location of the peaks in the 
spectra, are shown in brackets for each metabolite. 
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Assessment of spectral peak areas, which are proportional to metabolite concentration, 
revealed that urea was significantly reduced in the CSF of patients with IIH compared to 
subjects with other neurological conditions (IIH median concentration 29.7 (range 14.2-
37.5 arbitrary units (au)), MS median concentration 34.2 (range 25.1-42.1 au), CVD 
median concentration 32.3 (range 25.0-50.1 au) and other median concentration 34.8 
(range 15.6-46.0 au), p<0.05).  Acetate was found to be significantly elevated in the CSF 
of IIH patients compared to with other neurological conditions (IIH median concentration 
34.9 (range 14.4-61.1 au), MS median concentration 31.3 (range 15.6-45.1 au), CVD 
median concentration 39.0 (range 16.3-45.5 au) and other median concentration 27.5 
(range 14.8-52.4 au), p<0.05) (Figure 4-18).  
 
 
Figure 4-18 Significant metabolites in the IIH spectra 
 Box and whiskers plots with median and ranges showing (A) reduced CSF 
urea in the IIH cohort compared to subjects with other neurological 
diseases, (B) elevated CSF acetate in the IIH cohort compared to subjects 
with other neurological diseases. 
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4.4. Discussion 
1H NMR is a powerful technique for measuring multiple metabolites in a biofluid, thus 
providing a vast amount of information on both the high and low concentration 
constituents of a sample. Metabolomics provides an overview of a biofluid that represents 
the end-products of gene transcription, protein translation and environmental effects, all 
factors known to influence disease state. Additionally, the technique is automated, rapid 
(spectra are acquired in 10 minutes), reproducible and relatively sensitive (detection of 
metabolites in the nanogram range) (Holmes et al. 2006b). The data from this study, and 
others, (Nicoli et al. 1996; Subramanian et al. 2005; Holmes et al. 2006a; Holmes et al. 
2006b; Lutz et al. 2007) suggests that different neurological conditions are represented by 
unique biofluid metabolic fingerprints which may reflect distinct variations in underlying 
pathology. We have demonstrated that there are distinct differences in the spectra 
acquired from CSF and serum of patients with IIH, MS and CVD. 
The study used multivariate regression analysis to identify metabolite biomarker profiles 
in the CSF and serum of patients with IIH, MS and CVS.  Our analysis has shown that 1D 
spectra were more discriminating than 2D spectra for all diagnostic groups. Although 2D 
JRES reduce spectral congestion, the resonance from large macromolecules such as 
proteins can be lost (Viant 2003). Consequently, the signals from potentially 
discriminating protein bound metabolites may be lost, thus possibly reducing the 
sensitivity of the spectra.  
Despite the heterogeneity of the neurological patients analysed, we have demonstrated 
that there are distinct differences in the spectra acquired from the CSF and serum of 
patients with IIH, MS and CVD. We were able to identify patterns of metabolite variance 
in individual diagnostic groups and using statistical modelling we identified age, gender 
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and BMI specific disease biofluid metabolite profiles. These predicted diagnosis with a 
sensitivity and specificity of 80% in IIH and MS (CSF profiles) and 75% in CVD (serum 
profiles).  The heterogeneity of the control group was likely to have impaired the 
biomarker discovery and thus sensitivity and specificity of the metabolite profiles. Our 
approach, however, would yield biomarkers which could be transferred to a clinical 
setting, where we would aim to use biomarkers to help distinguish between different 
neurological diseases. Phenotypic features, such as gender and age (own unpublished 
data) are known to influence NMR spectra and our data highlights the importance of 
accounting for these variables when establishing metabolite profiles. Dietary factors, in 
the 24 hours preceding sample collection, are known to impact upon the metabolite 
profiles, even in fasted patients (Maher et al. 2007). Nutrition, however, was unlikely to 
have led to false biomarker discovery in our analysis, as each disease cohort represented a 
spectrum of dietary habits.  
Discrimination of patients with IIH was observed to be optimal using 1D CSF spectra 
(sensitivity 71% and specificity 70% when modelled against the whole control cohort and 
80% sensitivity and specificity when modelled against a matched control cohort). The 1D 
serum profile was also of value in IIH (sensitivity 70% and specificity 78%). This 
possibly implicates both CNS and systemic factors in IIH disease aetiology. This is the 
first identification of biomarkers specific to IIH and is thus an important step in defining 
the condition and advancing knowledge regarding the aetiology. A diagnostic test has not 
been previously documented for IIH and the identification of potentially diagnostic CSF 
and serum biomarker profiles may have important clinical implications in terms of 
expediting accurate diagnosis and monitoring disease progression. It will now be 
important to confirm that the metabolic biomarkers in IIH are distinct from other causes 
of elevated intracranial pressure. The single patient with secondary intracranial 
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hypertension, resulting from anaemia, did have a different biomarker profile to the IIH 
patients.  
Biomarker profiles in the MS patients were most accurately identified using 1D CSF 
spectra (sensitivity 83% but a specificity of 53%). The accuracy of the profile increased 
when the MS patients were compared to a matched control population (sensitivity and 
specificity 80%). Serum metabolite biomarkers in MS were not as discriminatory as that 
observed in the CSF. Although patients with MS can demonstrate systemic biochemical 
features, such as an inflammatory cytokine profile, this is usually during disease relapse 
(Carrieri et al. 1998). The samples in this study were collected during disease remission, 
and this may account for the absence of a systemic serum metabolite profile. 
Regression analysis of CSF metabolites did not discriminate patients with CVD from 
control subjects with sufficient sensitivity or specificity. Disease unique serum metabolite 
biomarker profiles however, were more accurate in identifying patients with CVD from 
matched controls (sensitivity and specificity 75%).  The pathological heterogeneity in the 
CVD cohort is a likely explanation for the reduced diagnostic precision e.g. patients with 
atherosclerotic and embolic CVD were grouped for analysis, but have differing aetiology. 
It is not possible to compare the accuracy of diagnostic metabolomics with other 
diagnostic tests for IIH, MS and CVD, as they do not exist. Numerous studies have 
evaluated the accuracy of the “Revised McDonald Criteria” in predicting which patients 
will progress from a clinically isolated syndrome to clinically definite MS, but these 
studies have not evaluated the ability of the criteria to exclude alternative diagnoses 
(Polman et al. 2005; Swanton et al. 2007). In addition, the McDonald criteria use a 
spectrum of clinical and para-clinical tests to define MS. The advantages of a single 
biofluid diagnostic test are clear. Further evaluation to define metabolite biomarker 
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profiles at different stages of MS would be of additional value. The diagnosis of CVD is 
less challenging. The differentiation of patients with MS from those with CVD in the 
context of an ambiguous MRI scan can, however, be problematic. In these situations, a 
combined approach using CSF and serum metabolomic profiles may facilitate diagnosis. 
Although we have identified disease unique metabolite profiles, the future use of 
metabolite biomarkers in the clinical environment will require optimisation to improve 
accuracy.  In our study, the accuracy of disease-unique metabolite profiles may have been 
affected by inherent inaccuracies in clinical diagnosis (Stacy and Jankovic 1992), co-
morbidities such as the possible coexistence of MS and CVS, and pathological 
heterogeneity in the disease cohorts (e.g. classification of both embolic and 
atherosclerotic CVD in the same cohort). Confirmation of diagnosis at post-mortem may 
ultimately improve disease classification. 
Technical advances in metabolomics are rapidly progressing as this approach moves from 
the field of analytical chemistry, into medicine. The interpretation of serum spectra is a 
particular problem due to variable protein binding of metabolites. Techniques to protein 
deplete samples prior to spectral acquisition, such as filtration and protein suppression 
during analysis, may be of benefit, and need to be validated in clinical metabolomics 
(Tiziani et al. 2008). Analytical techniques which eliminate phenotypic features such as 
gender and drug metabolites may also have a role and will need evaluation (Tiziani et al. 
2008). Ideally, accurate metabolomic profiles in non invasive biofluids such as urine, will 
need to be developed to negate the requirement for diagnostic LP.   
Disease treatment in neurology is predicted to advance over the next decade with the 
development of genetic, stem cell and immunomodulatory therapies. Biomarkers will be 
essential in the development and deployment of these therapies, to facilitate diagnosis, 
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guide prognosis and therapy, evaluate experimental pharmacotherapy and in addition 
provide surrogate endpoints and markers for clinical research (Feigin 2004; Lolli et al. 
2006; Staner 2006). Ideally, clinical biomarkers need to be highly sensitive and specific, 
generalisable, representative of disease pathology and reflect the diversity of clinical 
outcomes. Single biomarkers will rarely achieve these ideals and it is likely that 
composite endpoints will be required. There are, therefore, clear advantages to using 
metabolic biomarker profiles which represent multiple differentiating metabolites. The 
diagnostic ability of metabolite biomarkers will clearly need optimising and evaluating in 
larger patient cohorts, with a greater spectrum of more diagnostically challenging 
diseases.  
4.4.1. Metabolite interpretation 
Individual metabolites, highlighted in the weightings plot, warrant further evaluation to 
establish if they reflect pathogenic disease mechanisms or are, in fact, the consequence of 
the disease process. Interpretation of CSF metabolites is complex, as the origin of these 
metabolites is not established (metabolites may reflect systemic metabolism and 
subsequent transfer across the blood brain barrier or local CNS generation). As little is 
known about the pathogenesis of IIH (Sinclair et al. 2008), we were interested to note 
elevated levels of lactate in the CSF of these patients. Predominant lactate peaks have 
been identified in inflammatory CNS disease (Simone et al. 1996) possibly implicating an 
inflammatory component in IIH (Sinclair et al. 2008). Additionally, elevated levels of 
lactate have been identified in vitreous humour of rabbits with elevated intraocular 
pressure and are thought to reflect anaerobic metabolism (Ngumah et al. 2006).  In IIH, 
anaerobic metabolism may be attributed to reduced blood supply due to compressed 
vasculature from the elevated ICP. Additionally, elevated oxaloacetate levels, in 
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conjunction with reduced citrate levels in IIH, may represent impaired action of citrate 
synthase in the citric acid cycle. This, in conjunction with elevated ketone bodies (3-
hydroxybutyrate, an enantiomer of the ketone β-hydroxybutyric acid), may suggest a 
predominantly anaerobic environment, deficient in carbohydrate substrate in patients with 
IIH.  The findings of low urea and elevated acetate in the CSF of patients with IIH are of 
interest. Both of these compounds have been previously identified in the CSF 
(Commodari et al. 1991; Subramanian et al. 2005) but their significance is unclear. 
Further exploration of the role of urea and acetate in IIH is needed. 
 In the MS cohort, elevation of CSF glutamate, a known CNS neurotoxic trigger (Choi et 
al. 1987), compounded by low levels of oxaloacetate (an inhibitor of neuronal cell death) 
may contribute to axonal loss (Berry and Toms 2006) and represents an area for further 
study. Elevated levels of CSF acetate and reduced citrate are in keeping with previous 
studies (Lynch et al. 1993) (Simone et al. 1996). The implication of these metabolite 
alterations is unclear, although deranged CSF citrate has also been noted in Alzheimer’s 
disease (Ghauri et al. 1993). 
The reduced levels of serum betaine in patients with cerebrovascular disease is intriguing 
and may indicate a population at high risk of stroke, as betaine, a methyl donor, reduces 
levels of homocysteine, a known risk factor for cerebrovascular disease (Spence 2006). 
Additionally, elevated serum glucose is likely to reflect impaired insulin sensitivity in 
these patients, another established risk factor for stroke (Prakash and Matta 2008). 
Elevated lactate levels, also noted in earlier NMR studies (Hiraoka et al. 1994), and a 
proposed shift from aerobic to anaerobic cerebral glycolysis following a cerebrovascular 
event, have been previously documented in patients following cerebrovascular events 
(Meyer et al. 1968; Zupping et al. 1971). 
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4.4.2. Conclusion 
In summary, we have illustrated and validated the use of metabolomics to identify 
differences in metabolite profiles in patients with IIH, MS and CVD. Metabolomics offers 
great potential in establishing neurological biomarkers and efforts should concentrate on 
optimising spectral processing to increase diagnostic accuracy, evaluating the accuracy of 
urinary metabolite profiles and establishing a national neurological metabolite database. 
The novel identification of IIH specific metabolites is of particular importance, as 
understanding of disease aetiology is so limited. Absolute confirmation, by mass 
spectrometry, of the disease specific metabolites, is now required prior to detailed in vitro 
assessment. 
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Chapter 5. The role of weight loss in idiopathic intracranial 
hypertension 
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5.1. Introduction 
The following chapter details the effect of weight loss on IIH. To facilitate interpretation 
of the data, each section of the chapter has been divided into 3 sections. The first section 
addresses the therapeutic effect of weight loss on intracranial pressure, headache and 
visual parameters in patients with IIH. The second section describes the metabolic 
consequences of weight loss, particularly the effects on glucocorticoids and 11β-HSD1. 
Finally, the metabolic profile of patients with IIH has been compared to a population of 
healthy control subjects matched for age, gender and BMI. 
5.1.1. The clinical consequences of weight loss in idiopathic intracranial 
hypertension 
Introduction 
Evidence to guide therapeutic strategies in IIH is limited, as highlighted in the 2005 
Cochrane review which found insufficient evidence as to which treatments were 
potentially beneficial and which were harmful (Lueck and McIlwaine 2005). The 
condition has a striking association with obesity (greater than 93%) (Glueck et al. 2005)  
and, consequently, weight loss is frequently suggested as a critical treatment strategy.  
Nevertheless, there is only one prospective weight modifying study published in the 
English literature. This study was carried out over 35 years ago and noted subjective 
improvement in the papilloedema in nine subjects with IIH, on a low calorie rice diet 
(Newborg 1974); data supported by retrospective case note reviews (Johnson et al. 1998; 
Kupersmith et al. 1998; Wong et al. 2007) (discussed in section 1.11.3). These studies, 
however, relied upon subjective measures of papilloedema and included subjects with 
newly diagnosed IIH, many of whom are likely to improve, irrespective of any treatment 
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given. Furthermore, these studies did not monitor concomitant changes in ICP with either 
weight loss, or resolution of papilloedema. In this context, we initiated a detailed 
examination of the interplay between weight loss in IIH with objective measures of 
papilloedema, visual function, headache scores and crucially, changes in ICP. 
5.1.2. Effect of weight loss on the metabolic phenotype and 11β-HSD1, in 
idiopathic intracranial hypertension  
Introduction 
11β-HSD1 dysregulation in obesity has been previously established (Andrew et al. 1998; 
Stewart et al. 1999; Rask et al. 2001; Reynolds et al. 2001) and may be an important 
factor in obesity and disordered CSF dynamics in IIH patients (see section 1.5.1). Weight 
loss is know to modulate 11β-HSD1 activity in obese subjects (Tomlinson et al. 2004a; 
Tomlinson et al. 2008) and may underlie the therapeutic advantage demonstrated in IIH 
patients on a weight reduction program (section 5.3.1). 
Obesity is frequently associated with hyperlipidaemia, hypertension, glucose intolerance 
and fatty liver. Collectively, these features are known as the Metabolic syndrome, a state 
of impaired insulin sensitivity, predisposing to type 2 diabetes and atherosclerotic 
vascular disease, noted particularly in individuals with centrally distributed adiposity 
(Ginsberg 2000). Obesity is characterised by an enlarged white adipose tissue mass, 
which not only provides an energy store, but additionally represents an important 
endocrine organ that has the ability to secrete over a hundred factors, including proteins, 
cytokines, fatty acids and prostaglandins (Mercer et al. 1996; Fain 2006). The endocrine 
properties of adipose tissue enable communication with numerous other organs 
facilitating appetite regulation, energy homeostasis, insulin sensitivity, reproductive 
function, bone metabolism and immune modulation (Fantuzzi 2005).  Adipose 
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distribution and insulin sensitivity have not been previously investigated in IIH and may 
have important implications for the risk of metabolic syndrome these patients. 
In summary, we suggest that 11β-HSD1 may be involved in the pathogenesis of IIH and 
that therapeutic weight loss may be beneficial, due to manipulation of local 
glucocorticoids concentrations and 11β-HSD1. Additionally, we suggest that obesity in 
IIH may predispose IIH patients to the metabolic syndrome. We aim to characterise 11β-
HSD1, fasted metabolites and body composition in a cohort of patients with IIH before 
and after weight loss. 
5.1.3. Comparison of metabolic phenotype and 11β-HSD1 in idiopathic 
intracranial hypertension and control patients  
Introduction 
We have previously described the association between IIH and obesity, and have 
suggested that patients with IIH, akin to obese individuals, may be susceptible to the 
metabolic syndrome. In this section, we aim to further characterise the metabolic 
phenotype of IIH patients, compared to obese control subjects. 
5.2. Methods 
5.2.1. The clinical consequences of weight loss in idiopathic intracranial 
hypertension  
5.2.1.1. Study population 
Subjects with IIH were identified from the Birmingham and Midland Eye Centre, 
Sandwell and West Birmingham Hospitals NHS Trust, University Hospitals Birmingham 
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NHS Foundation Trust and University Hospitals of Leicester NHS Trust, following 
informed written consent (ethical approval from Dudley Local Research Ethics 
Committee (LREC) 06/Q2702/64). IIH was diagnosed according to the modified Dandy 
Criteria (Friedman and Jacobson 2002) with all patients having normal MRI, MRV, 
papilloedema (confirmed on slit lamp examination by a neuro-ophthalmologist), ICP 
greater than 25cmH2O and disease duration greater than 3 months at enrolment. Subjects 
were excluded if they had undergone previous CSF diversion or optic nerve sheath 
fenestration, were pregnant or planning to conceive, had significant co-morbidity (cardiac 
disease, unstable diabetes, alcohol or drug dependence) or were less than 16 years of age. 
All subjects meeting the inclusion and exclusion criteria were invited to take part in the 
study. 
5.2.1.2. Study design 
Twenty five IIH subjects were prospectively recruited into a three stage study: Stage 1 
consisted of a three month period of no new intervention (control phase); Stage 2 
comprised a three month intensive diet; and in Stage 3 subjects were followed for a 
further three months after completion of the diet (Figure 5-1). Weight loss was achieved 
using a previously validated (Tomlinson et al. 2004a), nutritionally complete, very low 
calorie total meal replacement liquid diet (VLCD) (Lipotrim, Howard Foundation, 
Cambridge, UK) which provided subjects with a total of 425 Kcal/day. No additional food 
was consumed and patients were advised to consume at least 2 litres of fluid per day.   
During Stage 2, subjects were weighed weekly and given dietetic advice.  
Subjects were evaluated at baseline and at the end of stages 1, 2 and 3.  Anthropometric 
data were collected and BMI was calculated from the weight divided by the square of the 
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height (kgm-2). The presence of symptoms (tinnitus, visual loss, diplopia, visual 
obscurations and headache) was noted. Medication use was also recorded. 
Assessment of visual function, under standardised luminescence, was carried out using a 
LogMAR chart to assess visual acuity, automated perimetry (Humphrey 24-2 central 
threshold) to measure the visual field mean deviation, a Pelli Robson chart to evaluate 
contrast sensitivity and a Farnsworth Munsell 100 Hue test to appraise colour vision.  
Papilloedema was evaluated using ultrasonography of the optic disc elevation and nerve 
sheath diameter (maximal retrobulbar pial diameter), using a high resolution brightness 
scan (B-scan), with emission frequency 20MHz and 10MHz respectively (Quantel 
Medical, Clermont–Ferrand, France).  Additionally, average axonal distention around the 
optic disc (a marker of papilloedema) was measured from the distension of the 
peripapillary RNFL thickness (vitreoretinal interface to photoreceptors) using OCT 
(Stratus OCTTM V4.0.1, Carl Zeiss, Meditec, Welwyn Garden City, UK). Masked  
papilloedema grading (Frisen rating scale with grade 5 most severe) of fundus 
photographs was also conducted at each visit by a neuro-ophthalmologist (Frisen 1982) 
(Table 1-6).  Disc ranking was also applied to each photograph by a masked neuro-
ophthalmologist: pairs of fundal photographs at the start and end of each stage were 
randomly ordered and labelled; the disc which appeared most swollen was selected. If no 
difference in the appearance of the disc was perceived, this was also noted. 
Headache phenotype (according to the International Headache Society (IHS) criteria) 
(Evers 2004) was assessed at baseline. A daily headache diary, completed in the week 
prior to each visit,  evaluated headache severity using a visual analogue pain scale (VAS), 
headache frequency (days/week) and analgesia use (days/week). A headache 
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questionnaire, HIT-6, (score range 36 – 78) was also completed (questionnaire illustrated 
in the appendix, section 7.2) (Kosinski et al. 2003).  
ICP was measured by LP by the same physician (Alex Sinclair) at baseline, 3 and 6 
months after all listed outcome measures had been assessed. Measurements were taken 
with the patient breathing steadily in the left lateral position, legs extended greater than 
90◦ at the hip, allowing adequate time to ensure a stable ICP reading. 
 
Figure 5-1 Schematic diagram of weight loss study design 
Visual assessments include measurement of: (1) papilloedema by 
ultrasonographic evaluation of optic disc elevation and nerve sheath 
diameter, as well as optical coherence tomography measurement of retinal 
nerve fibre layer; (2) LogMAR visual acuity; (3) Humphrey visual field 24-
2 mean deviation; (4) Pelli Robson contrast sensitivity; (5) Farnsworth 
Munsell 100 Hue colour assessment. Symptoms evaluated include 
headache, tinnitus, visual loss, obscurations and diplopia. *lumbar 
puncture is only carried out at baseline, 3 and 6 months. 
 
5.2.1.3. Statistical analysis 
Statistical analysis was performed as described (section 2.4). Additionally serial 
measurements were analysed using repeated measures ANOVA (for parametric or log 
transformed data) or Friedman’s test, with post hoc evaluation achieved using a Wilcoxon 
Signed-Rank test (for non-parametric data). Analysis of dichotomous variables was 
conducted using a Cochran’s Q test, and the Sign test was used to evaluate changes in 
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categorical data. Associations between clinical parameters and objective outcome 
measures were analysed using Pearson correlation for parametric data and Spearman rank 
correlation for non-parametric data. Missing data were excluded from analysis and data 
analysed only if present at all time points. The level at which the results were judged 
significant was p < 0.05 (or p < 0.017 for Wilcoxon signed rank test and Sign test as three 
pairwise comparisons were being made per variable). Right and left eye data correlated 
significantly and yielded analogous results. Right eye data are therefore quoted. 
5.2.2. Effect of weight loss on the metabolic phenotype and 11β-HSD1, in 
idiopathic intracranial hypertension  
Methods 
5.2.2.1. Study population 
The study population detail in section 5.2.1.1 were utilised for this study. Additional 
exclusion criteria included, hormone manipulating medication, significant co-morbidity 
including unstable diabetes and known endocrinopathies.  
5.2.2.2. Study design and sample collection  
The study was conducted according to that described in section 5.2.1.2; briefly, a three 
month observation period (stage 1) was followed by a three month VLCD (stage 2) 
(Lipotrim, Howard Foundation, Cambridge, UK).  At baseline, and the end of stages 1 
and 2, anthropological measures (BMI and waist circumference, measured at the level of 
the umbilicus), blood pressure (Dynamap, Critikon, Tampa, FL) and biofluid samples 
(blood, CSF and urine) where collected. Blood and CSF samples, were collected in a 
fasted state between midday and 14:00h. After collection, blood and CSF samples were 
promptly centrifuged at 176g for 10 minutes, aliquoted, stored at -80˚C and analysed after 
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a maximum of one freeze-thaw cycle.  Blood samples were evaluated for total cholesterol, 
triglycerides, glucose, insulin and HOMA scores calculated (section 2.3.4.). Cortisol and 
cortisone was measured in the serum and CSF using LC/MS (2.2.3). 24h urine samples 
were also collected (collection from first void of the day and thenceforth for 24h), the 
total volume noted and aliquots stored at -80˚C before analysis for steroid metabolites by 
GC/MS (section 2.2.2). A DEXA total body scanner (QDR 4500; Hologic, Bedford, MA) 
analysed body composition including fat distribution at the start and end of stage 2. 
Finally, evaluation for polycystic ovarian syndrome (PCOS), according to the Rotterdam 
ESHRE 2004 criteria (REA-SPCW 2004) was conducted at baseline (Table 5-1). PCOS 
biochemical investigation for hyperandrogenism included serum androstenedione, DHAS, 
SHBG and testosterone (section 2.3.4.3).  
Stage 2Stage 1
No new intervention Weight loss
Outcome measures assessed
•BMI,  waist circumference & BP
•Fasted serum cholesterol, TG, glucose & insulin
•CSF and serum cortisol and cortisone
•Urinary steroid metabolites
•DEXA scanning*
6 months3 months0 months
 
Figure 5-2 Schematic diagram of study design for metabolic phenotyping during 
weight loss 
Body mass index (BMI), blood pressure (BP), triglycerides (TG), 
cerebrospinal fluid (CSF). *Dual energy x-ray absorptiometry (DEXA) was 
only performed at 3 and 6 months. 
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Rotterdam PCOS Criteria (2 out of 3) (REA-SPCW 2004) 
1.Oligo (cycle length > 45 days) - or amenorrhoea (no menstrual period for 
the past 6 months). 
2.Clinical (hirsutism, acne & male pattern balding) and/or biochemical signs 
of hyperandrogenism. 
3.Polycystic ovaries and exclusion of other aetiologies (congenital adrenal 
hyperplasia, androgen-secreting tumours, Cushing’s syndrome). 
Table 5-1 Revised Rotterdam criteria for diagnosis of polycystic ovarian syndrome 
(PCOS)  
 
5.2.2.3. Comparison of weight loss in IIH, with non IIH obese subjects 
Non IIH obese subjects were previously investigated, using an identical study design 
(Tomlinson et al. 2004a; Tomlinson et al. 2008). In an exploratory analysis, which was 
not the primary aim of this study, the effect of weight loss on glucocorticoids, fasting 
metabolites, and body composition was compared between the IIH and non IIH obese 
patients (matched for gender, BMI ± 2 kgm-2 and age ± 5 years). The non-IIH obese 
patients represented a historical control cohort recruited following local advertisement.  
5.2.2.4. Statistical analysis 
Data were analysed as described in section 5.2.1.3. The level at which the results were 
judged significant was p < 0.05 (or p < 0.025 for Wilcoxon signed rank test, as two 
pairwise comparisons were being made per variable). 
 
5.2.3. Comparison of metabolic phenotype and 11β-HSD1 in idiopathic 
intracranial hypertension and control patients  
Methods 
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5.2.3.1. Study population 
Subjects with IIH were identified as described in section 5.2.2.1, using identical inclusion 
and exclusion criteria. A proportion of these patients were subsequently recruited into the 
weight loss study (sections 5.2.1.1).  Participants were fully informed and written consent 
was taken (ethical approval from Dudley Local Research Ethics Committee (LREC) 
06/Q2702/64). Control obese subjects were provided by Dr Jeremy Tomlinson 
(Birmingham Prospective Obesity, Diabetes Steroid metabolism study (BPODS cohort), 
South Birmingham LREC 04/q2707/278, approved 22/12 2004). Controls were recruited 
as part of a previous study (Tomlinson et al. 2004a; Tomlinson et al. 2008) following 
local advertisement. Those control subject using hormone manipulating medication or 
with significant past medical history (including diabetes) were excluded. 
5.2.3.2. Study design and sample collection 
The IIH and control subjects were matched for gender and BMI (± 2 kgm-2). For both the 
IIH and control subjects, anthropological measures, sample collection and processing 
(serum and urine), and DEXA scanning were conducted in an identical manor using the 
same equipment / assays techniques (described in section 5.2.2.2) (Figure 5-3). Screening 
for PCOS, was however, rigorously conducted in the IIH cohort, whilst control subjects 
were not formally screened (all control subjects with an existing diagnosis of PCOS were, 
however, excluded). 
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IIH Controls
Outcome measures assessed
•BMI,  waist circumference & BP
•Urinary steroid metabolites
•Fasted serum cholesterol, TG, glucose & insulin
•DEXA scanning
 
Figure 5-3 Schematic diagram of study design comparing IIH and control subjects 
Idiopathic intracranial hypertension (IIH), body mass index (BMI), blood 
pressure (BP), triglycerides (TG), dual energy x-ray absorptiometry 
(DEXA). 
 
5.2.3.3. Statistical analysis 
Statistical methodology is described in detail in section 2.4. Data were summarised using 
means and standard deviations. The IIH and control groups were compared using a two-
tailed, non-parametric t-test (Mann-Whitney). Where a significant correlation was noted 
between a variable and age, multivariable regression models were used to control for the 
effect of age. Missing data were excluded from analysis.  
 
5.3. Results 
5.3.1. The clinical consequences of weight loss in idiopathic intracranial 
hypertension  
Results 
Twenty-five patients were recruited, while 12 patients declined the invitation to 
participate in the study due to concerns about LP. The recruited subjects, and those 
declining study entry, had homogeneous characteristics. Amongst the recruited patients, 
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one was subsequently excluded as they were found to have anaemia, a secondary cause of 
raised ICP. Upon treatment of the anaemia, all signs and symptoms of IIH resolved. Two 
patients did not complete Stage 2 of the study, as they were unable to tolerate the diet, and 
a further two patients were lost to follow-up at the final study visit (9 months). Subjects 
dropping out of the study had similar clinical and anthropometric characteristics to those 
remaining in the study. Patient demographics are shown in Table 5-2. During the study 
44% of patients received an unchanging dose of acetazolamide. No other medications for 
IIH were used by study subjects.  There were minimal side effects associated with the 
VLCD; 3 patients complained of constipation, 2 of light headed feelings (ameliorated by 
increased fluid intake) and one described halitosis. No subjects proceeded to CSF 
diversion, or optic nerve sheath fenestration, during the study. 
 
Characteristic  
Number 25  
Age  34.4 ± 9.2 
Female gender 25 (100%)  
Ethnicity   
Caucasian 
African-Caribbean  
South West Asians (Indo-Pakistanis) 
 
20 (80%) 
3 (12%) 
2 (8%) 
Disease duration to enrolment  (months)  39.0 ± 49.2 
Acetazolamide therapy  11 (44%) 
Table 5-2 Baseline demographics 
 Mean and standard deviations are quoted. 
 
At baseline (Table 5-3), mean weight was 101.5 ± 16.0 kg (BMI 38.2 ± 5.0 kgm-2) and 
ICP was 39.8 ± 5.1 cmH2O. Universal papilloedema was confirmed using USG and OCT 
and graded most frequently as Frisen grade 2 (83% of cases) with the remainder grade 1 
(17%) (Figure 5-4A). At baseline, there was minimal evidence of visual loss, with 
LogMAR acuity recorded as -0.02 ± 0.10 and the average HVF mean deviation recorded 
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as -3.8 ± 4.1 (i.e. a low deviation from the variance observed in the general population). 
Eight subjects (40%) described symptoms of visual loss (e.g. blurred vision and blind 
spots). Visual obscurations were reported by 3 patients (15%), tinnitus by 10 patients 
(50%) and diplopia, which, due to subject understanding was not described at baseline, 
occurred in 7 patients (35%) at the diet onset. Headache was almost universally reported 
(19 patients, 95%) and represented a major source of morbidity (HIT-6 scores 57.5 ± 9.0). 
Baseline headache phenotyping identified that 60% of patients (12 out of 20) had 
migraineous headache (IHS 1.1, 1.2 and 1.5.1), in addition to headache attributed to IIH 
(IHS 7.1.1) and 35% described medication overuse (Evers 2004). 
As expected, none of the parameters measured altered significantly during Stage 1 (no 
intervention). Weight significantly reduced following the VLCD (Stage 2) by 15.7 ± 8.0 
kg, p<0.001 (-15.3 ± 7.0% of weight) (Figure 5-5A).  In conjunction with the weight 
reduction (Stage 2), there was a clinically and statistically significant drop in ICP (-8.0 ± 
4.2 cmH2O, p<0.001) (Figure 5-5B). 
All three techniques used to objectively evaluate different aspects of papilloedema 
showed significant improvement following weight loss (stage 2): Optic disc elevation 
measured by USG p=0.002 (Figure 5-6A), optic nerve sheath diameter p=0.004 (Figure 
5-6B) and peripapillary RNFL thickness p=0.001 (Figure 5-6C). There was, however, no 
significant improvement in the less discriminating Frisen grade during stage 1, 2 or 3 
(14% improved during stage 1 and 5% improved following stage 2, stage 3 and from the 
start of the diet to the final follow up, no deterioration in the disc was detected) (Figure 
5-4B).  Disc ranking was more discriminating at detecting changes in papilloedema; 
improved: deteriorated 43:19%, p=0.267 for stage 1, 55:23%, p=0.143 for stage 2, 
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45:25%, p=0.224 for stage 3 and 50:10%, p=0.039 from the start of the diet to the final 
follow up (Figure 5-4C). 
The actual LogMAR visual acuity score improved significantly (p<0.001), but this 
equated to an improvement by only one line (0.1) in 25.0% of subjects and was not 
deemed clinically significant. We did note a significant improvement in the Pelli Robson 
contrast sensitivity following weight loss (following stage 1, 16% improved and 13% 
deteriorated while following stage 2 (diet stage) 46% improved and 4% deteriorated, 
p=0.003). During the course of the study, small improvements were noted in HVF mean 
deviation (0.4 ± 1.6 for stage 1 (p=0.110) and 0.7 ± 2.4 for stage 2 (p=0.162)) and 
Farnsworth Munsell colour assessment (-21.4 ± 49.7 for stage 1 (p=0.012) and -23.6 ± 
45.3 for stage 2 (p=0.027)) (Table 5-3). This is likely  to  reflect a subject-related learning 
effect  and not a response to weight reduction (Castro et al. 2008). 
 
Headache (HIT-6) significantly improved, following weight loss, to a score of 46.9 ± 10.1 
(p=0.004) (Figure 5-7A). Additionally, significant improvements were noted in headache 
severity (VAS from 4.2 ± 2.8 to 1.9 ± 2.8, p=0.015) (Figure 5-7B), headache frequency 
(from 4.4 ± 2.9 to 2.1 ± 2.8 days per week, p=0.011) (Figure 5-7C) and weekly analgesic 
use from 2.2 ± 2.5 to 0.2 ± 0.4 days per week, p=0.007) (Figure 5-7D and Table 5-3). 
Patient symptoms (headache, tinnitus, obscurations and diplopia) showed significant 
improvement following VLCD (stage 2) (p<0.001, p=0.004, p=0.025 and p=0.008 
respectively) (Table 5-3). 
 
Change in ICP during the VLCD did not correlate with change in weight (r=0.280, 
p=0.209) (Figure 5-5C), or with changes in any of the other outcome measures. 
Interestingly, if one outlying patient, in whom the start diet LP pressure appears falsely 
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low (51 cmH2O at baseline, 36 cmH2O at diet onset and 33.5 cmH2O after the diet), is 
removed, the correlation becomes significant (r=0.440, p=0.046). All outcome measures 
including weight change (0.2 ± 2.5 kg, p=0.894) were unaltered at the final three months 
post-diet visit (end of Stage 3, Table 5-3), with the exception of headache symptoms 
(present in 50% of individuals at the final visit, compared to 58% at the end of the diet, 
p=0.002), the USG evaluation of papilloedema (nerve sheath diameter -0.4 ± 0.8, p=0.035 
and disc elevation -0.07 ± 0.15, p=0.059) and HVF mean deviation (-1.2 ± 2.0, p=0.009) 
which continued to improve. 
 
Data for the intention to treat analysis (25 patients at baseline, 24 patients at the start of 
the diet, 22 patients at the end of the diet and 20 patients at the end of the follow-up 
period) are illustrated in appendix 7.4. This analysis does not alter the overall meaning or 
significance of the results.  
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Study characteristics and symptom chronology at each assessment 
Characteristic Baseline Start Diet End Diet Final P value 
Patient numbers 20 20 20 20  
Weight (kg) 101.5 ± 16.0 102.5 ± 16.8 86.8 ± 15.6 87.0 ± 12.9 <0.001 
BMI (kgm-2) 38.2 ± 5.0 38.6 ± 5.3 32.6 ± 4.7 32.8 ± 4.4 <0.001 
Intracranial pressure (cm CSF) 39.8 ± 5.1 38.0 ± 5.0 30.0 ± 4.9 N/A <0.001 
Vision      
Ultrasonographic optic disc 
elevation (mm) 
1.02 ±  0.30 0.97 ± 0.31 0.82 ± 0.28 0.75 ± 0.26 0.002 
Ultrasonographic optic nerve 
sheath diameter (mm) 
4.5 ± 1.0 4.7 ± 1.0 4.0 ± 1.2 3.6 ± 1.2a 0.004 
Optical coherence 
tomography (Average optic 
disc elevation) (microm) # 
144.1 ± 45.5 135.0 ± 48.0 109.3 ± 27.9 108.2 ± 28.6 0.001 
LogMAR visual acuity‡ 
-0.02 ± 0.10 0.01 ± 0.11 -0.06 ± 0.09 -0.07 ± 0.08 <0.001a 
Pelli Robson contrast 
sensitivity‡ 
1.58 ± 0.17 1.61 ± 0.11 1.67 ± 0.05 1.68 ± 0.10 0.003 
Humphrey visual field 24-2 
mean deviation‡ 
-3.8 ± 4.1 -3.4 ± 3.7 -2.7 ± 3.0 -1.5 ± 1.8a ns 
Farnsworth Munsell 100 Hue 
colour assessment# 
110.7 ± 86.5 89.3 ± 84.6b 65.7 ± 54.9b 61.3 ± 62.0b ns 
Headache       
Headache Impact Test (HIT-
6)‡ 
57.5 ± 9.0 54.5 ± 1.0 46.9 ± 10.1 48.4 ± 9.6 0.004 
Headache severity (VAS 0-
10)‡ 
3.8 ± 2.4 
 
4.2 ± 2.8 
 
1.9 ± 2.8 
 
2.6 ± 2.7 0.015 
Headache Frequency 
(days/wk)‡ 
3.8 ± 2.9 
 
4.4 ± 2.9 
 
2.1 ± 2.8 
 
2.6 ± 3.1 
 
0.011 
Analgesic use (days/wk) ‡ 2.2 ± 2.7 2.2 ± 2.5 0.2 ± 0.4 1.0 ± 2.1 0.007 
Symptoms       
Headache† (n (%)) 19 (95) 19 (95) 12 (60) 10 (50) <0.001 
Tinnitus† (n (%)) 10 (50) 10 (50) 4 (20) 4 (20) 0.004 
Visual loss† (n (%)) 8 (40) 7 (35) 3 (15) 1 (5) 0.063 
Obscurations† (n (%)) 3 (15) 4 (20) 0 (0) 0 (0) 0.025 
Diplopia† (n (%)) 0 (0) 7 (35) 0 (0) 0 (0) 0.008 
Table 5-3 Study characteristics and symptom chronology at each assessment 
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Summary statistics represent values for cohort completing study (n=20). p 
values indicates significant changes following weight reduction (start diet 
versus end diet; stage 2). No significant changes were noted from baseline 
to start diet (stage 1) or from end diet to final visit (stage 3) unless 
indicated. A significant improvement noted but this was not found in the left 
eye. b significant change noted after each stage, therefore weight loss stage 
did not significantly improve variable.  All data analysed (at four time 
points, except ICP which was analysed at three time points) using repeated 
measures ANOVA unless stated otherwise. # indicates data was logged 
prior to analysis. ‡ indicates that a Friedman’s test was used for analysis 
and if significant a Wilcoxon Signed rank test was subsequently carried 
out, results of the latter are quoted in the table. † indicates that a 
Cochran’s Q test revealed a significant improvement in all variables and 
subsequently a Sign test was used to evaluate differences at each study 
stage. Abbreviations: CSF, cerebrospinal fluid; NS, not significant; VAS, 
Visual analogue score; wk, week.  
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Figure 5-4 Evaluation of fundal photography 
(A) The majority of discs were classified as Frisen grade 2 (83% at 
baseline, 73% start diet, 68% end diet and 65% at the final time point, all 
other discs were classified as grade 1). (B) There was no significant 
change in the Frisen grade during the study. (C) Disc analysed by ranking 
did reveal a significant improvement from the start of the diet to the end of 
follow up (10% deteriorated, 40% stable and 50% improved, p=0.039). 
(*p<0.05).Intention to treat analysis. 
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Figure 5-5 Weight and intracranial pressure assessment 
Scatter plots with means showing (A) weight loss, (B) intracranial pressure 
(ICP) change, (C) relationship between change in ICP and weight. *** 
indicates significant change from previous time point (p<0.001).  
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Figure 5-6 Quantification of papilloedema 
Scatter plots with means (A) ultrasonographic optic nerve elevation, (B) 
ultrasonographic optic nerve diameter, (C) optical coherence tomography 
retinal nerve fibre layer average distension. Significant changes are from 
previous time point (** p<0.01 and *p<0.05). 
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Figure 5-7 Headache assessment 
(A) Scatter plot with means showing Headache Impact Test-6 scores. 
Headache diary assessment of (B) headache severity, using a visual 
analogue pain score where 0 indicates no pain and  10 maximum pain, (C) 
headache frequency (number of days per week with headache) and (D) 
analgesic use (number of days analgesia used per week). Plots illustrate 
means and standard error of the mean. Significant changes are from 
previous time point (*** p<0.001, ** p<0.01 and * p<0.05). 
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5.3.2. Effect of weight loss on the metabolic phenotype and 11β-HSD1, in 
idiopathic intracranial hypertension  
Results 
 
25 subjects were enrolled and 22 completed the study (one was excluded, due to a 
secondary cause of IIH, and two were lost to follow-up). Results are analysed on an 
intention to treat basis and baseline demographics are shown in Table 5-2 and represent 
data for the whole cohort at each time point (25 patients at baseline, 24 patients at the start 
of the diet and 22 patients at completion of the study), consequently data quoted for 
changes between time points will reflect the differences noted in the cohort present at the 
end of the time period. Five IIH subjects (20%) had PCOS. As described in the previous 
section, weight remained stable during the observation period (Stage 1) (0.8 ± 3.1 kg) and 
there were no significant changes in any of the outcome measures. The VLCD (Stage 2) 
caused a significant reduction in weight (14.2 ± 7.8 kg, p<0.001), equivalent to loss of 
15.2 ± 7.8% of weight (BMI fell by 5.8 ± 3.0 kgm-2). The waist circumference also fell 
significantly (9.8 ± 5.4 cm, p<0.001).  
5.3.2.1. Urinary steroid metabolites 
No changes in the urinary steroid metabolites were noted over the observation period 
(Stage 1). Following the VLCD (Stage 2), there was a significant reduction in the 
THF+5α-THF: THE ratio (from 0.95 ± 0.30 start diet vs. 0.81 ± 0.25 end diet, p=0.001) 
(Figure 5-8A) (Table 5-4). The urinary free cortisol: cortisone ratio, an indicator of 11β-
HSD2 activity, did not change during the study suggesting that the change in THF+5α-
THF: THE reflected reduced 11β-HSD1 activity. In keeping with reduced 11β-HSD1 
activity, the total cortisol (Fm) to total cortisone (Em) metabolite ratio also fell (0.73 ± 
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0.22 vs. 0.63 ± 0.19, p=0.001).  The change in global 11β-HSD1 activity correlated 
significantly with the fall in ICP (r=0.504, p=0.028) (Figure 5-9A). Total glucocorticoid 
metabolites, reflecting daily cortisol secretion rate, also fell following weight loss 
(p=0.013) (Figure 5-8B). Measures of 5α-reductase activity decreased following the 
VLCD (5α-THF, p=0.002; 5α-THF:THF ratio, p=0.005; An, p=0.006; An:Et ratio, 
p=0.002; Table 2) (Figure 5-8C,D,E&F). The intra and inter-assay coefficient of variance 
was <10%.  
5.3.2.2. CSF and serum cortisol and cortisone 
Cortisol and cortisone levels in the CSF were lower than that observed in the serum 
(baseline cortisol 9.5 ± 5.0 nmoles/l vs 239 ± 116 nM/l   and cortisone 5.0 ± 2.0 nmoles/l 
vs 39.2 nmoles/l for CSF and serum respectively). Cortisol: cortisone ratios were lower in 
the CSF compared to the serum (1.9 ± 0.4 vs 6.0 ± 2.0 respectively), although in the 
absence of measuring free steroid levels, these ratios should be interpreted with caution.  
Absolute CSF and serum steroid concentrations did not change following weight loss 
(Table 5-4), but the change in CSF cortisone negatively correlated with change in weight 
(r= -0.512, p=0.018) (Figure 5-9B) and BMI (r= -0.444, p=0.044). Interestingly the CSF 
cortisol, measured at all time points (baseline, end of Stage 1 and 2) correlated 
significantly with subject age (baseline, r=0.533, p=0.006; start diet, r=0.487, p=0.016; 
end diet, r=0.663, p<0.001; all time points r=0.584, p<0.001 (Figure 5-9C). 
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Characteristic Baseline Start diet End diet p value 
Patient 
numbers 
 25 24 22  
Clinical 
features 
Weight (kg) 101.3 ± 16.5 101.3 ± 17.4 86.3 ± 15.5 <0.001 
BMI (kgm-2) 37.9 ± 4.9 38.1 ± 5.3 32.4 ± 4.9 <0.001 
Waist (cm) 111.1 ± 10.4 111.1 ± 10.0 101.0 ± 12.0 <0.001 
Urine 
(µg/24 h) 
THF+5αTHF:THE 0.89 ± 0.23 0.95 ± 0.30 0.81 ± 0.25 0.001 
Cortisol: cortisone 0.70 ± 0.19 0.75 ± 0.19 0.69 ± 0.30 0.456 
5αTHF:THF 1.18 ± 0.62 1.20 ± 0.64 0.93 ± 0.47 0.005 
5αTHF 1883.0 ± 1502.0 1868.9 ± 1370.0 1031.3 ± 925.3 0.002 
THF 1586.8 ± 971.2 1553.6 ± 659.2 1053.0 ± 648.5 0.020 
Total GC 
metabolites 
10745.1 ± 5902.6 10826.2 ± 5804.5 6995.4 ± 4480.2 0.013 
An 2424.0 ± 2121.1 2579.7 ± 2273.8 1536.7 ± 1609.6 0.006 
An:Et 1.42 ± 0.69 1.48 ± 0.90 1.16 ± 0.68 0.002 
An+Et+DHEA 5361.3 ± 4849.2 5352.3 ± 4920.2 3679.8 ± 4004.8 0.010 
Fm 4401.7 ± 2872.9 4384.9 ± 2372.3 2660.1 ± 1837.3 0.004 
Em 6343.5 ± 3144.6 6441.3 ± 6567.0 4335.3 ± 2730.9 0.022 
Fm:Em 0.68 ± 0.14 0.73 ± 0.22 0.63 ± 0.19 0.001 
CSF 
(nmoles/l) 
Cortisol 9.52 ± 5.00 8.36 ± 3.66 8.60 ± 3.56 0.852 
Cortisone 5.04 ± 1.99 
 
4.67 ± 1.69 
 
4.88 ± 1.56 
 
0.944 
Cortisol: 
Cortisone ratio 
1.85 ± 0.44 
 
1.81 ± 0.37 
 
1.76 ± 0.39 0.619 
Serum 
(nmoles/l) 
Cortisol 239.03 ± 115.66 194.48 ± 82.41 190.27 ± 92.63 0.708 
Cortisone 39.19 ± 15,78 37.66 ± 15.36 35.39 ± 10.64 0.932 
Cortisol : 
cortisone ratio 
6.01 ± 1.95 5.15 ± 1.01 5.15 ± 1.67 0.614 
Serum: 
CSF ratio 
Cortisol 26.33 ± 9.43 24.00 ± 7.49 24.61 ± 11.86 0.754 
Cortisone 8.20 ± 3.00 8.23 ± 1.92 7.69 ± 1.43 0.509 
Cortisol: cortisone 
ratio 
3.31 ± 0.95 2.94 ± 0.72 3.15 ± 1.24 1.00 
Table 5-4 Study characteristics and steroid metabolite changes during study 
Data summary statistics represent complete cohort at each time point. 
Mean and standard deviations shown. No significant changes were noted 
between baseline and start diet. p values represent changes from start diet 
to end diet. CSF indicates cerebrospinal fluid; BMI, body mass index; 
THF, tetrahydrocortisol; THE, tetrahydrocortisone; GC, glucocorticoids;  
An, androstenedione; Et, etiocholanolone; DHEA, 
dehydroepiandrosterone; Fm, total cortisol metabolites; Em, total 
cortisone metabolites. 
Chapter 5   
186 
 
Figure 5-8 Urinary steroid metabolite changes following weight loss 
Scatter plots with median and ranges illustrating significant reductions in: 
(A) 11β-HSD 1 activity (tetrahydrocortisol (THF) and 5αTHF) to 
tetrahydrocortisone (THE) ratio); (B) total glucocorticoid metabolites and 
5α reductase activity indicated by the (C) 5αTHF:THF ratio, (D) 5αTHF, 
(E) androsterone: etiocholanolone ratio and (F) androsterone. p values 
indicate change from previous time point (** p<0.01, *p<0.05). 
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Figure 5-9 Correlations of metabolic changes with clinical parameter 
(A) The change in urine 11β-HSD 1 activity correlated with change in 
intracranial pressure (ICP) following the diet. (B) The extent of weight loss 
inversely correlated with change in cerebrospinal fluid (CSF) cortisone 
following the diet. (C) Age demonstrated a linear correlation with CSF 
cortisol. THF indicates tetrahydrocortisol and THE tetrahydrocortisone. 
 
5.3.2.3. Fasted metabolite profiles 
The fasting serum cholesterol was observed to significantly reduce (0.62 ± 0.86 mmol/l, 
p=0.007) although the triglycerides did not significantly alter. BP was noted to fall with 
weight loss, although this showed considerable patient variability and did not reach the 
level of statistical significance (reduction of 2.9 ± 17.9 mmHg in stage 1 and 5.3 ± 17.5 
Chapter 5   
188 
mmHg in stage 2). The fasting glucose and insulin fell significantly (reduction of 0.13 ± 
0.95 mmol/l, p=0.021 and 6.6 ± 6.3 µU/ml, p<0.001 respectively). In keeping with the 
changes in glucose and insulin, the HOMA %B, %S and IR significantly improved 
(p=0.002, p=0.001 and p=0.001 respectively). The results are summarised in Table 5-5. 
 
Characteristic Baseline Start diet End diet p value 
Systolic BP (mmHg) 134.5 ± 15.9 130.4 ± 15.2 124.8 ± 13.7 0.135a 
Cholesterol (mmol/l) 4.9 ± 0.9 5.0 ± 1.0 4.5 ± 1.0 0.007 
Triglycerides (mmol/l) 1.57 ± 0.95 1.56 ± 1.11 1.24 ± 0.62 0.185a 
Glucose (mmol/l) 4.5 ± 0.7 4.7 ± 0.9 4.3 ± 0.5 0.021a 
Insulin (µU/ml) 14.8 ± 8.7 17.4 ± 11.7 10.7 ± 9.3 <0.001 
HOMA %B 191.2 ± 81.0 201.5 ± 108.9 158.0 ± 94.0 0.002 
HOMA %S 65.3 ± 30.7 61.3 ± 38.1 114.8 ± 78.8 0.001 
HOMA IR 1.88 ± 1.00 2.54 ± 2.37 1.30 ± 1.07 0.001 
Glucose : Insulin ratio 0.36 ± 0.15 0.37 ± 0.22 0.67 ± 0.49 <0.001a 
Table 5-5 Fasted metabolic profile before and after weight loss 
a significance level is p<0.025 as two pair-ways comparisons are being 
made per variable. Blood pressure (BP), Homeostasis Model Assessment 
(HOMA), percent beta cell function (%B), percent insulin sensitivity (%S), 
insulin resistance (IR). 
 
 
5.3.2.4.   Dual energy x-ray absorptiometry 
In keeping, with the weight loss observed following the VLCD (stage 2), fat mass was 
noted to reduce in both the trunk and limbs (p<0.001), although the fat was predominantly 
lost from the trunk (4.7 ± 3.7 % lost from the trunk with a relative increase in limb fat, 1.1 
± 2.1 %). The trunk: limb fat mass ratio was correspondingly noted to significantly 
decrease (p=0.014). Lean mass also fell with weight loss (p<0.001). Results are 
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summarised in Table 5-6. There was no correlation between ICP and measures of fat 
mass. 
Characteristic Start diet End diet Change p 
Total fat  mass (kg) 45.0 ± 9.8 36.1 ± 10.1 -9.10 ± 4.7 <0.001 
Total fat (%) 44.7 ± 3.9 40.6 ±5.3 -4.1 ± 2.7 <0.001 
Total lean mass (kg) 52.4 ± 6.1 49.1 ± 6.3 -3.9 ± 2.3 <0.001 
Total lean (%) 52.8 ± 3.6 56.6 ± 4.9 3.7 ± 2.6 <0.001 
Total BMC (g) 2417.5 ± 314.7 2415.2 ± 338.3 -12.6 ± 63.6 0.526 
Total BMC (%) 2.5 ± 0.4 2.8 ± 0.5 0.4 ± 0.2 <0.001 
Trunk fat  mass (kg) 22.2 ± 5.0 17.6 ± 5.4 -5.0 ± 2.8 <0.001 
Trunk fat (%) 44.9 ± 4.4 40.5 ± 6.0 -4.7 ±3.7 <0.001 
Trunk lean mass (kg) 26.2 ± 0.3 24.3 ± 0.4 0.2 ± 0.1 <0.001 
Trunk lean (%) 53.6 ± 4.3 57.8 ± 5.9 4.4 ± 3.6 <0.001 
Trunk BMC (g) 692.3 ± 96.5 675.4 ± 107. 7 -20.2 ± 54.5 0.179 
Trunk BMC (%) 1.4 ± 0.3 1.6 ± 0.3 0.2 ± 0.1 <0.001 
Limb fat mass (kg 21.8 ± 5.5 17.6 ± 5.1 -4.1 ± 2.1 <0.001 
Limb fat (%) 48.2 ± 4.9 48.7 ± 4.5 1.1 ± 2.1 <0.001 
Limb lean mass (kg) 23.0 ± 3.0 21.4 ± 2.9 -2.0 ± 1.5 <0.001 
Limb lean (%) 50.5 ± 4.3 53.9 ± 4.8 2.8 ± 2.5 <0.001 
Limb BMC (g) 1191.3 ± 143.8 1200.5 ± 151.4 5.9 ± 30.1 0.455 
Limb BMC (%) 2.7 ± 0.4 3.1 ± 0.5 0.4 ± 0.3 <0.001 
Trunk: limb fat mass 
ratio 
1.04 ± 0.23 1.01 ± 0.20 -0.06 ± 0.10 0.014 
Table 5-6 Dual energy x-ray absorptiometry body composition analysis following 
weight loss.  
BMC indicates bone mineral content. 
 
5.3.2.5. Comparison of glucocorticoid, metabolic, and body composition changes in 
IIH and non IIH obese subjects following weight loss  
After matching the IIH and non IIH obese patients, all subjects were female and there 
were no significant difference in BMI (p=0.369) or age (p=0.224) (Table 5-7).   
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Characteristic IIH Control p 
Number 22 13  
Gender (% female) 100 100  
Age (years) 34.4 ± 9.2 40.4 ± 13.5 0.224 
Weight (kg) 101.3 ±16.5 100.4 ± 12.5 0.863 
BMI (kgm-2) 37.9 ± 4.9 36.5 ± 4.8 0.369 
Waist (cm) 111.1 ± 10.4 104.3 ± 7.8 0.043 
Table 5-7 Baseline demographics of the IIH and non IIH obese control subjects 
embarking on a weight loss regimen 
 
The extent of weight loss, following the three months VLCD, was very similar between 
the two groups (IIH lost 15.2 ± 3.0 kg and controls lost 13.3 ± 4.4 kg). There was no 
statistically significant difference in the fasting metabolite changes (Table 5-8). Similarly, 
changes in the fat mass distribution were not statistically different (Table 5-8). The 
urinary steroid metabolites showed greater reduction in 11β-HSD1 activity (demonstrated 
by the THF + 5αTHF: THE ratio) in the IIH cohort, although this did not reach the level 
of statistical significance (IIH 0.23 ± 0.26 and controls 0.13 ± 0.14, p=0.667) (Figure 
5-10A). The GC metabolites also showed a trend towards a greater increase in the IIH 
subjects (IIH 3476.8 ± 52531.1 and controls 1669.8 ± 5139.4, p=0.250) (Figure 5-10B). 
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Characteristic IIH Control p 
Weight (kg) -15.2 ± 3.0 -13.3 ± 4.4 0.775 
BMI (kgm-2) -5.8 ± 3.0 -4.8 ± 1.5 0.555 
Waist (cm) -9.4 ± 5.9 -10.4 ± 5.5 0.649 
BP systolic -6.4 ± 19.6 -1.9 ± 8.9 0.568 
Fasting metabolites 
   
Cholesterol (mmol/l) -0.6 ± 0.9 0.6 ± 1.9 0.118 
TG (mmol/l) -0.3 ± 0.7 0.2 ± 0.7 0.087 
Glucose (mmol/l) -0.3 ± 0.6 0.1 ± 1.3 0.408 
Insulin (µU/ml) -6.7 ± 6.9 -6.2 ± 4.1 0.917 
HOMA %B -49.3 ± 63.8 -39.0 ± 44.4 0.709 
HOMA %S 51.8 ± 60.5 67.3 ± 64.7 0.500 
HOMA IR -1.3 ± 2.3 0.9 ± 0.6 0.862 
Glucose : Insulin ratio 0.29 ± 0.37 0.39 ± 0.32 0.110 
DEXA 
   
Total fat mass( kg) -9.10 ± 4.7 -9.3 ± 3.4 0.957 
Total Fat (%) -4.1 ± 2.7 -4.0 ± 2.4 0.986 
Trunk fat mass (kg) -5.0 ± 2.8 -4.9 ± 2.4 0.870 
Urinary steroid metabolites 
   
THF +5αTHF:THF -0.23 ± 0.26 -0.13 ± 0.14 0.667 
5αTHF:THF  -0.30 ± 0.40 -0.33 ± 0.38 0.672 
Total GC metabolites 
(µg/24h) 
-3476.8 ± 52531.1 -1669.8 ± 5139.4 0.250 
Table 5-8 Changes with weight loss noted in the idiopathic intracranial 
hypertension (IIH) and non IIH obese patients. 
TG indicates triglycerides, blood pressure (BP), Homeostasis Model 
Assessment (HOMA), percent beta cell function (%B), percent insulin 
sensitivity (%S), insulin resistance (IR), tetrahydrocortisol (THF), 
tetrahydrocortisone (THE) and glucocorticoids (GC). 
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Figure 5-10 Metabolite changes in IIH and idiopathic obesity 
Changes in 11β-HSD1 activity (tetrahydrocortisol (THF) + 5α THF/ 
tetrahydrocortisone (THE) ratio) and total glucocorticoid metabolites 
(GC) following a three months very low calorie diet in IIH and non IIH 
obese controls. 
 
5.3.3. Comparison of metabolic phenotype and 11β-HSD1 in idiopathic 
intracranial hypertension and control patients  
Results 
 
29 IIH and 47 control subjects were recruited. Baseline demographics are shown in Table 
5-9. There was no significant difference in the gender, weight, BMI or waist between IIH 
and control subjects (p=1.00, p=0.125, p=0.078 and p=0.343). The IIH patients were, 
however, significantly younger than the control subjects (32.8 ± 8.6 years compared to 
49.1 ± 6.9 years, p<0.001).  Six (20.7%) of the IIH patients had coexisting PCOS.  
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IIH Control p 
Female gender ((number (%)) 29 (100) 47 (100) 1.00 
Weight (kg) 96.1 ± 12.6 91.1 ± 14.4 0.125 
BMI (kgm-2) 36.2  ± 3.7 34.5 ± 4.3 0.078 
Waist (cm) 106.5 ± 10.2 104.2 ± 9.7 0.343 
Age (years) 32.8 ± 8.6 49.1 ± 6.9 <0.001 
BP systolic 130.3 ± 14.9 125.3 ±15.0 0.273 
Coexisting PCOS (number (%)) 6 (20.7) 0  
Table 5-9 Demographics of the idiopathic intracranial hypertension (IIH) and 
control subjects 
PCOS indicated polycystic ovarian syndrome 
 
5.3.3.1. Urinary steroid metabolites 
Global 11β-HSD1 activity, as indicated by the THF+5αTHF: THE ratio, did not 
significantly differ between the IIH patients and the obese controls (0.96 ± 0.36 and 0.94 
± 0.35 respectively, p=0.869). The 11β-HSD2 activity (free cortisol: cortisone ratio) was 
higher in IIH patients (0.71 ± 0.19 and 0.64 ± 0.45 respectively, p=0.005), however, this 
difference was lost following multivariate regression analysis to adjust for age (p=0.590). 
The total glucocorticoid metabolites, a determinant of HPA axis activity, were greater in 
the IIH than the control cohort (10396.9 ± 5227.3 µg24-1 and 8417.3 ± 4075.0 µg24-1 
respectively, p=0.027) and were independent of age.   
Cortisol inactivation by 5α reductase, which was independent of age, was significantly 
greater in the IIH than control patents (5αTHF: THF ratio, 1.15 ± 0.19 and 0.82 ± 0.38, 
p=0.009; 5αTHF, 1727.7 ± 1139.4 µg24-1 and 1162.4 ± 697.5 µg24-1, p=0.014 
respectively). Reduced 5β-reductase activity is unlikely to explain these results, as 
excretion of THF did not differ between groups. Androgen metabolism by 5α reductase 
was also higher in the IIH than control patients (An, 2377.6 ± 2119.0 µg24-1 and 1134.9 ± 
820.9 µg24-1, p=0.015; An+Et+DHEA, 5265.7 ± 4472.3 µg24-1 and 2519.0 ± 1727.9 
µg24-1, p=0.003, respectively). The differences in androgen metabolites were, however,  
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not maintained following multivariate regression analysis to adjust for the age differences 
between the groups (An, p=0.553 and An+Et+DHEA, p=0.736). The androgen 
metabolites negatively correlated with age in both IIH and control subjects even after 
adjustment for BMI (An, r=-0.418, p=0.030 and r=-0.411, p=0.005; An+Et+DHEA, r=-
0.474, p=0.001 and r=-0.376, p=0.010 respectively). The urinary metabolite changes are 
summarised in Table 5-10.  None of the urinary steroid metabolites, or ratios, 
demonstrated a linear relationship with ICP. 
 
Characteristic IIH Control p 
THF+5αTHF:THE 0.96 ± 0.36 0.94 ± 0.35 0.869 
F:E 0.71 ± 0.19 0.64 ± 0.45 0.005 
5αTHF:THF 1.15 ± 0.19 0.82 ± 0.38 0.009 
5αTHF 1727.7 ± 1139.4 1162.4 ± 697.5 0.014 
THF 1525.1 ± 612.2 1520.9 ± 946.5 0.303 
Total GC  10396.9 ± 5227.3 8417.3 ± 4075.0 0.027 
An 2377.6 ± 2119.0 1134.9 ± 820.9 0.015 
An: Et 1.38 ± 0.70 1.15 ± 0.52 0.200 
An+Et+DHEA 5265.7 ± 4472.3 2519.0 ± 1727.9 0.003 
Fm 4200.4 ± 2081.8 3435.2 ± 1765.5 0.055 
Em 6196.5 ± 3300.3 4982.2 ± 2442.5 0.060 
Fm: Em 0.74 ± 0.25 0.70 ± 0.20 0.677 
Table 5-10 Urinary steroid metabolite profiles in idiopathic intracranial 
hypertension (IIH) and control subjects 
Tetrahydrocortisol (THF), tetrahydrocortisone (THE), glucocorticoids 
(GC), androstenedione (An), etiocholanolone (Et), 
dehydroepiandrosterone (DHEA), total cortisol metabolites (Fm) and total 
cortisone metabolites (Em) (µg24-1). 
 
5.3.3.2. Fasted metabolite profiles 
The fasting serum cholesterol, triglycerides and glucose did not differ between groups 
(p=0.481, p=0.971 and p=0.328 respectively). The fasting insulin was higher in the IIH 
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subjects than controls (14.3 ± 6.4 and 10.8 ± 7.8 µU/ml, p=0.036 respectively). This was 
in keeping with a lower glucose: insulin ratio in the IIH patients (IIH, 0.4 ± 0.2 and 
controls, 0.8 ± 0.9, p=0.027). The HOMA scores showed a trend towards increased 
insulin resistance in the IIH cohort (HOMA IR 2.1 ± 2.1 in IIH and 1.6 ± 1.1 in controls) 
but this did not reach the level of statistical significance (p=0.147) (Table 5-11). 
 
Characteristic IIH Control p 
Cholesterol (mmol/l) 4.9 ± 1.1 5.1 ± 1.0 0.481 
Triglycerides (mmol/l) 1.5 ± 1.1 1.3 ± 0.6 0.971 
Glucose (mmol/l) 4.8 ± 0.9 4.7 ± 0.6 0.328 
Insulin (µU/ml) 14.3 ± 6.4 10.8 ± 7.8 0.036 
HOMA %B 170.0 ± 63.8 141.7 ± 55.6 0.073 
HOMA %S 67.8 ± 35.8 102.9 ± 76.3 0.140 
HOMA IR 2.1 ± 2.1 1.6 ± 1.1 0.147 
Glucose: Insulin ratio 0.41 ± 0.20 0.83 ± 0.87 0.027 
Table 5-11 Fasting metabolite profiles in idiopathic intracranial hypertension (IIH) 
and control subjects 
Blood pressure (BP), Triglycerides (TG), Homeostasis Model Assessment 
(HOMA), percent beta cell function (% B), percent insulin sensitivity (% S) 
and insulin resistance (IR). 
 
5.3.3.3. Dual energy x-ray absorptiometry 
Fat mass distribution did not differ between IIH and control subjects (Table 5-12). The 
total fat mass correlated with the total glucocorticoid metabolites measured by urinary 
GC/MS (IIH, r=0.691, p=0.001 and controls r=0.361, p=0.014). Trunk bone mineral 
content mass was higher in IIH subjects (IIH, 676.8 ± 92.0 and controls 582.8 ± 105.2, 
p<0.001), however, the difference was lost following multivariate regression analysis 
which accounted for age differences between the groups (p=0.138). Other differences in 
body composition noted between the groups were lost following correction for age.
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Characteristic IIH Control p 
Total fat mass (kg) 42.0 ± 7.5 39.3 ± 9.2 0.125 
Total fat (%) 43.9 ± 3.5 43.4 ± 4.4 0.655 
Total lean mass (kg) 50.9 ± 4.8 48.5 ± 6.4 0.100 
Total lean (%) 53.6 ± 3.3 54.2 ± 4.2 0.615 
Total BMC mass (kg) 23.7 ± 2.5 21.4 ± 3.3 0.004 
Total BMC (%) 2.5 ± 0.4 2.4 ± 0.4 0.494 
Trunk fat mass (kg) 20.5  ± 3.2 19.9 ± 5.2 0.194 
Trunk fat (%) 43.8 ± 3.4 43.4 ± 5.1 0.812 
Trunk lean mass (kg) 25.5 ± 2.8 25.1 ± 3.5 0.655 
Trunk lean (%) 54.7 ± 3.2 5.4 ± 5.0 0.558 
Trunk BMC mass (g) 676.8  ± 92.0 582.8 ± 105.2 <0.001 
Trunk BMC (%) 1.5 ± 0.3 1.3 ± 0.2 0.008 
Limb fat mass (kg) 20.5 ± 5.0 18.3 ± 4.3 0.139 
Limb fat (%) 46.3 ± 4.7 45.7 ± 5.0 0.791 
Limb lean mass (kg) 22.2 ± 2.5 20.4 ± 3.3 0.014 
Limb lean (%) 51.0 ± 4.4 516 ± 4.8 0.845 
Limb BMC mass (g) 1170.9  ± 104.1 1079.1 ± 241.3 0.030 
Limb BMC (%) 2.7 ± 0.4 2.7 ± 0.4 0.410 
Trunk: limb ratio 1.0 ± 0.2 1.1 ± 0.2 0.135 
Table 5-12 Dual energy x-ray absorptiometry (DEXA) body composition in 
idiopathic intracranial hypertension (IIH) and control subjects 
BMC indicates bone mineral content. 
 
5.3.3.4. Influence of polycystic ovarian syndrome 
The IIH patients with PCOS were removed, leaving 23 patients in the IIH cohort and 47 
in the control cohort (Table 5-13).  
 
IIH (no PCOS) Control P 
Female gender ((number (%)) 23 (100) 47 (100)  
Weight (kg) 93.9 ± 12.5 91.1 ± 14.4 0.419 
BMI (kgm-2) 35.4 ± 3.5 34.5 ± 4.3 0.367 
Waist (cm) 104.6 ± 10.4 104.2 ± 9.7 0.342 
Age (years) 33.6 ± 8.8 49.1 ± 6.9 <0.001 
BP systolic 131.4 ± 14.9 125.3 ±15.0 0.192 
Table 5-13 Demographics following exclusion of those IIH patients with coexisting 
polycystic ovarian syndrome (PCOS) 
Chapter 5   
197 
Following exclusion of the IIH patients with PCOS, there were no differences in the 
fasting serum metabolites (Table 5-14), or body composition between the groups.  
Differences in the 24 hour urinary steroid profiles between IIH and BMI matched controls 
were lost, with the exception of 5αTHF:THF (Table 5-15). This metabolite ratio, a 
reflection of 5α reductase activity, remained higher in the IIH cohort (IIH, 1.15 ± 0.61 and 
controls 0.82 ± 0.38, p=0.028) and did not correlate with age. 
 
Characteristic IIH (no PCOS) Control P 
Cholesterol (mmol/l) 4.9 ± 1.0 5.1 ± 1.0 0.543 
Triglycerides (mmol/l) 1.5 ± 1.2 1.3 ± 0.6 0.967 
Glucose (mmol/l) 4.8 ±0.9 4.7 ± 0.6 0.486 
Insulin (µU/ml) 16.6 ± 6.2 10.8 ± 7.8 0.116 
HOMA %B 159.5 ± 66.1 141.7 ± 55.6 0.395 
HOMA %S 73.1 ± 37.4 102.9 ± 76.3 0.432 
HOMA IR 2.1 ± 2.3 1.6 ± 1.1 0.451 
Glucose:  Insulin Ratio 0.45 ± 0.20 0.83 ± 0.87 0.185 
Table 5-14 Fasting metabolite ratios following exclusion of those IIH patients with 
coexisting polycystic ovarian syndrome (PCOS) 
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Characteristic IIH (no PCOS) Control P 
THF+5αTHF:THE 1.01 ± 0.38 0.94 ± 0.35 0.511 
F:E 0.69 ±0.20 0.64 ± 0.45 0.033 
5αTHF:THF 1.15 ± 0.61 0.82 ± 0.38 0.028 
5αTHF 1635.7 ± 1184.5 1162.4 ± 697.5 0.066 
THF 1461.2 ± 664.8 1520.9 ± 946.5 0.699 
Total GC  9726.0 ±5556.7 8417.3 ± 4075.0 0.172 
An 1799.2 ±1808.3 1134.9 ± 820.9 0.236 
An: Et 1.38 ± 0.73 1.15 ± 0.52 0.297 
An+Et+DHEA 4030.0 ± 3540.6 2519.0 ± 1727.9 0.076 
Fm 4014.9 ± 2211.1 3435.2 ± 1765.5 0.212 
Em 5711.1 ± 3489.8 4982.2 ± 2442.5 0.374 
Fm: Em 0.77 ±0.26 0.70 ± 0.20 0.279 
Table 5-15 Urinary steroid metabolite profiles following exclusion of those IIH 
patients with coexisting polycystic ovarian syndrome (PCOS) 
Differences in the F:E ratio were lost following multivariate regression to 
correction for age. Tetrahydrocortisol (THF), tetrahydrocortisone (THE), 
glucocorticoids (GC),  androstenedione (An), etiocholanolone (Et), 
dehydroepiandrosterone (DHEA), total cortisol metabolites (Fm) and total 
cortisone metabolites (Em) (µg24-1).  
 
5.4. Discussion 
5.4.1. The clinical consequences of weight loss in idiopathic intracranial 
hypertension  
Discussion  
This is the first prospective longitudinal study to demonstrate that weight loss is effective 
in reducing not only headaches and papilloedema, but also ICP in IIH. The study results 
provide an evidence base for therapeutic weight reduction in IIH. 
Whilst we acknowledge that LP only records a snap-shot assessment of ICP and does not 
reflect diurnal fluctuations, the minimal changes in ICP reported over Stage 1 (no 
intervention; -1.8 ± 5.5 cmH2O) indicate that the variability in ICP did not significantly 
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influence our data.  The absence of a direct relationship between weight loss and change 
in ICP, suggests a more complex relationship which may be influenced by a patient-
specific weight threshold for raised ICP. ICP fell to a “normal” level (below 25 cmH2O) 
in 4 patients (20%). In those patients whose ICP remained above 25 cmH2O, 81% (13 out 
of 16 patients) had become asymptomatic for tinnitus, visual loss, diplopia and visual 
obscurations after weight loss, compared with 25% (4 out of 16) of these subjects at 
baseline. These data highlight that it might not be necessary for IIH subjects to reduce 
their ICP to below defined normal levels (25cmH2O) in order to achieve significant 
symptomatic relief. This may, however, be an overly simplistic concept as obesity is 
known to marginally increase ICP (Whiteley et al. 2006) and it is possible that the CSF 
dynamics equilibrium in resolving IIH is re-set, such that apparent normality occurs at 
higher pressures. 
Papilloedema improved significantly following weight loss, as demonstrated using OCT 
(p<0.001), USG optic disc elevation (p=0.002) and optic nerve sheath diameter (p=0.004).  
The Frisen grade, designed to classify developing papilloedema (Frisen 1982), was found 
not to be sensitive enough to detect changes in resolving papilloedema. Disc ranking, was 
more discriminating than Frisen grading, but was only able to detect a significant change 
in the disc appearance from the start of the diet to the final follow up (start stage 2 to end 
stage 3). Delayed resolution of papilloedema, following reduction in ICP, has been 
previously reported post ventriculoperitoneal shunting in IIH (resolution over 0.6 to 7.0 
months) (Bynke et al. 2004) and is in keeping with the observation that USG measures of 
papilloedema continued to improve during the 3 months following the VLCD (stage 3).  
Evaluation of papilloedema in previous IIH therapeutic studies has relied upon subjective 
observation. Our use of objective imaging measures to quantify papilloedema marks an 
important advance in gauging optic disc swelling that will enhance IIH research and 
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contribute to future clinical trial design.  Although the potential application of USG and 
OCT in IIH monitoring has been previously described (Tamburrelli et al. 2000; Rebolleda 
and Munoz-Negrete 2009), the sensitivity in detecting changes in mild papilloedema 
(Frisen grade 1 (17%) and 2 (83%)) noted in our study suggests they are likely to have a 
seminal role in influencing future clinical practice and research. 
Symptoms (headache, tinnitus, obscurations and diplopia) all significantly improved 
following weight loss.  Headache impact, which was substantial at baseline (57.5 ± 9.0), 
significantly improved following weight loss (p<0.001) to a level which had no or little 
impact on daily life (46.9 ± 10.1) (disability quantification from  
www.headachetest.com/HIT6translations.html (Shin et al. 2008) (section 7.3). It is 
important to note that a subgroup continued to have severe HIT-6 scores following the 
diet, despite an equivalent weight and ICP reduction to that of the whole study cohort 
(Figure 5-7A). Alternative headache phenotypes may account for the headache morbidity 
in this subgroup. Headaches have been described in 68% of patients with IIH following 
resolution of the signs of IIH, typically episodic tension type headache or migraine 
(Friedman and Rausch 2002). 
The extent of weight reduction (loss of 15.3% of body weight) is of considerable 
importance, as this cohort of patients had all previously failed numerous weight loss 
strategies. The success of the VLCD is likely to reflect a combination of diet tolerability, 
ketosis (which enhanced hypothalamic satiety), weekly substantial weight loss (a 
powerful motivator for diet compliance and persistence), as well as individual weekly 
review sessions to monitor, motivate and provide nutritional counselling. 
The struggle for patients to achieve and maintain weight reduction is universally 
recognised.  Dietary weight loss, through VLCDs, gradual calorie restriction or 
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macronutrient exclusion (fat, carbohydrates or protein) may be as little as 2–4 kg at 2 
years (Sacks et al. 2009). Other non-diet strategies to encourage weight loss include 
pharmacological and surgical interventions. Obesity pharmacological therapies, are 
unlikely to achieve sufficient weight loss to significantly modify IIH; Orlistat reduces 
weight by a mean of 2.89 kg and Sibutramine reduces weight by 4.45 kg, at 12 months (Li 
et al. 2005). Additionally, the prescribing licence for Sibutramine has recently been 
withdrawn by the European Medicines Agency due to concerns about cardiovascular risk  
(Williams 2010). A more useful weight modifying drug may be Topiramate (reduces 
weight by 9.75 kg at 12 months in IIH (Çelebisoy et al. 2007)) with additional potential to 
reduce CSF secretion via carbonic anhydrase inhibition (Rosenfeld 1997) and efficacy in 
treating coexisting migraine. Gastric weight reduction surgery may be effective and 
resolving papilloedema has been reported in a series of 8 patients (Sugerman et al. 1995). 
Although the advantage of this approach has been limited by unacceptable morbidity (6 of 
the 8 patients), recent studies indicate safety and efficacy of laparoscopic bariatric 
surgery, and provide rationale for the re-evaluation of this technique in IIH (Flum et al. 
2009). 
We recognise that the non-randomised controlled study design needs to be taken into 
account when evaluating our data. Patient acceptability and ethical considerations 
prevented recruitment to a control cohort (which would need to undergo serial lumbar 
puncture). However, a major strength of this study is that all patients had chronic stable 
IIH (disease duration 39.0 ± 49.2 months). This reduced the risk of bias due to the 
possibility of rapid spontaneous resolution of IIH, which is a recognised phenomenon in 
some patients with acute IIH. A consequence of selecting a chronic IIH cohort was that 
visual impairment was minimal and papilloedema mild (Frisen grades all 2 or less) in the 
majority of patients at enrolment. Patients with a history of declining vision, requiring 
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CSF diversion surgery, or other aggressive treatment, were not included in our study. 
Visual function (LogMAR score and HVF) was preserved at baseline in this IIH cohort 
and a clinically significant improvement was not noted or expected. We did note a 
significant improvement in the Pelli Robson contrast sensitivity. Repeated measurements 
in contrast sensitivity identify variability of one triplet (3 letters) (Lovie-Kitchin and 
Brown 2000) and although the mean values changed very little during our study, 
significantly more patients show an improvement following weight loss than after the 
baseline observation period. Contrast sensitivity may consequently represent a useful tool 
to monitor visual changes in IIH. The statistically significant improvement noted in the 
LogMAR score was not deemed clinically significant, as only 25.0% improved by greater 
than one line and, consequently, the changes noted may merely reflected inherent 
variability when repeatedly taking measurements (Gibson and Sanderson 1980). It is, 
however, noteworthy that, despite studying a chronic IIH cohort with little visual 
impairment, we observed clinically and statistically significant improvements in 
symptoms and papilloedema. 
Our study is the first to confirm the relationship between weight loss and reduction in 
ICP. Weight loss is also effective in reducing headaches and papilloedema in patients with 
IIH. It provides an evidence base for clinicians to advise and encourage IIH patients to 
embark upon and maintain a weight reducing diet. Our data suggests that weight loss 
clinics may have a role in the management of IIH.  The long term effectiveness and health 
economics of this approach will require critical evaluation in a further study comparing 
weight reduction using NHS dieticians with specially designated weight reduction clinics 
in IIH. 
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5.4.2. Effect of weight loss on the metabolic phenotype and 11β-HSD1, in 
idiopathic intracranial hypertension  
Discussion  
The pathogenesis of IIH is not established, however, the association with obesity and ICP 
dysregulation is well recognised (Sinclair et al. 2008). We suggest that IIH, like obesity, 
may result from dysregulation of 11β-HSD1 activity and that therapeutic weight loss may 
be beneficial due to manipulation of 11β-HSD1. We have, therefore, characterised 
glucocorticoid metabolism in IIH subjects before and after significant weight reduction 
(loss of 15.2 ± 7.8% of body weight).  
We observed a reduction in global 11β-HSD1 activity, as assessed by the urinary 
THF+5α-THF: THE ratio, but unchanged free cortisol: cortisone ratio, following weight 
loss. The greatest reduction in global 11β-HSD1 activity occurred in IIH subjects who 
experienced the largest fall in ICP (r=0.504, p=0.028). Previous studies of weight loss in 
non IIH obese subjects, do not report significant changes in urinary 11β-HSD1 activity 
(Tomlinson et al. 2004a; Tomlinson et al. 2008). Interestingly, however, unpublished sub-
analysis of females from the idiopathic obesity cohort indicate a trend towards decrease in 
11β-HSD1 activity. It is possible therefore, that following weight loss, there are gender 
differences in 11β-HSD1 activity. Weight loss may also cause tissue specific changes in 
11β-HSD1, as indicated by elevated adipocyte 11β-HSD1 mRNA expression in obese 
patients following weight reduction (Tomlinson et al. 2004a; Tomlinson et al. 2008). 
Adipose expression of 11β-HSD1 would be an avenue for future research in IIH. 
When comparing the weight induced changes in urinary steroid metabolites, in IIH and 
non IIH obese subjects, we found no significant difference. This study was not, however, 
designed for this sub-analysis, the analysis was carried out using historical obese controls, 
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and additionally, it is likely that the low numbers of patients, particularly in the control 
group (n=13), lead to the analysis being insufficiently powered to detect significant 
changes. It is interesting, however, that the fall in global 11β-HSD1 activity in IIH subject 
was nearly double that noted in non IIH subjects. A dedicated and appropriately powered 
study is needed to investigate this area further. 
Reduced 5α-reductase activity, as assessed by the urinary 5α-THF:THF and An:Et ratio, 
was demonstrated in the IIH subjects following weight loss and has also been noted in 
obese cohorts (Tomlinson et al. 2008). The precise role of 5α-reductase (a cortisol 
inactivating enzyme) which is highly expressed in liver and adipose tissue, is under 
investigation (Andrew et al. 1998).  Decreased 5α-reductase activity, with consequent 
reduced inactivation of cortisol, may account for the diminished HPA axis drive, indicated 
by the reduced total urinary metabolite excretion noted in the IIH cohort. The observed 
reduction in 5α-reductase activity is not solely a reflection of cortisol metabolism, as 5α-
reductase also has a key role in activating testosterone to 5α dihydrotestosterone 
(Bruchovsky and Wilson 1968). Changes in androgen metabolism may have therapeutic 
implications in the female biased condition of IIH. Interestingly, both 5α-reductase and 
11β-HSD1 are regulated by oestrogen with  higher levels demonstrated in females (Mode 
and Norstedt 1982) (Low et al. 1994). Five of the IIH subjects (20%) met the diagnostic 
criteria for PCOS (REA-SPCW 2004), a condition with a similar obese female phenotype 
associated with enhanced 5α reductase activity (Vassiliadi et al. 2009). The role of 5α 
reductase activity in PCOS, and the potential for dysregulation in IIH, will be discussed 
further in section 5.4.3. 
To further analyse 11β-HSD1 expression in the CP, we carried out the novel 
quantification of both cortisol and cortisone in CSF using LC/MS.   CSF cortisol and 
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cortisone levels were observed to be much lower in the CSF than serum with 
concentrations mirroring those observed in aqueous humour (Rauz et al. 2001), although 
much lower than that demonstrated in other fluids such as synovial fluid (Hardy et al. 
2008).  These results pose many questions, not least the impact of cortisol binding 
globulin (CBG) on free glucocorticoid levels in the CSF. Previous studies  suggest that 
free cortisol levels in the CSF mirror that observed in the serum, with 20% of CSF 
cortisol bound to protein (Carroll et al. 1976). CSF cortisone concentrations have, to our 
knowledge, not been previously evaluated. As serum cortisone has limited binding to 
CBG, and thus total levels are a close approximation to free cortisone levels (Cooper et al. 
2005), equilibration across the blood brain barrier (BBB) would be predicted. However, 
CSF levels are notably lower than those measured in serum (serum: CSF cortisone ratio 
8.2) suggesting local conversion of cortisone to cortisol by 11β-HSD1. Neither the CSF 
nor serum cortisol or cortisone levels significantly changed with weight loss. However, it 
is likely that this approach to measuring in vivo changes in CP 11β-HSD1 activity is too 
simplistic as CSF glucocorticoids will reflect both local tissue steroid metabolism as well 
as glucocorticoid transfer across the BBB. Future study of BBB function and free CSF 
steroid levels in IIH may shed light on this area. The lack of significant change in serum 
glucocorticoid levels mirrors findings in non IIH obese subjects and is in keeping with 
decreased cortisol secretion (mediated by reduced 11β-HSD1) offset by increased  adrenal 
cortisol secretion driven by the HPA axis  (Tomlinson et al. 2008).  
Weight loss correlated with CSF cortisone levels (r= -0.512, p=0.018) in that those 
individuals who lost the most weight had the highest CSF cortisone. Whilst we did not see 
changes in CSF cortisol, these observations may reflect a reduction in 11β-HSD1 activity. 
The significant correlation of age with CSF cortisol noted in our study is of interest as 
elevated CSF cortisol has been linked to memory deficits and Alzheimer’s disease 
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(Lupien et al. 1998; Popp et al. 2009). In this context CSF cortisol levels require further 
study in larger mixed age cohort. 
We acknowledge that a stress effect of the VLCD may have impacted on our results, 
however, as there was no significant difference in the serum cortisol levels from baseline 
to that measured following the diet, we feel this is unlikely. We also accept that the 
benefits of therapeutic weight loss in IIH may not relate exclusively to 11β-HSD1 as 
changes in adipose tissue, an active endocrine organ, with subsequent alterations on the 
inflammatory cytokine and adipokine profiles, particularly leptin (Ball et al. 2009b), may 
have impacted on CSF dynamics.  
Features of the metabolic syndrome, including fasting serum cholesterol, glucose and 
insulin resistance (measured by the HOMA %B, %S, IR and glucose: insulin ratio), 
significantly improve following weight reduction. The degree of change was mirrored in 
the non IIH obese cohort (Table 5-8). The precise mechanism by which weight loss 
improves insulin resistance is unknown. In both our study and others, decreased global 
glucocorticoids are associated with improved insulin sensitivity and the significant 
reduction noted in 5α reductase activity may be crucial (Tomlinson et al. 2008). 11β-
HSD1 inhibitors also have insulin sensitising effects (Bhat et al. 2008; Lloyd et al. 2009; 
Zhang et al. 2009a) suggesting that the decreased global 11β-HSD1 activity noted 
following weight loss in the IIH cohort may have impacted on insulin sensitivity. Further 
characterisation of metabolic features in IIH compared to control subjects will be 
considered in the next section of the chapter (section 5.4.3). 
Changes in body composition were also seen before and after weight loss in IIH subjects. 
Both the fat and lean mass were noted to reduce following the diet and we observed that 
the proportion of fat lost from the trunk was greater than that lost from the limbs. It is 
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interesting to speculate that loss of abdominal fat is key in therapeutic weight reduction in 
IIH.  As this study does not directly compare the therapeutic effects of loss of abdominal 
fat to loss of limb fat, firm conclusions cannot be drawn.  
In summary, this study describes global reduction in 11β-HSD1 activity with weight loss 
which correlates with improved ICP in IIH patients. The CSF glucocorticoid studies 
represent an approach to determining CP 11β-HSD1 activity but further investigation to 
disentangle the effects of serum steroid dialysis across the BBB relative to CP steroid 
generation are needed. The use of LC/MS does, however, utilise a novel technique to 
quantify CSF glucocorticoids. Our previous in vitro characterisation of 11β-HSD1 in CP 
and AGT highlights the potential for glucocorticoid manipulation of CSF dynamics 
(Chapter 3). These studies raises the possibility that elevated 11β-HSD1 may represent a 
pathogenic mechanism in IIH. Future work will need to investigate the functional 
consequence of 11β-HSD1 manipulation on CSF secretion and IIH. Inhibition of 11β-
HSD1 activity may, however, represent a therapeutic strategy for the treatment of IIH. 
 
5.4.3. Comparison of metabolic phenotype and 11β-HSD1 in idiopathic 
intracranial hypertension and control patients  
Discussion  
We sought to evaluate the metabolic phenotype in IIH patients by comparing the urinary 
steroid profiles, fasting metabolites and body composition with a cohort of BMI matched, 
healthy control subjects.  
11β-HSD1 activity, inferred from the THF+5αTHF:THE ratio, and 11β-HSD2 activity, 
inferred from the free cortisol: cortisone ratio, were found to be similar in IIH patients 
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compared to obese healthy control subjects. This does not exclude the potential for 11β-
HSD dysregulation in IIH, as urine metabolites estimate global 11β-HSD activity, but do 
not necessarily reflect tissue specific or pathogenic 11β-HSD activity. The assessment of 
other markers of 11β-HSD, such as hepatic 11β-HSD activity, estimated from cortisol 
generation curves, and adipose 11β-HSD mRNA expression, have proven useful in 
establishing 11β-HSD1 dysregulation in obesity and maybe of interest in IIH (Stewart et 
al. 1999; Rask et al. 2001; Paulmyer-Lacroix et al. 2002; Tomlinson et al. 2002; Li et al. 
2007). Comparing the cortisol and cortisone levels in the CSF of IIH and healthy obese 
patients would also be valuable, although ethical considerations are likely to prevent the 
collection of CSF from healthy obese controls.  
The novel finding of enhanced 5α reductase activity in patients with IIH is of interest. The 
5αTHF: THF ratio and 5αTHF were significantly higher in IIH patients compared to 
obese controls (p=0.009, p=0.014 respectively). It is unlikely that the differences noted in 
5α reductase activity were a result of age differences between the cohorts, as age did not 
have a significant relationship with either variable. This is in keeping with other studies, 
which found no significant relationship between 5α reductase and age (Vassiliadi et al. 
2009). Androgen metabolites, also indicative of increased 5α reductase activity, were 
higher in the IIH patients (An, p=0.015 and An+Et+DHEA, p=0.003). Of note, six of the 
IIH cohort described symptoms of hyperandrogenism (hirsutism, acne and male pattern 
balding). Of these, 3 were confirmed as having PCOS. Elevated 5α reductase activity has 
been linked to hirsutism (both idiopathic and that noted in PCOS) (Serafini and Lobo 
1985; D'Amico and Roehrborn 2007) and may explain the hirsutism noted in the IIH 
patients. The elevated androgen metabolism in the IIH patients likely reflects the younger 
age of this cohort as the significant differences noted between groups was lost following 
multivariate regression analysis accounting for age. The androgen metabolites correlated 
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significantly with age, reflecting the established pattern of androgen levels increasing 
until menopause and falling thereafter (Sowers et al. 2009).  
Elevated 5α reductase activity in IIH patients has not been previously described. 5α 
reductase is a pivotal enzyme in both cortisol and androgen metabolism.  There are two 
isoforms of 5α reductase (Russell and Wilson 1994). The type 1 isoform is localised to 
chromosome 5 (Jenkins et al. 1991) and is located predominantly in the liver, adipose, 
non-genital skin, cerebellum and hypothalamus, as well as in the sebacceous glands and 
scalp following puberty. The type 2 isoform is localised to chromosome 2 (Jenkins et al. 
1991) and is expressed in high levels in the prostate, androgen sensitive tissue and liver 
(Thigpen et al. 1993). Deficiency of 5α reductase type 2, an autosomal recessive disorder, 
manifests as male pseudohermaphroditism. This is due to impaired activation of 
testosterone to DHT, which is essential for the development of male genitalia (Andersson 
et al. 1991). 5α reductase type 1 deficiency has not been described in humans. 
Enhanced 5α reductase activity has been demonstrated in obesity (Andrew et al. 1998) 
and, additionally, adipose tissue demonstrates 5α reductase activity (Andrew et al. 1998), 
but the precise role in obesity is not established. 5α reductase activity is also known to be 
regulated by oestrogen, with sexual dimorphism (higher levels in females) demonstrated 
in rodents (Mode and Norstedt 1982).  BMI and gender are unlikely to account for the 
elevated 5α reductase activity noted in IIH, as the control cohort was gender and BMI 
matched.  
PCOS is also associated with elevated 5α reductase activity.  PCOS affects approximately 
10-15% of women and is a heterogeneous condition, comprising of clinical and 
biochemical hyperandrogensism, oligo/amenorrhoea and metabolic syndrome 
(Tsilchorozidou et al. 2004). Increased 5α reductase activity has been demonstrated in 
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urinary metabolites in PCOS (Stewart et al. 1990; Chin et al. 2000; Fassnacht et al. 2003; 
Tsilchorozidou et al. 2003; Vassiliadi et al. 2009). Additionally, elevated levels of 5α 
reductase are found in ovarian tissue of PCOS patients (Jakimiuk et al. 1999). Since the 
description “diabetes of bearded women” nearly a century ago (Achard 1921), there has 
been growing interest in the association of PCOS to insulin resistance, defined as a 
reduced glucose response to a given amount of insulin (Tsilchorozidou et al. 2004). This 
association occurs in both the lean and obese PCOS patients (Dunaif et al. 1989). The 
potential role of 5α reductase and cortisol metabolism, in insulin resistance, is not yet 
defined, but remains an area of interest (Horton et al. 1993; Vassiliadi et al. 2009). Of 
note, finasteride (an inhibitor of 5α reductase type 2) is effective in treating hirsutism 
(Petrone et al. 1999), and altering ovarian morphology (Arie et al. 2004) in PCOS, but 
long term effects on insulin resistance have not been studied.  
In this study, enhanced 5α reductase activity was demonstrated in IIH patients and, as 
PCOS and IIH share a similar phenotype (both groups of patients are typically obese 
women of childbearing age), it is possible that the increased 5α reductase activity seen in 
the IIH patients reflected coexisting PCOS.  We, therefore, reanalysed the IIH cohort 
without the six PCOS patients.  5α reductase activity, indicated by the 5αTHF: THF ratio, 
(the most representative of 5α reductase activity (Stewart et al. 1990)), was still 
significantly higher in the IIH patients following exclusion of the PCOS patients 
(p=0.028).  It is possible, therefore, that 5α reductase activity is important in the 
pathogenesis of IIH.   
20.7% of the IIH cohort met the diagnostic criteria (REA-SPCW 2004) for PCOS. 
Although the small size of the IIH cohort limits interpretation, this figure is greater than 
the background incidence of PCOS (10-15%) (Tsilchorozidou et al. 2004).  The incidence 
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of coexisting PCOS and IIH may in fact be greater than the figure suggested in our study; 
one centre reported that between 39 and 57% of IIH patients were found to have PCOS 
(Glueck et al. 2003; Glueck et al. 2005).  This raises the possibility that, together, IIH and 
PCOS represent a spectrum of disorders in obese female patients which are characterised 
by enhanced 5α reductase activity. The nature of this relationship clearly needs further 
clarification; particularly the possible role of 5α reductase in ICP dynamics. Of interest, 
initial characterisation of human CP and AGT epithelial cells confirmed expression of 5α 
reductase 1 (Figure 3-7). 
The total glucocorticoid metabolites, an indicator of HPA axis drive were higher in the 
IIH cohort (p=0.027) than in obese controls. Enhanced HPA axis activity (following both 
stimulation by ACTH and suppression by dexamethasone) has been noted in obesity and 
PCOS (Pasquali et al. 1993; Duclos et al. 2001), particularly amongst those with central 
obesity (Pasquali et al. 1993; Duclos et al. 2001). The mechanism for HPA axis activation 
in obesity is debated although considerable evidence is accumulating to suggest that 
dysregulation of peripheral cortisol metabolism by 11β-HSD1 and 5α reductase is crucial 
(Stewart et al. 1990; Andrew et al. 1998; Stewart et al. 1999; Rask et al. 2001; Reynolds 
et al. 2001; Tomlinson et al. 2008). It is interesting to speculate that the increased HPA 
axis activity in IIH patients, which was more than what would be expected from their 
BMI alone, reflects pathogenic cortisol dysregulation. 
Study of the fasting serum metabolites revealed that IIH patients had elevated HOMA IR 
scores at baseline (2.1 ± 2.1), indicative of insulin resistance (normal scores are less than 
1 (Wallace et al. 2004)). The IIH patients had significantly higher insulin and glucose: 
insulin ratio than control subjects (insulin 14.3 ± 6.4 µU/ml in IIH and 10.8 ± 7.8 µU/ml 
in controls, p=0.036 and glucose: insulin ratios 0.41 ± 0.20 in IIH and 0.83 ± 0.87 in 
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controls, p=0.027). The HOMA %B, %S and IR scores were also indicative of inferior 
insulin sensitivity in the IIH, compared with the control group, although differences did 
not reach the level of statistical significance. Following removal of the IIH patient with 
PCOS from the IIH cohort absolute values for insulin, HOMA %B, %S, IR and glucose: 
insulin ratio remained very similar and continue to showed a trend towards increased 
insulin resistance in the IIH patients compared to controls, however, differences were no 
longer significant (insulin 16.6 ± 6.2 µU/ml in IIH and 10.8 ± 7.8 µU/ml in controls, 
p=0.116 and glucose: insulin ratio 0.45 ± 0.20 in IIH and 0.83 ± 0.87 in controls, 
p=0.185). It is possible that the PCOS patient in the IIH cohort contributed to the insulin 
resistance noted, however, it is also very likely that exclusion of the PCOS patients, and 
consequently reduction in the IIH cohort size, meant that the comparison was no longer 
adequately powered to elicit a significant difference. It is important to note that although 
diabetic patients were excluded from the control cohort, identification of PCOS was not 
undertaken. Consequently, the control cohort may have contained patients with PCOS. In 
summary, the IIH patients, both with and without PCOS, had elevated HOMA IR scores 
(greater than two) indicating impaired insulin sensitivity and consequently may be at 
increased risk of developing diabetes (Costa et al. 1998). Longitudinal evaluation of 
insulin sensitivity in IIH will shed light on this area.  
DEXA scanning did not identify a difference in fat mass distribution between IIH and 
control subjects. It is, therefore, unlikely that fat distribution dictates which obese patients 
develop IIH. Centrally distributed obesity  has been previously suggested as causative in 
IIH (Sugerman et al. 1995) and although this is unlikely in light of these DEXA results, it 
remains possible that preferential loss of abdominal fat may be of  therapeutic benefit 
(section 5.3.2.4). The BMC was lower in the control subjects in keeping with their 
increased age and consequent tendency to osteopenia. 
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It is suggested that the results of this study are interpreted with caution as the control 
population, whilst universally female and matched for BMI, were not matched for age. 
Although careful analysis and the use of multivariate regression should have eliminated 
bias, due to the age differences of the cohorts, this cannot be completely excluded. 
Additionally, interpretation of the study was compromised through the use of a historical 
obese control cohort. The obese controls may have had underlying methodological 
differences to the IIH cohort, despite all attempts to standardised collection of 
anthropometric and DEXA data through the use of similar techniques and equipment, as 
well as processing the urine and serum samples using identical assays methodologies. The 
analysis of IIH patients, carried out following the exclusion of the PCOS patients, is 
particularly likely to be prone to bias as the obese control cohort were not rigorously 
screened for PCOS, consequently impairing the reliability of these analyses. It will be 
important to replicate these results in a large gender, BMI and age matched study using 
contemporary obese control subjects screened for PCOS. 
In summary, this study suggests that IIH patients have enhanced 5α reductase activity and 
elevated total glucocorticoid metabolites (reflecting HPA axis activity), in conjunction 
with greater insulin resistance, compared with BMI matched control subjects. Although a 
difference in global 11β-HSD1 activity was not noted between IIH and control subjects, 
alterations in tissue specific activity may exist. It is possible that regulation of cortisol by 
both 5α reductase and 11β-HSD1 is important in IIH and ICP dynamics. Further 
evaluation of the interplay between these two enzymes and their potential role in CSF 
secretion and drainage would be of interest. These studies also suggest that IIH patients 
have a degree of insulin resistance that is at least that expected from their BMI and is 
greater in those with coexisting PCOS. Insulin resistance in the IIH patients, akin to obese 
individuals, may increase their risk of developing future metabolic complications. 
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Longitudinal evaluation of insulin sensitivity, diabetes and vascular events, would further 
clarify the risk of metabolic syndrome in IIH subjects. 
Independence: Lipotrim, Howard Foundation, Cambridge, United Kingdom had no 
involvement in study funding,  design, data collection, analysis, data interpretation or 
report writing of these studies. 
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6.1. Conclusions 
The pathogenesis of IIH, a condition of raised ICP in obese women, has not been 
established. This thesis examined the role of obesity, 11β-HSD1 and metabolic changes in 
the pathogenesis and treatment of IIH. Initial in vitro studies explored the role of 11β-
HSD in the regulation of CSF dynamics. We confirmed 11β-HSD1 expression and 
activity in the CP of an animal model, the NZWAR, and subsequently in human tissue. 
Together, these finding highlight the capability of the CP to generate cortisol and possibly 
influence CSF cortisol levels. Autocrine effects of CP cortisol on the glucocorticoid 
signalling pathway may in turn influence CSF secretion. In order to further examine CSF 
secretion, a HCPEpi cell line was analysed. This was found to have a comparable pattern 
of 11β-HSD1 expression and activity to human CP tissue and was consequently deemed a 
representative model for future study of CP function.  
Study of the AGT, the CSF drainage structure, was not possible in the NZWAR due to the 
microscopic nature of the granulations preventing reliable identification. Characterisation 
of post mortem human AGT identified 11β-HSD1 in the epithelial cap cells of the 
granulation. Although enzyme activity was not demonstrated, key elements of the 
glucocorticoid signalling cascade (including GRα and MYOC) were identified, 
highlighting the potential of the AGT to act as a glucocorticoid target tissue, influenced 
by paracrine actions of cortisol. Characterisation of a human AGEpi cell line, established 
by our collaborators (Holman et al. 2005), mirrored that of AGT and, therefore, may 
represent a suitable model for future evaluation of the functional consequences of cortisol 
on CSF drainage.  
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We suggested that IIH, a condition almost exclusively found in the obese population 
(Giuseffi et al. 1991; Wall and George 1991), was characterised by a deranged metabolic 
profile and consequently utilised a metabolomics approach to define a unique metabolite 
profile in the CSF and serum.   Proton NMR spectroscopy, coupled with computer 
modelling (PCA and PLS-DA), were therefore used to identify those metabolites which 
most accurately defined IIH, as well as two control conditions (MS and CVD). We found 
that phenotypic features influenced the metabolite profile. Consequently, evaluation of 
metabolite profiles from disease populations matched for gender, age and BMI, revealed 
diagnostic metabolites with highest accuracy (80% sensitivity and sensitivity in IIH CSF).  
Defining disease specific, diagnostic metabolite biomarkers was a novel use for 
metabolomics (Sinclair et al. 2009). This will require further evaluation, comparison 
between centres and ultimately standardisation, particularly as current techniques for data 
processing vary widely. In the setting of IIH, identification of potentially diagnostic 
metabolites may ultimately prove useful in a clinical setting, particularly if profiles are 
evaluated in non invasive fluids such as urine. Additionally, longitudinal evaluation of IIH 
metabolite profiles will indicate the utility of biomarker profiles in disease monitoring.  
We have however, established proof of concept of this technique, and suggest that the 
application of metabolomics to other more diagnostically challenging diseases may well 
be of value.  
To enhance our understanding of the pathogenesis of IIH the metabolite profile was also 
used to identify the predominant metabolites in the CSF of IIH patients (lactate, 
oxaloacetate, glucose, acetate and 3-hydroxybutyrate). Interpretation of these metabolites 
is complicated, as they may reflect the cause or the consequence of disease. Additionally, 
the precision of our metabolite identification is dependent on the accuracy of established 
metabolite libraries. Thus, before detailed investigation of the association between 
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metabolites and IIH aetiology, metabolite identity should be confirmed using mass 
spectroscopy. It was interesting to note, that although the CSF metabolite profiles most 
accurately defined IIH (sensitivity and specificity 80%), the serum profiles were also 
acceptable (sensitivity 70% and specificity 78%), potentially implicating both CNS and 
systemic factors in the aetiology of IIH. Further exploration of the role of both the CSF 
and serum metabolites may augment our knowledge of the underlying disease process in 
IIH. 
To more accurately define the role of obesity, metabolic changes and 11β-HSD1 in IIH, 
clinical studies were conducted. Through the use of a VLCD, we were able to evaluate the 
effect of weight loss on: 1) ICP, and treatment of IIH and 2) metabolic changes. We 
demonstrated that weight reduction is of therapeutic value in IIH, significantly reducing 
ICP, papilloedema and headaches. Ideally the study would have utilised a randomised 
control design, but ethical considerations, regarding the acceptability of performing three 
LP’s on control patients who were not undergoing a potentially beneficial intervention, 
prevented this more robust method of study. A large, multicentered, randomised study of 
the effect of weight loss is, however, being initiated in the United Sates and we await the 
results. Our IIH cohort suffered no significant side effects as a result of weight reduction, 
a recent report of cerebellar tonsillar herniation following weight loss in IIH (Graber et al. 
2009 ) is, however, noted. The extent of this problem will need to be monitored in future 
clinical studies. This study was the first to use objective assessment of papilloedema in a 
trial setting. The utility of USG measurement of optic disc elevation and nerve sheath 
diameter, as well as OCT in quantifying papilloedema, was demonstrated. These novel 
techniques may be useful in both a clinical and research setting to aid identification of 
papilloedema and monitor disease progression. The techniques now require evaluation 
over a greater range of Frisen grades (most of the discs evaluated in our study had mild 
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papilloedema with Frisen grade 1 or 2), and inter and intra observer variability needs to be 
closely scrutinised.  
Having established the role of therapeutic weight loss in IIH, we sought to evaluate 
whether the benefits noted, related to alterations in metabolism and 11β-HSD1.  The 
urinary, serum and CSF metabolite profiles were, therefore, assessed using GC/MS and 
LC/MS both before and after weight reduction. A reduction in global 11β-HSD1 activity 
was identified following weight reduction, which correlated significantly, with reduction 
in ICP. Assessment of CSF and serum glucocorticoids did not identify reduced cortisol, as 
one might have expected in the setting of reduced 11β-HSD1 activity. There was, 
however, a significant correlation between increased levels of cortisone (potentially 
indicating reduced 11β-HSD1 activity) and weight loss. The interpretation of serum and 
CSF glucocorticoids were complicated by the regulatory effects of the HPA axis 
correcting the serum glucocorticoid levels as well as the potential for transfer of steroids 
across the BBB. 
Our final comparison of IIH subjects, with a cohort of gender and BMI matched controls, 
did not identify divergent urinary 11β-HSD1 activity between the groups. Tissue specific 
differences in 11β-HSD1 were not investigated but would be of future interest. We found 
evidence of activation of the HPA axis (elevated total glucocorticoid metabolites) in the 
IIH patients which was significantly higher than that identified in matched control 
subjects. Additionally, HPA axis activation fell following therapeutic weight loss in IIH. 
Increased HPA axis drive is recognised in obesity (Pasquali et al. 1993; Duclos et al. 
2001), but it is interesting to note that the elevation in HPA axis activity seen in IIH was 
greater than that noted in subjects with idiopathic obesity. Dysregulation of 11β-HSD1 
may be a factor contributing to HPA axis activation, although the influence of 5α 
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reductase may also be important. Our results also indicated increased 5α reductase 
activity in IIH subjects compared to matched controls. Additionally, levels of 5α 
reductase fell following therapeutic weight loss. Inactivation of cortisol by 5α reductase 
has been implicated in driving the HPA axis (Stewart et al. 1990). The role of 5α 
reductase in IIH and CSF dynamics has not been previously explored, but may well be 
important. 
Idiopathic obesity is associated with the development of the metabolic syndrome and 
consequent increased mortality and morbidity. As IIH patients are phenotypically obese, 
we suggested that they may also have an increased risk of developing the metabolic 
syndrome.  We demonstrated evidence of insulin resistance (HOMA IR score greater than 
2) in the IIH subjects and additionally elevated insulin levels and glucose: insulin ratios, 
when compared to subjects with idiopathic obesity (BMI matched).  The BP and lipid 
profiles were, however, similar in IIH and idiopathic obese subjects. These results suggest 
that IIH subjects have reduced insulin sensitivity, although interestingly, this was 
primarily related to those with coexisting PCOS. The long term consequences of insulin 
resistance in this relatively young cohort of IIH subjects will require prospective 
evaluation.  
Despite the almost ubiquitous association of obesity with IIH, not all obese subjects 
develop IIH. Centrally distributed adiposity has been previously cited as causative, due to 
pressure effects elevating intra-abdominal pressure, which subsequently elevates intra-
thoracic pressure and cerebral venous pressure and finally ICP (Sugerman et al. 1995). A 
recent study however, evaluated waist: hip ratios in IIH and obese individuals and found 
lower ratios in IIH subjects. They concluded that fat preferentially accumulated in the 
lower body in IIH subjects (Kesler et al. 2009). We assessed body composition using 
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DEXA scanning in IIH and matched subjects with idiopathic obesity and found no 
difference in the distribution of fat mass. DEXA scanning before and after weight loss did 
however indicate that preferential loss of central fat mass may be most therapeutically 
beneficial. Our data suggested that it was unlikely that fat distribution was causative in 
IIH. The explanation as to why a proportion of obese subjects develop IIH remains 
unknown.  
In summary, our in vitro studies suggested that both the CP and AGT express 11β-HSD1 
and have the potential, to act as glucocorticoid target tissues, which may be important in 
CSF dynamics and ICP regulation in IIH. We have demonstrated the therapeutic efficacy 
of weight loss in IIH and provided evidence that the beneficial effects may relate to 
alterations in the glucocorticoid profile driven 11β-HSD1 and potentially, 5α reductase.  
6.2. Future directions 
6.2.1. In vitro studies 
The in vitro studies confirmed expression of 11β-HSD1 and key element of the 
glucocorticoid signalling pathway in human CP and AGT, with the potential for cortisol 
generation by 11β-HSD1 demonstrated in the CP. A progression to this work would be to 
investigate the functional consequences of glucocorticoids and 11β-HSD1 on CSF 
secretion and drainage. Monolayers of HCPEpi cells grown on a permeable supports 
designed to measure a volumetric readout (Haselbach et al. 2001; Speake et al. 2001), 
would provide a suitable model to explore the ability of CP cells to produce CSF under a 
variety of conditions (cortisol, cortisone, dexamethasone, aldosterone, GE, RU38486 (a 
GR inhibitor) and RU26752 (a MR inhibitor)) defining the functional impact of 
glucocorticoids on CSF secretion. Functional studies using real-time RT-PCR could also 
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be used to define the induction of expression of putative target genes involved in CSF 
production (αENaC, βENaC, sgk-1, Na+K+ATPase subunits) following incubation of CP 
cells with corticosteroid receptor agonists (cortisol, dexamethasone, and aldosterone).  
The permeability of AGEpi cells could be similarly investigated in conjunction with the 
regulation of MYOC by glucocorticoids.   
Further work using animal models would also be of value. Using intraventricular pressure 
recording in mice (Nawashiro et al. 2002), we could explore the effect of 11β-HSD1 
inhibitors on ICP. Within the secretory cells of the CP epithelium, 11β-HSD1 is unlikely 
to represent the only regulator of CSF secretion, as numerous ion channels are involved in 
CSF secretion (Figure 1-6). Through the use of intraventricular monitoring, in conjunction 
with intraventricular administration of selective ion channel and 11β- HSD1 inhibitors, we 
could start to unravel the extent to which 11β-HSD1 influences total CSF secretion. ICP 
has not been studied in the 11β-HSD1 knockout or over-expression mouse. This area may 
also be worthy of further assessment, although these mice appear to have no overt CSF 
phenotype. 
The measures of CSF cortisol, as a reflection of tissue specific (CP) 11β-HSD1 activity, 
were difficult to interpret, due to the influence of steroid dialysis across the BBB.  Study 
of systemic and CSF radio-labelled cortisol in animal models, with normal and elevated 
ICP, may improve our understanding of this area.  
In addition to unravelling the role of 11β-HSD1 in IIH, the studies have demonstrated 
elevated 5α reductase in IIH patients. 5α reductase levels were also demonstrated to fall 
with therapeutic weight loss. It is possible therefore, that in addition to 11β-HSD1, 
cortisol regulation by 5α reductase may have a role in IIH. 5α reductase has not been 
previously investigated in the context of CSF dynamics, although our work demonstrated 
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expression of 5α reductase1 in HCPEpi and AGEpi. A detailed examination of the 
localisation, activity and function of 5α reductase in CP and AGT is therefore warranted. 
6.2.2. Clinical studies 
The clinical studies have confirmed the therapeutic benefit of weight loss in IIH. Global 
11β-HSD1 activity fell in conjunction with weight reduction and ICP, supporting our 
hypothesis that the pathogenesis of IIH is influenced by elevated 11β-HSD1. To further 
explore the role of systemic dysregulation of 11β-HSD1, analysis of adipose tissue 11β-
HSD1 expression and hepatic 11β-HSD1 activity in IIH subjects and matched controls, 
would be of interest. Evaluation of CP and AGT cortisol and cortisone concentrations in 
IIH subjects would be very interesting; however, the low morbidity associated with IIH 
has meant that postmortem brain tissue is not currently available in European brain banks.  
11β-HSD1 inhibitors, used in the context of obesity and the metabolic syndrome, are 
currently the focus of considerable research (Boyle and Kowalski 2009). A randomised 
control study examining the therapeutic potential of 11β-HSD1 inhibitors in IIH is 
ultimately required to establish proof of concept. We also acknowledge that this thesis has 
not explored the potential contribution of H6PD in the pathogenesis of IIH. This area will 
need exploring in light of recent studies demonstrating the ability of H6PD to regulate 
11β-HSD1 (Zhang et al. 2009b) and additionally modulate the effect of 11β-HSD1 
inhibition (Balazs et al. 2009). 
Recent work describing familial cases of IIH (Corbett 2008), highlight the potential for a 
genetic influence in IIH. Polymorphisms in the 11β-HSD1 gene have been described, 
which influence the function of 11β-HSD1 (Malavasi et al. 2009), although it is not clear 
if these polymorphisms have pathogenic implications for the metabolic syndrome 
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(Robitaille et al. 2004; Ku et al. 2009; Miyamoto et al. 2009). Further characterisation 
and DNA banking of familial IIH cases would be of value, particularly in relation to 
identifying polymorphisms in 11β-HSD1. 
The use of objective measures (USG and OCT) to quantify papilloedema, mark an 
important step in optic disc monitoring. Although not included in this thesis, additional 
disc measurements were taken using Heidelberg Retina Tomography alongside the USG 
and OCT measurement. We plan to compare these techniques to ascertain the most 
accurate, consistent, and cost effective technique. Discriminatory, clinically relevant, 
objective outcome measures have been lacking in previous IIH studies. Our successful 
utilisation of objective papilloedema measures in conjunction with headache diaries, 
disability scales (HIT-6), as well as visual contrast sensitivity measures, will impact on 
the planning of future IIH studies. Pelli Robson contrast sensitivity was noted to be a 
sensitive technique to monitor changes in vision in the IIH subjects, despite clinically 
insignificant changes in acuity. The use of low contrast, letter acuity charts, which have 
been noted as discriminatory in MS associated optic neuritis (Mowry et al. 2009), would 
be worthy of investigation in the setting of IIH. 
In the future, we aim to accurately characterise the clinical and metabolic phenotype of a 
longitudinal cohort of IIH patients. This will involve the establishment a bio-bank of 
blood, urine and CSF samples with corresponding clinical data. Large studies of this 
nature are essential to determine much needed information on disease progression, 
remission, and severity in the context of metabolic changes. Epidemiological data may 
well reveal subtypes of disease, with differing disease courses. It is interesting to 
speculate that these disease subtypes may have differing aetiologies, which will require 
tailored investigation of pathogeneses, and potentially individualised treatment. 
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7.1. Ethical approval 
Permission for all aspects of this study was obtained from the local research ethics 
committees and all participants gave written informed consent. 
1. Evaluation of Hormones and Obesity Mediators on Cerebrospinal Fluid (Solihull 
LREC 04/Q2706/65. Approved 15/01/2005) 
2. Evaluation of 11Beta-HSD in Human Choroid Plexus and Arachnoid Granulation 
tissue (Dudley LREC 06/Q2702/19. Approved 20/03/2006) 
3. The Impact of Weight Loss on Idiopathic Intracranial Hypertension (Dudley 
LREC 06/Q2702/64. Approved 06/09/06) 
 
Chapter 7   
227 
 
7.2. Headache Impact Test-6 
 
Headache Impact Test- 6 
This questionnaire was designed to help you describe the way you feel and what you 
cannot do because of  your headache. 
To complete, please circle one answer for each 
question     
1 
When you have headaches, how often is the pain severe? 
Never Rarely Sometimes Very Often Always 
2 
How often do headaches limit your ability to do usual daily activities 
including household work, work, school, or social activities? 
Never Rarely Sometimes Very Often Always 
3 
When you have a headache, how often do you wish you could lie down? 
Never Rarely Sometimes Very Often Always 
4 
In the past 4 weeks, how often have you felt too tired to do work or daily 
activities because of your headaches? 
Never Rarely Sometimes Very Often Always 
5 
In the past 4 weeks, how often have you felt fed up or irritated because of 
your headaches? 
Never Rarely Sometimes Very Often Always 
6 
In the past 4 weeks, how often did your headache limit your ability to 
concentrate on work or daily activities? 
Never Rarely Sometimes Very Often Always 
  
 
  
 
    
    
    
    
  
Column 1 
(6 points each) 
Column 2 
(8 points each) 
Column 3 
(10 points each) 
Column 4 
(11 points each) 
Column 5 
(13 points each) 
            
          
 
        
Total 
Score 
          
        
Higher scores indicate greater 
impact on your life. 
Score range is 36 - 78. 
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7.3. Interpretation of Headache Impact Test-6 
 
If You Scored 60 or More 
Your headaches are having a very severe impact on your life. You may be experiencing disabling pain and other 
symptoms that are more severe than those of other headache sufferers.  
 
If You Scored 56 – 59 
Your headaches are having a substantial impact on your life. As a result you may be experiencing severe pain and 
other symptoms, causing you to miss some time from family, work, school, or social activities. 
 
If You Scored 50 – 55 
Your headaches seem to be having some impact on your life.  
 
If You Scored 49 or Less 
Your headaches seem to be having little to no impact on your life at this time.  
 
http://www.headachetest.com/HIT6/PDFS/English.pdf  (Shin et al. 2008) 
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7.4. Intention to treat analysis of the IIH patients in the 
weight loss study 
Characteristic Baseline Start Diet End Diet Final P value 
Patient numbers 25 24 22 20  
Weight (kg) 101.3 ± 16.5 101.3 ± 17.4 86.3 ± 15.5 87.0 ± 12.9 <0.001 
BMI (kgm-2) 37.9 ± 4.9 38.1 ± 5.3 32.4 ± 4.9 32.8 ± 4.4 <0.001 
Intracranial pressure (cm CSF) 39.5 ± 4.6 37.8 ± 4.7 29.7 ± 4.7 N/A <0.001 
Vision      
Ultrasonographic optic disc 
elevation (mm) 
1.02 ±  0.27 0.98 ± 0.29 0.81 ± 0.26 0.75 ± 0.26 0.002 
Ultrasonographic optic nerve sheath 
diameter (mm) 
4.6 ± 1.0 4.5 ± 1.2 4.1 ± 1.3 3.6 ± 1.2a 0.004 
Optical coherence tomography 
(average optic disc elevation) 
(microm) # 
142.2 ± 43.6 136.3 ± 46.3 111.4 ± 27.4 108.2 ± 28.6 0.001 
LogMAR visual acuity‡ 0.04 ± 0.28 0.09 ± 0.42 -0.02 ± 0.23 -.07 ± 0.08 <0.001a 
Pelli Robson contrast sensitivity‡ 1.56 ± 0.17 1.57 ± 0.14 1.66 ± 0.08 1.68 ± 0.10 0.003 
Humphrey visual field 24-2 mean 
deviation‡ 
-4.5 ± 4.3 -3.4 ± 3.4 -2.8 ± 2.9 -1.5 ± 1.8a ns 
Farnsworth Munsell 100 Hue 
colour assessment# 
114 ± 78.1 88.5 ± 76.8b 71.6 ± 54.3b 59.2 ± 61.1b ns 
Headache       
Headache Impact Test (HIT-6)‡ 59.2 ± 9.0 54.8 ± 9.3 46.7 ± 10.1 48.4 ± 9.6 0.004 
Headache severity (VAS 0-10)‡ 4.2 ± 2.4 
 
4.0 ± 2.9 
 
1.9 ± 2.7 
 
2.6 ± 2.7 0.015 
Headache Frequency (days/wk)‡ 4.3 ± 2.9 
 
4.3 ± 3.1 
 
2.0 ± 2.7 
 
2.6 ± 3.1 
 
0.011 
Analgesic use (days/wk) ‡ 2.4 ± 2.6 2.3 ± 2.6 0.3 ± 0.7 1.0 ± 2.1 0.007 
Symptoms       
Headache† (n (%)) 24 (96) 23 (96) 14 (58) 10 (50) <0.001 
Tinnitus† (n (%)) 15 (60) 14 (58) 4 (17) 4 (20) 0.004 
Visual loss† (n (%)) 11 (44) 9 (38) 3 (13) 1 (5) 0.063 
Obscurations† (n (%)) 5 (20) 6 (26) 0 (0) 0 (0) 0.025 
Diplopia† (n (%)) 2 (8) 9 (38) 0 (0) 0 (0) 0.008 
Table 7-1 Intention to treat analysis showing the study characteristics and symptom 
chronology at each assessment during the weight loss study 
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Data summary statistics represent complete cohort at each time point 
(intention to treat analysis). p values indicates significant changes 
following weight reduction (start diet versus end diet; (stage 2). No 
significant changes were noted from baseline to start diet (stage 1) or from 
end diet to final visit (stage 3) unless indicated. A significant improvement 
noted but this was not found in the left eye. b significant change noted after 
each stage, therefore weight loss did not significantly improve variable.  
All data analysed using repeated measures ANOVA (at four time points, 
except ICP which was analysed at 3) unless stated otherwise. # indicates 
data was logged prior to analysis. ‡ indicates that a Friedman’s test was 
used for analysis and if significant a Wilcoxon Signed rank test was 
subsequently carried out, results of the latter are quoted in the table. † 
indicates that a Cochran’s Q test revealed a significant improvement in all 
variables and subsequently a Sign test was used to evaluate differences at 
each study stage. Abbreviations: CSF, cerebrospinal fluid; NS, not 
significant; VAS, Visual analogue score; wk, week. 
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